Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 1 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Title Page  
Protocol Title:  A Randomized, Open -label, Phase 3 Study 
Comparing Once -weekly vs Twice -weekly 
Carfilzomib in Combination With Lenalidomide 
and Dexamethasone in Subjects With Relapsed 
or Refractory Multiple Myeloma (A.R.R.O.W.2)   
Short Protocol Title:  A Study Comparing Once -weekly vs 
Twice -weekly Carfilzomib in Combination with 
Lenalidomide and Dexamethasone in Subjects 
With Relapsed or Refractory Multiple Myeloma  
Protocol Number:  20180015  
Investigational Product:  Carfilzomib  
Trade Name:  Kyprolis 
Sponsor  Name of Sponsor:  Amgen Inc.   
Address:  One Amgen Center Drive  
Thousand Oaks, CA 91320, United States  
Telephone Number:  1-805-447-1000  
Key 
Sponsor 
Contact Name:  
Address:  One Amgen Center Drive  
Thousand Oaks, CA 91320, United States  
Telephone Number:   
Email Address:   
EudraCT Number:  2018‐000665‐36 
NCT Number:  03859427  
Protocol Date:  Document Version  Date  
Original  04 October 2018  
Amendment 1  10 October 2019  
Amendment 2  24 August 2020  
Amendment 3  12 August 2021  
Superseding 
Amendment 3 02 September 2021  
 
Version/Date:  Data Element  Standards Version  
6.1 
 
This protocol was developed, reviewed, and approved in accordance with Amgen’s 
standard operating procedures.  The format and content of this protocol is aligned with 
Good Clinical Practice:  Consolidated Guidance (ICH E6).  

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 2 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Confidentiality Notice  
This document contains confidential information of Amgen Inc.  
This document must not be disclosed to anyone other than the site study staff and 
members of the institutional review board/independent ethics 
committee/institutional scientific review board or equivalent.  
The information in this document cannot be used for any purpose other than the 
evaluation or conduct of the clinical investigation without the prior written consent 
of Amgen Inc.  
If you have questions regarding how this document may be used or shared, call 
the Amgen Medical Information number:  US sites, 1 -800-77-AMGEN; Canadian 
sites, 1 -866-50-AMGEN; Amgen’s general number in the US, 1 -805-447-1000.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 3 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Investigator’s Agreement:  
I have read the attached protocol entitled A Randomized, Open -label, Phase 3 Study 
Comparing Once -weekly vs Twice -weekly Carfilzomib in Combination With Lenalidomide 
and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma 
(A.R.R.O.W.2)  , dated 02 September 2021 , and agree to abide by all provisions set 
forth therein.   
I agree to comply with the International Council for Harmonisation (ICH) Tripartite 
Guideline on Good Clinical Practice (GCP), Declaration of Helsinki, and applicable 
national or regional regulations/guidelines.    
I agree to ensure that Financial Disclosure Statements will be completed by: me 
(including, if applicable, my spouse [or legal partner] and dependent children) and my 
sub-investigators (including, if applicable, their spouses [or legal partners] and  
dependent children) at the start of the study and for up to 1 year after the study is 
completed, if there are changes that affect my financial disclosure status.  
I agree to ensure that the confidential information contained in this document will not be 
used f or any purpose other than the evaluation or conduct of the clinical investigation 
without the prior written consent of Amgen Inc.  
 
_______________________________  
Signature  
 
_______________________________  ____________________________  
Name of Investigator  Date (DD Month YYYY)  
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 4 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Table of Contents  
Table of Contents  ................................ ................................ ................................ ... 4 
1. Protocol Synopsis  ................................ ................................ ................................ . 10 
2. Study Schema and Schedule of Activities  ................................ .............................  18 
2.1 Study Schema  ................................ ................................ ...........................  18 
2.2 Schedule of Activities  ................................ ................................ ................  19 
3. Introduction  ................................ ................................ ................................ ...........  28 
3.1 Study Rationale  ................................ ................................ .........................  28 
3.1.1  Justification for Primary Endpoint  ................................ ..............  29 
3.1.2  Justification for the Clinical Outcome Assessments 
Endpoints  ................................ ................................ ..................  30 
3.2 Background  ................................ ................................ ...............................  31 
3.2.1  Disease  ................................ ................................ .....................  31 
3.2.2  Amgen Investigational Product Background:  
Carfilzomib  ................................ ................................ ................  31 
3.3 Benefit/Risk Assessment  ................................ ................................ ...........  32 
3.3.1  Therapeutic Context  ................................ ................................ .. 32 
3.3.2  Key Benefits  ................................ ................................ ..............  33 
3.3.3  Key Risks  ................................ ................................ ..................  34 
3.3.3.1  Risks  ................................ ................................ ....... 35 
4. Objectives, Endpoints and Hypotheses  ................................ ................................ . 38 
4.1 Objectives and Endpoints  ................................ ................................ ..........  38 
4.2 Hypotheses  ................................ ................................ ...............................  41 
5. Study Design  ................................ ................................ ................................ ........  41 
5.1 Overall Design  ................................ ................................ ..........................  41 
5.2 Number of Subjects  ................................ ................................ ...................  43 
5.2.1  Replacement of Subjects  ................................ ...........................  43 
5.2.2  Number of Sites  ................................ ................................ .........  43 
5.3 End of Study  ................................ ................................ .............................  43 
5.3.1  End of Study Definition  ................................ ..............................  43 
5.3.2  Study Duration for Subjects  ................................ .......................  44 
5.4 Justification for Investigational Product Dose  ................................ ............  44 
5.5 Patient Input on Study Design  ................................ ................................ ... 45 
6. Study Population  ................................ ................................ ................................ .. 45 
6.1 Inclusion Criteria  ................................ ................................ ......................  46 
6.2 Exclusion Criteria  ................................ ................................ .....................  47 
6.3 Subject Enrollment  ................................ ................................ ....................  50 
6.4 Screen Failures  ................................ ................................ .........................  51 
7. Treatments  ................................ ................................ ................................ ...........  51 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 5 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
7.1 Treatment Procedures ................................ ................................ ...............  52 
7.1.1  Investigational Product: Carfilzomib  ................................ ...........  52 
7.1.1.1  Dosage Formulation  ................................ ................  52 
7.1.1.2  Dosage, Administration, and Schedule  ....................  52 
7.1.1.3  Intravenous Prehydration  ................................ ........  53 
7.1.1.4  Starting Dose in Hepatic Insufficiency  .....................  54 
7.1.2  Non-investigational Products  ................................ .....................  54 
7.1.2.1  Dexamethasone:  Dosage, Administration, 
and Schedule  ................................ ..........................  54 
7.1.2.2  Lenalidomide  ................................ ...........................  54 
7.1.3  Medical Devices  ................................ ................................ ........  55 
7.1.4  Other Protocol -required Therapies  ................................ ............  55 
7.1.4.1  Antiviral Prophylaxis  ................................ ................  56 
7.1.4.2  Prophylaxis for Hepatitis B Reactivation  ..................  56 
7.1.4.3  Thromboprophylaxis  ................................ ................  56 
7.1.4.4  Tumor Lysis Syndrome Prophylaxis  ........................  56 
7.1.4.5  Proton -pump Inhibitor  ................................ ..............  56 
7.1.4.6  Bisphosphonate or Monoclonal Antibody 
Therapy  ................................ ................................ ... 56 
7.1.4.7  Prophylaxis for Pneumocystis Jirovenci ...................  57 
7.1.5  Other Treatment Procedures  ................................ .....................  57 
7.1.6  Product Complaints  ................................ ................................ ... 57 
7.1.7  Excluded Treatments, Medical Devices, and/or 
Procedures During Study Period  ................................ ...............  57 
7.1.7.1  Anticancer Therapeutic or Radiation  .......................  57 
7.1.7.2  Corticosteroids  ................................ ........................  58 
7.1.7.3  Plasmapheresis  ................................ .......................  58 
7.1.7.4  Myeloid Growth Factors  ................................ ..........  58 
7.2 Method of Treatment Assignment  ................................ .............................  58 
7.3 Blinding  ................................ ................................ ................................ ..... 59 
7.4 Dose Modification  ................................ ................................ ......................  59 
7.4.1  Dosage Adjustments, Delays, Rules for Withholding or 
Restarting, Permanent Discontinuation  ................................ ..... 59 
7.4.1.1  Amgen Investigational Product:  
Carfilzomib  ................................ ..............................  59 
7.4.1.2  Non-Amgen Non -Investigational Product:  
Lenalidomide  ................................ ...........................  63 
7.4.1.3  Non-Amgen Non -Investigational Product:  
Dexamethasone  ................................ ......................  64 
7.5 Preparation/Handling/Storage/Accountability  ................................ ............  64 
7.6 Treatment Compliance  ................................ ................................ ..............  64 
7.7 Treatment of Overdose  ................................ ................................ .............  64 
7.8 Prior and Concomitant Treatment  ................................ .............................  64 
7.8.1  Prior Treatment  ................................ ................................ .........  64 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 6 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
7.8.2  Concomitant Treatment  ................................ .............................  65 
8. Discontinuation Criteria  ................................ ................................ .........................  65 
8.1 Discontinuation of Study Treatment ................................ ...........................  65 
8.2 Discontinuation From the Study  ................................ ................................  66 
8.2.1  Reasons for Removal From Washout, Run -in or 
Invasive Procedures  ................................ ................................ .. 67 
8.2.2  Reasons for Removal From Study  ................................ .............  67 
8.3 Lost to Follow -up ................................ ................................ .......................  67 
9. Study Assessments and Procedures  ................................ ................................ .... 68 
9.1 General Study Periods  ................................ ................................ ..............  68 
9.1.1  Screening, Enrollment and/or Randomization  ............................  68 
9.1.2  Treatment Period  ................................ ................................ ....... 68 
9.1.3  Safety Follow -up ................................ ................................ ........  69 
9.1.4  Long -term Follow -up ................................ ................................ .. 69 
9.1.5  End of Study  ................................ ................................ ..............  69 
9.2 Description of General Study Assessments and Procedures  .....................  70 
9.2.1  General Assessments  ................................ ...............................  70 
9.2.1.1  Informed Consent  ................................ ....................  70 
9.2.1.2  Demographics  ................................ .........................  70 
9.2.1.3  Medical History  ................................ ........................  70 
9.2.1.4  Physical Examination  ................................ ..............  70 
9.2.1.5  Physical Measurements  ................................ ..........  71 
9.2.1.6  Substance Abuse History  ................................ ........  71 
9.2.1.7  Performance Status ................................ .................  71 
9.2.2  Efficacy Assessments  ................................ ................................  71 
9.2.2.1  SPEP, UPEP, SFLC, SIFE, and UIFE  .....................  71 
9.2.2.2  Bone Marrow Sample Evaluation Including 
FISH and MRD[ -]CR Assessment  ...........................  72 
9.2.2.3  Bone Lesion Assessment (Skeletal 
Survey, CT, or PET/CT)  ................................ ..........  73 
9.2.2.4  Extramedullary Plasmacytoma  ................................  73 
9.2.2.5  Progressive Disease Assessment  ...........................  74 
9.2.3  Safety Assessments  ................................ ................................ .. 74 
9.2.3.1  Adverse Events  ................................ .......................  74 
9.2.3.2  Vital Signs  ................................ ...............................  77 
9.2.3.3  Electrocardiograms (ECGs)  ................................ ..... 77 
9.2.3.4  Other Safety  ................................ ............................  78 
9.2.4  Clinical Laboratory Assessments  ................................ ...............  79 
9.2.4.1  Pregnancy Testing  ................................ ..................  79 
9.2.4.2  Prespecified Biomarker Assessments  .....................  80 
9.2.5  Pharmacokinetic Assessments  ................................ ..................  80 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 7 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.2.6  Pharmacodynamic Assessments (Only for Subjects 
Participating in the Optional Intensive PK/PDn 
Substudy)  ................................ ................................ ..................  80 
9.2.7  Clinical Outcome Assessments  ................................ .................  80 
9.2.7.1  EORTC QLQ -C30 ................................ ...................  80 
9.2.7.3  Patient -reported Convenience With 
Carfilzomib -dosing Schedule Question  ....................  81 
9.2.7.5  Cancer Therapy Satisfaction 
Questionnaire (CTSQ)  ................................ .............  81 
9.2.9  Optional Substudies  ................................ ................................ .. 83 
9.2.9.1  Intensive 
Pharmacokinetic/Pharmacodynamic 
Substudy  ................................ ................................ . 83 
9.2.10  Other Assessments  ................................ ................................ ... 83 
10. Statistical Considerations  ................................ ................................ ......................  83 
10.1  Sample Size Determination  ................................ ................................ ....... 83 
10.2  Analysis Sets, Subgroups, and Covariates  ................................ ................  84 
10.2.1  Analysis Sets  ................................ ................................ .............  84 
10.2.1.1  Intent -to-Treat Population  ................................ ........  84 
10.2.1.2  Safety Population  ................................ ....................  84 
10.2.1.3  Per-Protocol Population  ................................ ..........  84 
10.2.2  Covariates  ................................ ................................ .................  84 
10.2.3  Subgroups  ................................ ................................ .................  85 
10.2.4  Handling of Missing and Incomplete Data  ................................ .. 85 
10.3  Statistical Analyses  ................................ ................................ ...................  86 
10.3.1  Planned Analyses  ................................ ................................ ...... 86 
10.3.1.1  Interim Analysis and Early Stopping 
Guidelines  ................................ ...............................  86 
10.3.1.2  Primary Analysis  ................................ .....................  87 
10.3.1.3  Final Analysis  ................................ ..........................  87 
10.3.2  Methods of Analyses  ................................ ................................ . 87 

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 8 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
10.3.2.1  General Considerations  ................................ ...........  87 
10.3.2.2  Efficacy Analyses  ................................ ....................  88 
10.3.2.3  Safety Analyses  ................................ ......................  89 
11. References  ................................ ................................ ................................ ...........  91 
12. Appendices  ................................ ................................ ................................ ...........  95 
12.1  Appendix 1.  List of Abbreviations and Definitions of Terms  ......................  96 
12.2  Appendix 2.  Clinical Laboratory Tests  ................................ ......................  99 
12.3  Appendix 3.  Study Governance Considerations  ................................ ..... 102 
Data Monitoring  Committees and Independent Review 
Committee  ................................ ................................ ...............  102 
Regulatory and Ethical Considerations  ................................ ....................  103 
Recruitment Procedures  ................................ ................................ ..........  103 
Informed Consent Process  ................................ ................................ ...... 104 
Data Protection/Subject Confidentiality  ................................ ...................  106 
Publication Policy  ................................ ................................ ....................  106 
Investigator Signatory Obligations  ................................ ...........................  107 
Data Quality Assurance  ................................ ................................ ...........  107 
Source Documents  ................................ ................................ ..................  109 
Study and Site Closure ................................ ................................ ............  110 
Compensation  ................................ ................................ .........................  110 
12.4  Appendix 4.  Safety Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up and Reporting  ................................ ..... 111 
Definition of Adverse Event  ................................ ................................ ..... 111 
Definition of Serious Adverse Event  ................................ ........................  112 
Recording Adverse Events and Serious Adverse  Events  ........................  113 
Evaluating Adverse Events and Serious Adverse Events  ........................  114 
Reporting of Serious Adverse Event  ................................ ........................  115 
12.5  Appendix 5.  Contraceptive Guidance and Collection of 
Pregnancy and Lactation Information  ................................ ......................  121 
12.5.1  Risks Associated With Pregnancy  ................................ ...........  121 
12.5.2  Counseling  ................................ ................................ ..............  121 
12.5.2.1  Female Subjects of Childbearing Potential  ............  121 
12.5.2.2  Female Subjects Not of Childbearing 
Potential  ................................ ................................  122 
12.5.2.3  Male Subjects:  ................................ .......................  122 
12.5.3  Definition of Females of Childbearing Potential  .......................  122 
12.5.4  Contraception Methods  ................................ ...........................  123 
12.5.4.1  Contraception Methods for Female 
Subjects  ................................ ................................  123 
12.5.4.2  Contraception Methods for Male Subjects  .............  124 
12.5.4.3  Unacceptable Methods of Birth Control for 
Male and Female Subjects  ................................ .... 125 

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 9 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.5.5  Pregnancy Testing ................................ ................................ ... 125 
12.5.5.1  Female Subjects  ................................ ...................  125 
12.5.5.2  Male Subjects:  ................................ .......................  126 
12.5.6  Additional Precautions  ................................ .............................  126 
12.5.7  Collection of Pregnancy Information  ................................ ........  126 
12.5.8  Collection of Lactation Information  ................................ ...........  128 
12.6  Appendix 6.  Sample Storage and Destruction  ................................ ........  131 
12.7  Appendix 7.  Hepatotoxicity Stopping Rules: Suggested Actions 
and Follow -up Assessments and S tudy Treatment Rechallenge 
Guidelines  ................................ ................................ ...............................  133 
12.8  Appendix 8.  Guidelines for Documenting Prior Treatment  ......................  134 
12.9  Appendix 9.  ECOG Performance Status  ................................ ................  135 
12.10  Appendix 10.  2018 ESH/ESC Office Blood Pressure 
Measurement  ................................ ................................ ..........................  136 
12.11  Appendix 11.  Summary of International Myeloma Working 
Group - Uniform Response Criteria  ................................ .........................  137 
12.12  Appendix 12.  Patient -reported Convenience With 
Carfilzomib -dosing Schedule Question  ................................ ....................  140 
 
List of Tables  
Table 2 -1.  Schedule of Activities  ................................ ................................ ...................  19 
Table 7 -1.  Dose Decrements for Carfilzomib  ................................ ................................  59 
Table 7 -2.  Dose Modification Guidelines for Thrombocytopenia and 
Neutropenia  ................................ ................................ ............................  60 
Table 7 -3.  Dose Modification Guidelines for Nonhematologic Toxicities  .......................  61 
Table 12 -1.  Analyte Listing  ................................ ................................ .........................  100 
List of Figures  
Figure 2 -1.  Study Schema  ................................ ................................ ............................  18 
Figure 12 -1.  Sample Electronic Serious Adverse Event Contingency Report 
Form  ................................ ................................ ................................ ..... 116 
Figure 12 -2.  Pregnancy and Lactation Notification Forms  ................................ ...........  129 
 

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 10 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
1. Protocol Synopsis  
Protocol Title:  A Randomized, Open -label, Phase 3 Study Comparing Once -weekly vs 
Twice -weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in 
Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)   
Short Protocol Title:  A Study Comparing Once -weekly vs Twice -weekly Carfilzomib in 
Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or 
Refractory Multiple Myeloma  
Study Phase:  3 
Indication:  relapsed or refractory multiple myeloma (RRMM)  
Rationale  
The ASPIRE study demonstrated the superiority of the combination of carfilzomib 
(Kyprolis) with lenalidomide and dexamethasone (KRd; 27  mg/m2 twice -weekly) over 
lenalidomide with dexamethasone (Rd).  Superiority of the KRd regimen was 
demonstrate d in terms of median progression -free survival (PFS) (26.3 vs 17.6  months, 
hazard ratio [HR]  = 0.69), overall response rate (ORR) ( 87.1% vs 66.7%, odds 
ratio [OR] = 3.47) (Stewart et al, 2015) , health -related quality -of-life (Stewart et al, 2016) , 
as well as overall survival (OS) (median OS:  48.3 vs 40.4  months, HR  = 0.79  
[Siegel  et al, 2018]) . 
Safety results from the final analysis were consistent with the known safety profile of 
carfilzomib, with no new safety signals observed after extended follow -up.  
Despite  the favorable benefit -risk profile of the KRd regimen, as demonstrated in the 
ASPIRE study, compliance with the currently available twice -weekly KRd dosing 
schedule may be less than optimal because of the convenience -related attributes of this 
regimen.    
The purpose of this study is to:  
 Compare efficacy of a once -weekly combination of KRd (56  mg/m2) with the on -label 
twice -weekly combination of KRd  (27 mg/m2)  
 Compare PFS, patient -reported convenience and other patient -reported outcomes,  
OS, and mi nimal residual disease (MRD) rate between the 2 regimens  
 Describe the safety profile of once -weekly KRd 56  mg/m2 and twice -weekly 
KRd 27 mg/m2 in subjects with RRMM with 1 to 3 prior lines of therapy.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 11 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Objectives/Endpoints   
Objectives  Endpoints  
Primary 
 compare efficacy of 
56 mg/m2 carfilzomib administered 
once -weekly in combination with 
lenalidomide and dexamethasone 
(KRd 56 mg/m2) to 
27 mg/m2 carfilzomib administered 
twice -weekly in combination with 
lenalidomide and dexamethasone 
(KRd 27 mg/m2) in subjects with 
relapsed or refractory multiple 
myeloma (RRMM) with 1 to 3 prior 
lines of therapy   overall response, defined as the best 
overall response of stringent complete 
response [sCR], complete response 
[CR], very good partial response 
[VGPR], and partial response [PR] per 
International Myeloma Working Group 
Uniform Response Criteria 
[IMWG -URC] over the duration of the 
study  
Key Secondary  
 compare progression -free survival 
(PFS) between treatment arms   PFS over the duration of the study  
 compare patient -reported 
convenience with carfilzomib -dosing 
schedule between treatment arms   convenience as measured by the 
Patient -reported Convenience With 
Carfilzomib -dosing Schedule Question 
after cycle 4 of treatment  
Secondary  
 describe safety and tolerability in 
treatment arms   incidence of treatment -emergent 
adverse events  
 compare additional efficacy 
parameters between treatment arms   time to response (TTR)  
 duration of response (DOR)  
 time to progression (TTP)  
 compare overall survival (OS) 
between treatment arms   OS over the duration of the study  
 compare rate of minimal residual 
disease negative (MRD[ -]) in bone 
marrow aspirates between treatment 
arms   MRD[ -]CR, defined as achievement of 
CR or better by Independent Revi ew 
Committee (IRC) per IMWG -URC and 
achievement of MRD negativity as 
assessed by next -generation 
sequencing method at a 10-5 
threshold over the duration of the 
study  
 MRD[ -] status at 12  months, defined 
as achievement of MRD negativity at 
12 months (±  4 weeks) from 
randomization, as assessed by 
next-generation sequencing method 
at a 10-5 threshold  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 12 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Objectives  Endpoints  
Secondary (continued)  
 compare patient -reported physical 
functioning and role functioning 
between treatment arms   physical functioning and role 
functioning over time as measured by 
the Physical Functioning and Role 
Functioning scales of the  European 
Organization for Research and 
Treatment of Cancer Quality -of-life 
Questionnaire Core 30 
(EORTC  QLQ -C30) over the duration 
of the study  
 compare patient -reported treatm ent 
satisfaction between treatment arms   treatment satisfaction as measured by 
the Satisfaction With Therapy (SWT) 
scale of the Cancer Therapy 
Satisfaction Questionnaire (CTSQ) 
after cycle  4 of treatment   
Hypotheses  
Once -weekly KRd 56  mg/m2 is non -inferior in terms of efficacy when compared with 
twice -weekly KRd 27  mg/m2.   
Overall Design  
This is a phase 3, multicenter, open -label, randomized study in subjects with RRMM  who 
have received 1 to 3 prior therapies.  T he study will consist of  a screening period of up to 
28 days, a treatment duration of up to 12 cycles of 28  days, and a 30 -day safety 
follow -up period.    
Subjects  will receive the study drug(s) determined by randomization for a maximum of 
12 cycles.  No crossover between the treatment arms is allowed.  After discontinuation 
of study drug(s) subjects will have a safety follow -up visit 30 (+3) days after the last dos e 
of all study drug(s).  After end of study, subjects may continue treatment per local 
standard of care at the discretion of the investigator.   
All subjects will be assessed for multiple myeloma disease response according to the 
International Myeloma Work ing Group -Uniform Response Criteria (IMWG -URC) 
(Section  12.11 ) every 28  ± 7 days from cycle 1 day 1 through the end of cycle 12 or 
disease progression  until death, loss to follow -up, withdrawal of full consent , or until first 
subsequent antimyeloma treatment  (whic hever occurs first), regardless of cycle duration, 
dose delays or treatment discontinuation.     
Subjects who end study drug(s) before completing 12  cycles without confirmed 
progressive disease (PD) are required to complete disease response assessments and  
report new antimyeloma treatment every 28  ± 7 days until 12 months after 
randomization, first subsequent antimyeloma treatment, death, loss to follow -up, 
withdrawal of full consent, or confirmed PD, whichever occurs first.  For applicable study 
subjects, long term follow -up will commence after the 30 -day safety follow -up visit.  All 
subjects with confirmed disease progression within 12  months of randomization will be 
followed for survival every 28  7 days until 12  months after randomization, death, loss 
to follow -up, or withdrawal of full consent, whichever comes first (Section 9.1.4 ).  For 
applicable study subjects, long -term follow -up will commence 28 days after the safety 
follow -up visit.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 13 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
The disease assessment schedule is independent of treatment schedules.   
Subjects will be randomized in a 1:1 ratio to 1 of 2 arms:  
 Arm 1:  KRd using once -weekly carfilzomib 56  mg/m2  
 Arm 2:  KRd using twice -weekly  carfilzomib 27  mg/m2  
Randomization will be performed using an interactive voice/web response system 
(IxRS) .  Subjects will be stratified based on the following criteria:  original (not revised) 
International Staging System (ISS) stage at the time of study entry (stage 1 or 2 vs stage 
3), prior lenalidomide treatment (yes vs no), prior proteasome inhibitor (PI) treatment 
(yes vs no), prior anti -CD38 exposure (yes vs no).   
All subjects  enrolled will have pharmacokinetic samples assessed.  Approximately 
15 subjects in each arm will be invited to participate in the intensive pharmacokinetics 
(PK)/pharmacodynamics (PDn) substudy at selected sites.  Sparse PK samples will be 
collected from the rest of the subjects, eg, subjects who do not consent to participate in 
the intensive PK/PDn substudy.  See Sections 9.2.5  and 9.2.6  for more details.  
An independent  data monitoring committee (DMC) will be convened for this study and 
will a ct in an advisory capacity to the sponsor with respect to safeguarding the interests 
of study subjects, assessing interim data, monitoring the overall conduct of the study, 
and providing with recommendations relating to continuing, modifying, or stopping t he 
study based on these findings (International Council for Harmonisation Good Clinical 
Practice [ICH GCP 5.5.2]).  Details of the DMC will be described in the DMC Charter.  
The initial assessment from this committee will be planned after 30  subjects 
(approximately 15 for the experimental arm and 15 for the control arm) have been 
enrolled and have finished the first cycle of treatment to ensure safety of all arms.  
A provision will be made allowing an early follow -up DMC meeting to be decided at the 
time of  the initial assessment.  The DMC will meet approximately every 6 months to 
review safety data on a regular basis, and once to review the efficacy data for futility.  
The interim analysis for futility is planned to occur when the first  230 subjects have be en 
randomized and had a best overall response (BOR) assessed by the date when 
treatment was completed, confirmed PD or death occurred, subject was lost to follow -up, 
withdrew consent, or started new therapy, whichever occurred first.   
The individual  subject disease response and disease progression for this study will be 
independently assessed by an Independent Review Committee (IRC) in accordance with 
the IMWG -URC (Section  12.11 ).  The membership criteria and operational details of the 
IRC will be described i n the IRC Charter.  The IRC will centrally review the disease -
related tests and assessments (Section  9.2.2 ) to evaluate disease progressions and 
responses without the knowledge of randomization assignments or Investigator’s 
disease assessments.  The IRC assessment will be used for the primary analysis of 
efficacy endpoints except for MRD rate and clinical outc ome assessments (COA) 
endpoints.    
Number of Subjects  
Approximately  460 subjects will be enrolled in the study, with approximately 230 subjects 
per each arm.   
Summary of Subject Eligibility Criteria  
This study will enroll adults ≥  18 years of age  with RRMM.  Subjects must have 
measurable disease per IMWG consensus criteria for response assessment in multiple 
myeloma, Eastern Cooperative Oncology Group Performance Status (ECOG  PS) of  2, 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 14 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
and at least partial response (PR) to at least 1 line of pri or therapy.  Subjects must also 
have received at least 1 but not more than 3 prior lines of therapy for multiple myeloma 
including relapse or progression after the most recent myeloma treatment  prior to 
enrollment .   
 
For a full list of eligibility criteria, please refer to Section  6.1 to Section  6.2. 
Treatments  
For both arms  
Each  subject’s first dose of carfilzomib will be calculated based upon baseline body 
surface area (BSA) using the Mosteller formula.  In subjects with BSA > 2.2  m2, the dose 
should be capped based on a BSA of 2.2 m2.  The dose for each subject should not be 
revised unless the subject has a change in body weight of > 20% (gain or loss) in which 
case the BSA should be recalculated.  Carfilzomib dose is to be recalculated using the 
updated BSA and applied until su ch time that any future weight change requires further 
BSA recalculation.  The dose can also be modified in response to toxicity following the 
dose modification guideline tables using the most current BSA if this has been 
recalculated since the first cycle  due to weight change.  
In subjects with normal renal function, lenalidomide  will be taken once -daily orally  on 
days 1 to 21  of each cycle at a dose of 25  mg.  In subjects with renal impairment (mild to 
moderate or severe), please refer to the regional pro duct label.   
Dexamethasone  should  be taken weekly orally or by intravenous (IV) infusion at a dose 
of 40  mg.  When dexamethasone is administered on the same day as carfilzomib, it 
should be started and completed within at least 4  hours of the start of car filzomib 
infusion.  A 30  minute interval between the end of the dexamethasone infusion and the 
start of the carfilzomib infusion  is recommended.   All doses should be administered on 
the scheduled days  2 days.   
Arm 1 (once -weekly KRd 56  mg/m2): 
Carfilzomib  will be administered once -weekly IV as a 30 ± 5 minute infusion using an 
infusion pump  on days 1, 8, and 15 of each 28 -day cycle.  The dose will be 20  mg/m2 on 
day 1 of the first cycle and 56  mg/m2 beginning with day 8 of cycle 1 and thereafter .  All 
carfilzomib doses should be administered on the scheduled day  2 days, and the day 8 
and 15 doses should have at least a 5 -day treatment -free interval.  Dose delays  > 2 
days are only permitted during the start of a new cycle (for more information s ee Section  
7.4.1 ). 
Arm 2 (twice -weekly KRd 27  mg/m2): 
Carfilzomib  will be administered twice -weekly IV as a 10 ± 5 minute infusion using an 
infusion pump  on days  1, 2, 8, 9, 15, and 16 of each 28 -day cycle.  The dose will be 
20 mg/m2 on days 1 and 2 of the first cycle and 27  mg/m2 beginning with day 8 of cycle 1 
and thereafter.   
Every effort  should be made to maintain the days  1, 2, 8, 9, 15, and 16 every  28-day 
schedule.  If this is not possible, then priority should be to maintain consecutive 
dosing  days.  For example, if  day 1 of a new cycle is started 2  days later than originally 
scheduled, the entire cycle should shift by 2  days, such that the new day s 1, 2, 8, 9, 15, 
and 16 of the next cycle are maintained.  There must always be at least 5 days between 
the second dose of 1  week and the first dose of the following week (ie, between days 2 
and 8, and days 9 and 15).  Mid -cycle doses that are missed shou ld not be made up, 
unless these parameters are maintained.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 15 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Procedures  
Written  informed consent must be obtained from all subjects or legally acceptable 
representatives before any study -specific screening procedures are performed.  The 
following procedu res will occur per the Schedule of Assessments:  demographics, 
medical history, substance use history, complete physical examination, physical 
measurements, 12 -lead electrocardiogram (ECG) with QTc interval, vital signs, ECOG 
PS, echocardiogram (ECHO), rev iew of adverse events and serious adverse events, 
recording of concomitant medications and antimyeloma therapies.  Imaging studies will 
be performed for bone lesions (all subjects) and soft tissue plasmacytoma evaluation (if 
clinically indicated).  Central  laboratory testing will be performed to confirm disease 
status and/or stage, including collection of bone marrow samples for minimal residual 
disease negative (MRD[ -]) testing, cytomorphology, fluorescence in situ hybridization 
(FISH), and for confirmatio n of CR or sCR.  Additional central laboratory testing will 
include hematology, serum chemistry, hepatic and renal function.  Eligibility labs are to 
be confirmed by central laboratory prior to enrollment.  Samples will also be taken to 
perform PK and PDn assessments.  Local laboratory testing will include coagulation 
factors, hepatitis B serology and hepatitis B virus (HBV) DNA testing, and pregnancy 
testing for females of childbearing potential.  Clinical outcome assessments will be 
measured using questio nnaires and individual questions.   
For a full list of study procedures, including the timing of each procedure, please refer to 
Section  9.2 and the Schedule of Activities in  Table 2 -1. 
Statistical Considerations  
The sample  size was determined so that the primary objective could be tested via 
synthesis method at 1 -sided 2.5% significance level with 80% power, including an 
interim analysis for futility when the first 230 subjects have been randomized and had a 
BOR asses sed by the date when treatment was completed, PD/death occurred, patient 
dropped out or started new therapy, whichever occurred first.  
A sample  size of 460 subjects is needed to achieve 80% power for demonstrating that 
once weekly - KRd 56  mg/m2 preserves a t least 60% of twice -weekly KRd 27  mg/m2 
effect in terms of ORR at a 1 -sided 2.5% significance level using the synthesis method.  
This calculation assumes a true relative risk (RR) of 1 with ORR = 86.6% for both arms 
(once weekly - KRd 56  mg/m2 vs twice -weekly KRd  27 mg/m2), and an interim analysis 
for futility at 50% information fraction using O’Brien -Fleming beta-spending function.  
The reference ORR = 86.6% was determined based on the BOR observed by the end of 
12 cycles of treatment in ASPIRE study (Amge n data on file).   
The hypotheses for the primary and key secondary objectives (ORR, PFS, and 
convenience after cycle 4 of treatment) will be tested using a fixed sequence hierarchical 
testing procedure to control the family -wise type I error rate at 1 -sided 0.025 level.  The 
testing is ordered as follows: non -inferiority of ORR, non -inferiority of PFS, and 
superiority of patient -reported convenience after cycle 4 of treatment.  Starting with the 
hypothesis of ORR, if any hypothesis in the sequence is rejec ted at a 1 -sided 
significance level of 0.025, then the subsequent hypothesis will be tested.  Otherwise, if 
any hypothesis failed to be rejected, then the subsequent hypotheses will not be tested.  
Primary /final analyses of efficacy endpoints will be based  on the intent -to-treat 
population, which includes all randomized subjects.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 16 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Endpoint  Statistical Analysis Methods  
Primary Overall response over the duration of the study:  Clopper -Pearson 
method for by treatment overall response rate  (ORR) estimate and 
CI.  Mantel -Haenszel  stratified RR for the inference of treatment 
effect.  
The synthesis approach will be used to show that once -weekly 
KRd 56 mg/m2 preserves at least 60% of twice -weekly KRd 
27 mg/m2 effect vs Rd.  
Secondary  PFS over the duration of the study : Kaplan -Meier (KM) estimates 
for PFS distribution by treatment and PFS rates and CI at 6 and 12 
months, stratified Cox proportional hazards (PH) model for HR and 
CI estimate.  The synthesis approach will be used to show that 
once -weekly KRd 56  mg/m2 preserves at least 50% of twice -weekly 
KRd 27 mg/m2 effect vs Rd.  
Patient -reported convenience after cycle 4 of treatment:  
Cochran -Mantel -Haenszel method will be used to evaluate the 
treatment effect (OR) for whether carfilzomib dosing is reported as 
conv enient or inconvenient; a logistic regression model including 
the randomization stratification factors and treatment group will be 
considered for sensitivity analysis  
Time to response: mean, SD, median, minimum and maximum 
among responders.  
Duration of re sponse (DOR): KM method among responders.  
Time to progression (TTP): KM method and stratified Cox PH 
model.  
OS over the duration of the study : KM estimates for OS distribution 
by treatment and OS rates and CI at 6 and 12 months, stratified 
Cox PH model fo r HR and CI estimate.  
MRD[ -]CR: proportion of MRD[ -]CR will be reported with CI 
calculated using Clopper -Pearson method.  
MRD[ -] status at 12 months from randomization: proportion of 
MRD[ -] will be reported with CI calculated using Clopper -Pearson 
method.  
Physical functioning and role functioning (EORTC  QLQ -C30) over 
time: repeated measures analysis of covariance adjusting for the 
baseline covariates.  A restricted maximum likelihood -based mixed 
model for repeated measures (MMRM) will be considered as 
sensi tivity analysis.  
Patient -reported treatment satisfaction (CTSQ) after cycle  4 of 
treatment: analysis of covariance at the corresponding fixed time 
point.  
Exploratory  Will be described in the statistical analysis plan finalized before 
database lock.  
Safety analyses will be based on the safety population (defined as all randomized 
subjects who have received at least 1 dose of any study treatment [carfilzomib, 
lenalidomide, or dexamethasone]).  The number and percentage of subjects 
experiencing 1 or more ad verse events will be summarized by treatment group, 
relationship to study treatment, and severity.  Changes from baseline and shift in toxicity 
grade in safety laboratory test results, left ventricular ejection fraction  and vital signs will 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 17 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
be summarized u sing descriptive statistics.  Adverse events and safety laboratory test 
results will be graded for severity using the National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI -CTCAE) Version 5.0.  
Subjects ’ demographics and disease char acteristics, in addition to prior and concomitant 
medications and study treatment exposure, will be summarized descriptively for each 
treatment group.   
For a full description of statistical analysis methods, please refer to Section  10. 
Sponsor Name : Amgen Inc.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 18 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
2. Study Schema and Schedule of Activities  
2.1 Study Schema  
Figure 2-1.  Study Schema  
Safety follow -up
C1D130 days after 
last dose of all 
study drug(s)Screening (up to 28 days)
Randomization 1:1
C12D1Twelve 28 -day cycles:
KRd56 once -weekly (N ~ 230)
K  (20/56 mg/m2 IV 30 min): days 1, 8, 15
Twelve 28 -day cycles:
KRd27 twice -weekly (N ~ 230)
K (20/27 mg/m2 IV 10 min): days 1, 2, 8, 9, 15, 16
C6D1
For both arms:
Lenalidomide (25 mg): days 1 -21; Dexamethasone (40 mg weekly; oral or IV)Open -label Treatment PeriodStratified by:
•ISS stage
•Prior lenalidomide
•Prior proteasome inhibitor
•Prior anti -CD38 exposure
LTFU/EOS
Up to 12 
months after 
randomization
 
CxDx = cycle X day X; d = dexamethasone; EOS = End of Study; IV = intravenously; K = Kyprolis (carfilzomib); LTFU = long -term follow -up; R = lenalidomide.  
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 19 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
2.2 Schedule of Activities  
Table 2-1.  Schedule of Activities  
PROCEDURE  Scree 
ninga  
(up to 
28 days 
before 
rand) Treatment Period  
Cycles 1 to 12  Safety FU  
(30 [+3]  
days after 
last dose)  LTFUb 
(every 28  
7 days) Notes Day 1 2 8 9 15 16 22 
GENERAL AND SAFETY A SSESSMENTS  
Informed consent  X           
Inclusion and exclusion criteria  X           
Demographics  X           
Medical history  X          Including multiple myeloma history  
Substance use  X          Tobacco only  
Complete physical examination  X        X   
Physical 
measurem
ents Height  X           
BSA X (X)         BSA should be calculated during screening per Mosteller 
formula and utilized to calculate required study drug doses.  
BSA should be recalculated if weight changes by more than 
20% (gain or loss) from weight used at the most recent BSA 
calculation . 
Weight  X X          
12-lead ECG with 
QTc interval
   X (X)   Screening and as clinically indicated.  
cycle 1     X       To be performed at the end of carfilzomib infusion  cycle 2    X         
Vital signs (once -weekly arm)  X X  X  X   X  Checked prior to administration of carfilzomib in all cycles.  In 
cycles 1 and 6, an additional blood pressure measurement 
post-carfilzomib infusion will be collected (within 30 minutes of 
the end of infusion).  Vital signs (twice -weekly arm)  X X X X X X X  X  
ECOG  performance status  X        X   
Echocardiogram  X (X)       
X  During treatment every 6 months (±  2 weeks)  from C1D1 until 
SFU and additionally  as clinically indicated.  An ECHO m ust 
be performed within 72  hours of the onset of a suspected  
cardiac failure event . 
Page 1 of 8  
Footnotes are defined on the last page of the table.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 20 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Table 2-1.  Schedule of Activities  
PROCEDURE  Scree 
ninga  
(up to 
28 days 
before 
rand) Treatment Period  
Cycles 1 to 12  Safety FU  
(30 [+3]  
days after 
last dose)  LTFUb 
(every 28  
7 days) Notes Day 1 2 8 9 15 16 22 
Survival           (X) Subjects who terminate early from study treatment (less than 
12 complete cycles) will be f ollowed every 28  ± 7 days after 
safety follow -up visit until 12 months after randomization, 
death, loss to follow -up or withdrawal of full consent, 
whichever comes first.  
Subsequent antimyeloma therapies           (X) All subjects who have ended study treatment without a 
confirmed PD will be f ollowed every 28 ± 7 days until 12 
months after randomization, first subsequent antimyeloma, 
death, loss to follow -up, withdrawal of full consent, or 
confirmed PD, whichever comes first.  
Adverse events/serious adverse eventsc Continuous    
Concomitant therapies review  Continuous    
LABORATORY ASSESSMEN TS 
Pregnancy 
test (FCBP 
only)  Serum  X        X  At screening: 10 to 14 days prior to C1D1  
Urine or serum cycle 1 
(predose)   X  X  X  X   
Within 24 hours prior to dose of lenalidomide.  Urine or serum cycle 2 to 
12 (predose; regular 
menses)   X         
Urine or serum cycle 2 to 
12 (irregular menses)   X    X     
Hematology  X X       
X  Hematology and chemistry samples from screening may be 
used for C1D1 if taken within 3  days prior to C1D1.  
Hematology and chemistry samples taken  within 48  hours of 
D1 of subsequent cycles may be used for treatment 
decisions.    Laboratory  results must be evaluated for 
potential dose modification assessment prior to dosing.  Chemistry  X X       
X  
Page 2 of 8  
Footnotes are defined on the last page of the table.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 21 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Table 2-1.  Schedule of Activities  
PROCEDURE  Scree 
ninga  
(up to 
28 days 
before 
rand) Treatment Period  
Cycles 1 to 12  Safety FU  
(30 [+3]  
days after 
last dose)  LTFUb 
(every 28  
7 days) Notes Day 1 2 8 9 15 16 22 
LABORATORY ASSESSMEN TS (CONTINUED)  
Screening laboratory assessments  X    Assessments must be done within 2 8 days prior to 
randomization  
See Table 12 -1 for more details.   
Coagulation tests  X     
2 microglobulin  X (X)   At screening and as clinically indicated.  
NT-proBNP  X    At screening.   
Quantitative immunoglobulins  X (X)   During screening, assessments must be done within 2 8 days 
prior to randomization.  
To be repeated only in case of clinical need, such as recurrent 
infections  
Hepatitis B virus  X (X) (X)  For subjects with unknown hepatitis serology status or who 
have not had hepatitis serology tested  within 6  months of 
screening: perform local serology testing for HBsAg, anti -HBs, 
and anti -HBc.   
Local testing f or HBV DNA will be performed for subjects with 
any of the following:  a known history of hepatitis B, positive 
serology, or who seroconvert to positive status during 
treatment .  HBV DNA testing will be repeated every 12  weeks  
( 2 weeks) or more frequently if clinically indicated through 
SFU.  An appropriate specialist should be consulted for all 
subjects who test positive.  
See Section  9.2.3.4.3   
Page 3 of 8  
Footnotes are defined on the last page of the table.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 22 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Table 2-1.  Schedule of Activities  
PROCEDURE  Scree 
ninga  
(up to 
28 days 
before 
rand)  Treatment Period  
Cycles 1 to 12  Safety FU  
(30 [+3]  
days after 
last dose)  LTFUb 
(every 28  
7 days)  Notes  Day 1 2 8 9 15 16 22 
DISEASE -SPECIFIC ASS ESSMENTS  
SPEP/UPEP/SFLC/SIFE/ UIFEd 
X (X) X (X) Screening disease -specific assessments must be done within 
28 day screening window  and repeated on C1D1 if not 
performed within 14 days (of C1D1) .  See Section  9.2.2.1 . 
 
Disease assessments at the safety follow -up visit and during 
LTFU are not required for subjects with confirmed PD or have 
started new antimyeloma therapy  or if assessments were 
performed within 14  days prior to the safety follow -up visit.  Serum calcium  
Bone lesion assessment  X (X)  
(X) A standard of care bone lesion radiographic assessment 
performed within 45 days of Cycle 1 Day 1 may be used as 
the Screening assessment, and does not need to be repeated, 
unless standard of care method of assessment is different 
from as specified above, i e, MRI bone lesion assessment 
would not be allowed to substitute for the Screening bone 
lesion assessment.  It will be repeated if worsening clinical 
symptoms suggest PD or as clinically indicated.  Not required 
during LTFU for subjects with confirmed PD.  
Plasmacytoma evaluation  (X) (X)  (X) Will be done at screening only if clinically suspected.  
Screening evaluation may be done within the 28  day 
screening window , if performed as a part of standard of care.   
For subjects with a history of plasmacytoma, c linical 
assessment will be performed locally every 28 (  7) days from 
C1D1.  Radiological exam will be performed only to confirm a 
response of PR or better, or to confirm PD, or as clinically 
indicated (see  
Section  9.2.2.4  for more detail)  
Not required during LTFU for subjects with confirmed PD.  
Page 4 of 8  
Footnotes are defined on the last page of the table.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 23 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Table 2-1.  Schedule of Activ ities 
PROCEDURE  Scree 
ninga  
(up to 
28 days 
before 
rand) Treatment Period  
Cycles 1 to 12  Safety FU  
(30 [+3]  
days after 
last dose)  LTFUb 
(every 28  
7 days) Notes Day 1 2 8 9 15 16 22 
DISEASE -SPECIFIC ASS ESSMENTS (CONTINUED)  
Bone 
marrow 
sample  For MRD [-] assessment  X (X)   Within the 28 -day screening window , at CR or better, and at 
12 months from randomization (±  4 weeks) for all subjects 
regardless of cycles.  A bone marrow aspirate is required for 
MRD analysis .  MRD sample is sent frozen (12-month 
sample may be omitted if an MRD analysis with confirmed 
results was performed within 4  months of the scheduled test 
at 12  months from randomization, or if the subject has started 
new anti -myeloma therapy prior to 12 -month landmark, or if 
disease progression is recorded) . 
Cytomorphology  X (X)  
(X) Screening, bone marrow aspirate slides for cytomorphology  
obtained be used as baseline if taken within 45 days prior to 
randomization and are sent to the central laboratory for 
processing (see Section  9.2.2.2 ). 
FISH analysis for 
cytogenetic risk  X    See Section  9.2.2.2 .  A bone marrow aspirate is required and 
will be taken no later than C1D1 predose (ie, during 28 -day 
screening period or C1D1). Note: DO NOT FREEZE the 
FISH sample tube.   
Immunohistochemisty t o 
confirm sCR   (X)  (X) When parameters suggest CR has been reached, collect a 
bone marrow sample: a biopsy or an aspirate clot to enable 
immunohistochemistry to assess sCR.  (At minimum a bone 
marrow aspirate is required for plasma ce ll% and MRD ).  
Page 5 of 8  
Footnotes are defined on the last page of the table.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 24 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Table 2-1.  Schedule of Activities  
PROCEDURE  Scree 
ninga  
(up to 
28 days 
before 
rand) Treatment Period  
Cycles 1 to 12  Safety FU  
(30 [+3]  
days after 
last dose)  LTFUb 
(every 28  
7 days) Notes Day 1 2 8 9 15 16 22 
SPARSE PHARMACOKINETIC ASSESSMENTS (ONLY FOR SUBJECTS NOT PARTICIPATING IN OPTIONAL INTENSIVE PK/PDN SUBSTUDY)  
Cycle 2 only   X          Predose (within 5 min before the start of infusion)  
 15 minutes after the start of infusion (± 5 min) for once -
weekly arm only  
 Immediately prior to (within 2 min before) the end of 
infusion  
 30 min after the end of infusion (±  5 min)  
INTENSIVE PHARMACOKINETIC ASSESSMENTS (ONLY FOR SUBJECTS IN OPTIONAL INTENSIVE PK/PDN SUBSTUDY)  
Cycle 1   X  X      
 Day 1 only:  
 Predose (within 5 min before the start of infusion)  
 Immediately prior to (within 2 min before) the end of 
infusion  
Day 8 only:  
 Predose (within 5 min before the start of infusion)  
 15 minutes after the start of infusion (± 5 min) for once -
weekly arm only 
 Immediately prior to (within 2 min before) the end of 
infusion  
 15 min, 60 min, and 2 hr after the end of infusion 
(± 5 min) 
Cycle 2   X  X        Predose (within 5 min before the start of infusion)  
 Immediately prior to (within 2 min before) the end of 
infusion  
 60 minutes after the end of infusion (± 5 min)  
Page 6 of 8  
Footnotes are defined on the last page of the table.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 25 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Table 2-1.  Schedule of Activities  
PROCEDURE  Scree 
ninga  
(up to 
28 days 
before 
rand) Treatment Period  
Cycles 1 to 12  Safety FU  
(30 [+3]  
days after 
last dose)  LTFUb 
(every 28  
7 days) Notes Day 1 2 8 9 15 16 22 
PHARMACODYNAMIC ASSESSMENTS (ONLY FOR SUBJECTS IN OPTIONAL INTENSIVE PK/PDN SUBSTUDY)  
Cycle 1   X  X       Day 1 only:  
 Predose (within 5 min before the start of infusion)  
Day 8 only:  
 Predose (within 5 min before the start of infusion)  
 60 minutes (± 5 min) after the end of infusion  
Cycle 2   X  X  X      Predose (within 5 min before the start of infusion)  
 60 min after the end of infusion (± 5 min)  
Cycle 3 to 7   X          Predose (within 5 min before the start of infusion)  
 60 min after the end of infusion (± 5 min)  
CLINICAL OUTCOME ASS ESSMENTS – TO BE COM PLETED PRIOR TO ANY STUDY P ROCEDURE  
EORTC QLQ -C30   (X)       X  
Before dosing on day 1 of cycle 1, 3, 5, 7, 9, and 12   
Patient -reported convenience with 
carfilzomib -dosing schedule  
single -item question   (X)       
X  Before dosing on C2D1, C5D1, and C12D1 for subjects still 
receiving carfilzomib . 
CTSQ   (X)       X  Before dosing on C2D1, C5D1, and C12D1.   
Page 7 of 8  
Footnotes are defined on the last page of the table.  

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 26 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Table 2-1.  Schedule of Activities  
PROCEDURE  Scree 
ninga  
(up to 
28 days 
before 
rand) Treatment Period  
Cycles 1 to 12  Safety FU  
(30 [+3]  
days after 
last dose)  LTFUb 
(every 28  
7 days) Notes Day 1 2 8 9 15 16 22 
STUDY TREATMENT ADMI NISTRATION  
Once-weekly arm  
Carfilzomib   X  X  X     Cycle 1: 20  mg/m2 on days 1; 56  mg/m2 on days 8, 15  
Cycles 2 -12: 56 mg/m2 each dosing day  
Dexamethasone   X  X  X  (X)   40 mg (oral or IV)  weekly.   Day 22 administration is for cycles 
1 to 9 only and may be self -administered at home  
IV prehydration   (X)  (X)  (X)     As clinically indicated (Section  7.1.1.3 ) 
Lenalidomide   Days 1 to 21   
 In subjects with normal renal function, lenalidomide will be 
taken once -daily on days 1 to 21 at a dose of 25  mg.  In 
subjects with renal impairment (mild to moderate or severe), 
please refer to the regional product label.  
Twice-weekly arm  
Carfilzomib   X X X X X X    Cycle 1: 20  mg/m2 on days 1 and 2; 27  mg/m2 on  
days 8, 9, 15, and 16  
Cycles 2 to 12: 27 mg/m2 each dosing day  
Dexamethasone   X  X  X  (X)   40 mg (oral or IV)  weekly .  Day 22 administration is for cycles 
1 to 9 only and may be self -administered at home  
IV prehydration   (X) (X) (X) (X) (X) (X)    As clinically indicated (Section  7.1.1.3 ) 
Lenalidomide   Days 1 to 21   
 In subjects with normal renal function, lenalidomide will be 
taken once -daily on days 1 to 21 at a dose of 25  mg.  In 
subjects with renal impairment (mild to moderate or severe), 
please refer to the regional product label.  
Page 8 of 8  
anti-HBc = hepatitis B core antibody; anti -HBs = hepatitis B surface antibody; BSA = body surface area; C = cycle; CR  = complete response; CTSQ = Cancer Therapy 
Satisfaction Questionnaire; CxDx = cycle X day X; D = day; ECOG = Eastern Cooperative Oncology Group; ECG = electrocardiogram; EORTC  = European 
Organization for Research and Treatment of Cancer; EORTC QLQ -C30 = EORTC Quality -of-life Questionnaire Core 30;
 FCBP  = females of childbearing potential; 
FISH  = fluorescence in -situ hybridization; FU = follow -up; IV = intravenously; HBsAg  = hepatitis B surface antigen; HBV  = hepatitis B virus; LTFU = long -term 
follow -up; MRD  [-] = minimal residual disease negative; NT-proBNP  = N terminal of the prohormone brain natriuretic peptide; PD  = progressive disease; 
PDn = pharmacodynamics; PK  = pharmacokinetics ; PR = partial response; rand = randomization; sCR = stringent complete response;
SFLC = serum -free light chain; SIFE = serum immunofixation; SOC = standard of care; SPEP  = serum  protein 
electrophoresis; UIFE  = urine immunofixation; UPEP  = urine protein electrophoresis  
 (X) = Parentheses indicate that the particular test is situational at that time point, as specified in the respective notes.  
a If the assessments are repeated duri ng screening, then the most recent result prior to randomization should be used to determine eligibility.  

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 27 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
b LTFU is up to 12  months after randomization.  
c If the investigator becomes aware of serious adverse events suspected to be related to IP or fatal serious adverse events (re gardless of causality) after completion of 
the protocol -required reporting period, then these serious adverse events will be report ed to Amgen within 24 hours following the investigator’s awareness of the 
event on the Events CRF.  Please refer to Section 9.2.3.1.1.3  for additional  details.  
d.Disease response assessments are to be performed every 28 ± 7 days from C1D1 through the end of C12 or until confirmed PD, wh ichever comes first, regardless of 
cycle duration, dose delays, or treatment discontinuation.  After discontinuation fr om study treatment, subjects who do not have confirmed PD are required to 
continue disease response assessments and report new antimyeloma treatment and will be followed every 28 ± 7 days until 12 months after randomization, first 
subsequent antimyeloma tr eatment, death, loss to follow -up, withdrawal of full consent, or confirmed PD , whichever comes first.    
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 28 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
3. Introduction  
3.1 Study Rationale  
Recently, the International Myeloma Working Group (IMWG) published 
recommendations on management of relapsed multiple myeloma and advocated a 
regimen containing carfilzomib (K),  preferably in combination with lenalidomide (R) and 
dexamethasone (d) (Laubach et al, 2016); such a regimen (27  mg/m2 KRd,  
twice -weekly) was approved for treatment of relapsed multiple myeloma based on the 
results of ASPIRE study (Stewart et al, 2015).   
ASPIRE was the first phase 3 randomized study demonstrating that a triplet combining 
non-conventional chemotherapy agents and carfilzomib had significant improvement in 
outcomes when compared with a doublet in patients who had received 1 to 3 prior lines 
of therapy and whose disease had not progressed during treatment with bortezomib or 
lenalidomide plus dexamethasone (if it was their most recent treatment).  In this study, 
the addition of carfilzomib to lenalidomide and dexamethasone reduced the risk of d eath 
or progression by 31% when compared with lenalidomide and dexamethasone alone 
(hazard ratio [HR]  = 0.69, p  < 0.0001) which translated into a median progression -free 
survival (PFS) of 26.3 months.  Further, KRd 27  mg/m2 twice -weekly was associated 
with a high overall response rate (ORR) of 87.1% (odds ratio [OR]  = 3.47; p < 0.0001) 
(Stewart  et al, 2015), increasing rapidly by end of cycle 4 of treatment, and 
demonstrated a statistically significant 8 -month improvement in median overall survival 
(OS) (HR  = 0.794; p = 0.0045) (Siegel et al, 2018) .  Also, the rate of complete or 
stringent complete response (CR/sCR) has a steep increase by end of 12 cycles of KRd 
27 mg/m2 twice -weekly (Dimopoulos et al, 2018).  These positive results were seen 
despite a less intensified carfilzomib dosing after 12 cycles of therapy and limiting 
carfilzomib treatment to the first 18  cycles of therapy.   
For the approved dose schedule of KRd , carfilzomib is administered intravenously (IV) 
on 2 consecutive days for 3 weeks (ie, days 1, 2, 8, 9, 15, and 16) of each 28 -day cycle.  
The frequency of dosing in this regimen demands a substantial time commitment and 
potential financial challenges for  patients and caregivers, as carfilzomib is generally 
administered in an outpatient clinic.  This time commitment can be particularly 
burdensome for patients with transportation or mobility challenges 
(Barrett -Lee et al, 2007).  As a result, compliance wit h the currently available twice -
weekly dose schedule for the KRd regimen may be less optimal and can reduce the 
ability to achieve deep responses and the longest possible survival.    
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 29 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
A more time -efficient once -weekly dosing schedule can help improve patie nt adherence 
to treatment with antimyeloma IV agents.   Two studies of once -weekly vs twice -weekly 
dosing schedules of bortezomib as combination therapy showed similar efficacy 
between the 2 regimens; however, patients with multiple myeloma treated once -weekly 
were more concordant, received higher doses, had fewer dose reductions, and were 
treated for longer durations compared with patients treated twice -weekly 
(Bringhen  et al, 2010; Reeder  et al, 2010).   These studies provide clinical evidence that 
a once -weekly schedule can result in improved dosing and longer duration of therapy 
when compared with a twice -weekly schedule, while preserving benefit to the patients 
and allowing for a schedule that is less burdensome.   
Exploring a KRd regimen aimed at improvi ng tolerability, treatment convenience, and 
patient satisfaction while preserving clinical benefit to the patients is expected to address 
the challenges patients may face with the on -label twice -weekly KRd 27  mg/m2 dose 
regimen and is an important consider ation for improving treatment outcomes.   
3.1.1 Justification for Primary Endpoint  
The ORR over the duration of the study is used as the primary endpoint to establish 
non-inferiority in terms of efficacy of a once -weekly KRd regimen (56  mg/m2) when 
compared wit h weekly KRd dose regimen with the on -label twice -weekly KRd 27  mg/m2 
dose regimen.  A positive correlation between ORR and PFS is supported by ASPIRE 
overall response and PFS rates ( Stewart et al, 2015), as well as  by the data from 
meta -analysis of 7 phas e 3 studies with different treatment regimens for this study 
population (Teng et al, 2018).   
In the pivotal ASPIRE study (the historical study for the non -inferiority analysis), the 
analysis of ORR was statistically significant and consistent with the tre atment effect 
observed in PFS (primary endpoint) and OS.  The ORR was 87.1% (95% CI: 83.4, 90.3) 
in the KRd arm versus 66.7% (95% CI: 61.8, 71.3) in the Rd arm (OR [95% CI]:  3.47 
[2.41, 5.00]; p < 0.0001) and corresponded with a 9 -month improvement in medi an PFS 
and an 8 -month improvement in OS.  The mean time to response (TTR) was 1.6 months 
in the KRd arm ( Siegel et al, 2018; Stewart et al, 2015) and the response rate increased 
rapidly by end of cycle 4 plateauing after that.  By the end of 12 cycles of t reatment in 
the ASPIRE study, the best ORR was 86.6% (Amgen data on file), with a CR/ sCR rate 
steeply increasing (Dimopoulos et al, 2018), and Kaplan -Meier event -free rate for PFS 
was 74.6% (HR = 0.55) (Amgen data on file)  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 30 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
In the supplementary appendix of  the e -publication, Stewart et al present a landmark 
analysis of PFS within the KRd group among patients who achieved partial response 
(PR) or better compared with patients who did not achieve a response of PR or better, 
providing evidence that the respond ers had significantly longer subsequent PFS than 
nonresponders (p  < 0.001).  The Simon -Makuch landmark transient -state method at the 
end of 2 months from randomization was used to minimize the bias in favor of 
responders represented by the time necessary t o reach the response (Simon and 
Makuch, 1984) .   
Results of an ongoing Study 20140241 (CFZ013) evaluating once -weekly dosing 
regimens of KRd (56  and 70  mg/m2) support the proposed ORR as a primary endpoint.  
After a median treatment time of 39 weeks, ORR w as 90% for subjects treated with 
56 mg/m2.  The combined dose cohort, including subjects that were treated with weekly 
doses of 56  and 70  mg/m2 (N = 56) reached an ORR of 89.3% after a median treatment 
time of 33 weeks (Amgen data on file).    
Additional su pportive evidence for the appropriateness of the primary endpoint ORR 
involves a model -based meta -analysis of 7 phase 3 studies in subjects with relapsed 
and refractory multiple myeloma (RRMM), which included ASPIRE and ENDEAVOR 
studies ( Teng et al, 2018) .  This meta -analysis assessed the relationship between ORR 
and PFS.  The results from these phase 3 studies showed that responses are attainable 
within the first 4 months of treatment and demonstrated a linear relationship between 
ORR and median PFS, with a strong correlation (R2 = 0.84) ( Teng  et al, 2018).  The 
selected studies encompass a broad representation of treatment regimens, with 
12 treatment arms used to evaluate the relationship of ORR and PFS. The median time 
to response (defined as achievement of PR or better) in this meta -analysis was  
4 months in 6 of the 7 studies with available information (Teng et al, 2018).   
These evidences indicate that ORR over duration of the study is an appropriated 
predictor of PFS and will be a suitable indicator o f efficacy to establish non -inferiority 
between once -weekly and twice -weekly KRd dose regimens.   
3.1.2 Justification for the Clinical Outcome Assessments Endpoints  
Treatment convenience and satisfaction are significant endpoints adding to the 
health -related qu ality-of-life (HRQOL) of RRMM patients (Moreau et al, 2011).  Results 
of the phase 3 A.R.R.O.W. study comparing once -weekly dosing of Kd (70  mg/m2) with 
twice -weekly Kd (27  mg/m2) demonstrated that subjects who were receiving 
once -weekly carfilzomib reported higher odds of convenience and satisfaction than 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 31 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
subjects receiving twice -weekly carfilzomib (Study 20140355).  However; this clinical 
outcome assessment (COA) was exploratory and was not corrected for multiplicity.  
Therefore, the same patient -reported convenience with carfilzomib -dosing schedule 
question will be used in this study as a secondary endpoint (corrected for multiplicity) to 
compare patient -reported convenience with carfilzomib -dosing schedule between 
treatment arms.   Response categories include ‘very convenient, convenient, 
inconvenient, and very inconvenient,’ and differ from the response categories to the 
question in ARROW, which also included ‘neutral’ as a response.    
3.2 Background  
3.2.1 Disease  
Multiple myeloma, a  clonal neoplastic proliferation of plasma cells, is the second most 
common hematologic malignancy and is responsible for approximately 80  000 annual 
deaths worldwide (1% of all cancer deaths).  The estimated incidence of multiple 
myeloma worldwide was 114  000 patients, which represents 0.8% of all cancers.  The 
5-year prevalence of multiple myeloma worldwide was estimated 229  000 persons 
(Ferlay  et al, 2015).  Multiple myeloma is a disease of older adults, with a median age at 
diagnosis of 69 years (Noone  et al, 2018).  As the world’s older population 
(age  65 years) continues to grow (from 8.5% [617 million] of the world’s population in 
2013 to a projected 17% [1.6 billion] in 2015) (He et al, 2016), the incidence of multiple 
myeloma is expected to increa se.   
3.2.2 Amgen Investigational Product Background :  Carfilzomib  
Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor (PI) that binds selectively 
and irreversibly to the 20S proteasome, the proteolytic core particle within the 26S 
proteasome.  Co nsequently, proteasome function after therapy can only be regained by 
de novo proteasome synthesis.  Specifically, carfilzomib inhibits the chymotrypsin -like 
catalytic activity of the β5 subunit over the caspase -like catalytic activity of the 
β1 subunit or  the trypsin -like catalytic activity of the β2 subunit, resulting in the 
accumulation of proteasome substrates and ultimately growth arrest and apoptosis  
(Hoy, 2016).  Carfilzomib extensively penetrates all tissues, but the brain.  It is 
metabolized large ly extra -hepatically and rapidly cleared from the circulation by biliary 
and renal excretion (t 1/2 = 15 to 30 minutes); <  1% is excreted intact 
(Kortuem  and Stewart,  2013).  
Carfilzomib entered clinical studies in September 2005.  On 20 July 2012, Kyprolis® 
(carfilzomib for injection) was granted accelerated approval by the US Food and Drug 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 32 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Administration (FDA) for the treatment of patients with multiple myeloma who have 
received at least 2 prior therapies, including bortezomib and an immunomodulatory 
agents  (IMiD), and have demonstrated disease progression on or within 60  days of 
completion of the last therapy.  The initial accelerated approval was based on the results 
of the phase 2 PX -171-003-A1 study in the United States.  Subsequent full approval in 
the United States and globally were based on 2 phase 3 studies: PX -171-009 ASPIRE 
and 2011 -003 ENDEAVOR.  Following these approvals, Kyprolis in combination with 
either lenalidomide and dexamethasone or dexamethasone alone is indicated for the 
treatment of RRM M.  The exact indication wording varies by region.  
As of 19 July 2018, an estimated 4132 subjects have been treated with carfilzomib in 
company -sponsored clinical studies since the beginning of the development program 
and approximately 88 964 patients have been exposed to carfilzomib in the 
postmarketing setting.   
A detailed description of the chemistry, pharmacology, efficacy, and safety of carfilzomib 
is provided in the Carfilzomib Investigator’s Brochure (IB).   
3.3 Benefit/Risk Assessmen t 
The following benefit -risk assessment supports the conduct of this clinical study .  
Reference should be made to the  Carfilzomib IB for further data on  carfilzomib . 
3.3.1 Therapeutic Context  
Relapsed or refractory multiple myeloma treatment has evolved rapidly in recent years.  
Progress has been made in autologous stem cell transplantation along with the 
introduction of several breakthrough drugs, including IMiD and PI, which led to a 
signific ant increase in response rate as well as survival rate (Kumar et al, 2012).  While 
treatment for multiple myeloma will typically induce remission, multiple myeloma is 
characterized by a recurring pattern of remission and relapse.  With each subsequent 
line of treatment, the duration and depth of response decreases (Cook et al, 2018) and 
patients eventually develop treatment resistance (Papadas and Asimakopoulos, 2017).  
It is not uncommon for patients to be treated with 3 or more lines of therapy.  
The goal  of treatment for RRMM is to achieve the longest PFS and subsequently OS.  
The depth of response is associated with OS and a critical factor to achieving that goal 
(Chanan -Khan and Giralt, 2010; Richardson et al, 2007).  Additional goals include: 
control d isease to prevent or delay associated complications (such as bone fractures, 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 33 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
renal insufficiency, and infections), to maintain an acceptable HRQOL, and to provide 
relief of pain and other disease -related symptoms.   
3.3.2 Key Benefits  
Triplet therapy combini ng a PI with an IMiD and steroid remains an important and 
commonly used option for many patients with RRMM .  The key benefits of carfilzomib as 
a triplet therapy for patients RRMM include:  increases in OS, PFS, and ORR; as well as 
improvements in quality -of-life. The evidence for these benefits is based on the pivotal, 
phase  3 randomized study (Study  PX-171-009 [hereafter referred to as ASPIRE], 
N = 792 subjects) and an ongoing open -label, multicenter, phase 1b dose -finding and 
dose evaluation study (NCT02 335983; Study CFZ 013, N  = 56).  
ASPIRE evaluated KRd 20/27 mg/m2 twice -weekly vs Rd for treatment of relapsed 
multiple myeloma: the addition of carfilzomib to lenalidomide and dexamethasone 
reduced the risk of death or progression by 31% when compared wit h lenalidomide and 
dexamethasone alone.  The median PFS with carfilzomib was 26.3 months compared 
with 17.6  months without carfilzomib (HR  = 0.69, 95% CI: 0.57, 0.83; p  < 0.0001).  
Further, KRd 27  mg/m2, twice -weekly was associated with a higher ORR of 87.1% vs 
66.7% in the control arm (OR  = 3.47; p < 0.0001) (Stewart et al, 2015) and improved OS 
by 8-month (median OS 48.3 vs 40.4 months; HR = 0.79; p = 0.0045) 
(Siegel  et al, 2018) .   
The ongoing Study CFZ013 evaluates once -weekly KRd in patients with RRMM and 
newly diagnosed multiple myeloma (NDMM).  As of data cut -off 22 February 2018, 
available efficacy results from 56 subjects with either RRMM or NDMM treated with 
weekly KRd 56  mg/m2 or KRd 70  mg/m2 has shown similar efficacy (as determined by 
ORR) with either KRd 56  mg/m2 or KRd 70  mg/m2 (90.0% versus 89.1%, respectively) to 
the effect previously reported for twice -weekly KRd (27  mg/m2) in the randomized 
phase  3 ASPIRE study (Biran et al, 2018).  These results complement the significant 
efficacy results of carfilzomib as a triplet therapy.   
The European Organization for Research and Treatment of Cancer Quality -of-life 
Questionnaire Core 30 (EORTC  QLQ -C30) instrument with a GHS/QOL subdomain was 
used to assess HRQOL as a secondary endpoint in ASPIRE.  Sub jects had higher  
QLQ -C30 global health status/quality of life (GHS/QOL) scores in the KRd group versus 
the Rd group over 18  cycles of treatment (overall treatment difference:  4.23, 95% CI:  
2.09, 6.37 [Stewart et al, 2016]), with a nominal 1 -sided p  = 0.0001.  Thus, in ASPIRE 
KRd improved overall health and quality -of-life compared with Rd, respectively.     
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 34 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
3.3.3 Key Risks  
Multiple important identified and potential risks for carfilzomib have been identified based 
on pooled safety data from completed studi es where carfilzomib was used in 
combination (with lenalidomide -dexamethasone, cyclophosphamide dexamethasone, 
melphalan prednisone, or carboplatin etoposide), with dexamethasone alone, or in 
monotherapy studies (n = 2944).  Dose modification instructions for the management of 
toxicities is provided in Section  7.4.   
Although the key identified risks (ie, cardiac failure, acute renal failure, and 
hypertension) are underlying comorbidities in patients with multiple myeloma 
(Kistler  et al, 2014; Christia nsen et al, 2011; Knauf et al, 2009), these risks were 
identified as key risks with carfilzomib based on a greater incidence and severity of 
adverse events in the carfilzomib treatment groups versus the comparators in the 
randomized clinical studies.  The combination of KRd has been studied in the 
randomized clinical study ASPIRE (A Randomized, Multicenter, Phase 3 Study 
Comparing Carfilzomib, Lenalidomide, and Dexamethasone [KRd] vs Lenalidomide and 
Dexamethasone [Rd] in Subjects with Relapsed Multiple Mye loma).  The information 
about the key risks from this study has been summarized below in Section 3.3.3.1 .  
Additional info rmation regarding important identified risks as well as adverse drug 
reactions for carfilzomib are detailed in the Carfilzomib IB.  
Embryo -fetal toxicity is associated with REVLIMID (lenalidomide) treatment.  
Investigators and subjects must comply with th e requirements of restricted distribution 
programs if one is present in the local region; (eg, REVLIMID Risk Evaluation and 
Mitigation Strategy [REMS] program in the United States).  Additional information 
regarding risks for lenalidomide are described in REVLIMID United States Prescribing 
Information (USPI) and REVLIMID Summary of Product Characteristics (SmPC) or local 
prescribing information.   
Warnings for dexamethasone include anaphylactoid reactions, cardio -renal toxicities, 
endocrine toxicities, infe ctions, and ophthalmic toxicities.  Dexamethasone is approved 
for the palliative treatment of neoplastic diseases.  Additional details regarding the risks 
of dexamethasone are provided in the prescribing information (Dexamethasone USPI, 
Dexamethasone SmPC) .  The risks of dexamethasone in this study are expected to be 
similar with the overall safety profile described in the labeling information.   
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 35 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
3.3.3.1 Risks 
3.3.3.1.1  Cardiac Toxicity  
New onset or worsening of pre -existing cardiac failure (eg, congestive heart failure, 
pulmonary edema, decreased ejection fraction), including fatalities, have occurred after 
administration of carfilzomib.  In clinical studies with carfilzomib, these event s occurred 
throughout the course of carfilzomib therapy.   
Incidence of cardiac failure events reported in ASPIRE was as follows: all grades: KRd: 
7.1%, Rd:  4.1%; serious adverse events: KRd: 4.1%, Rd: 2.1%; grade ≥ 3 adverse 
events : KRd: 4.3%, Rd: 2.1%.  Most of the cardiac failure adverse events (all grades) 
were resolved (KRd: 3.3%, Rd: 1.5%) or stabilized/not resolving (KRd:  2.6%, Rd: 1.5%) 
or resolved with sequelae (KRd: 0.5%, Rd:  0%).  Fatal outcomes were reported for 0.8% 
subjects from the KRd group and 1.0% from the Rd group.  Cardiac failure adverse 
events (all grades) leading to discontinuation of any investigational product were 
reported for 0.5% of subjects from the KRd group and 0.8% of subjects from the Rd 
group.   
Once -weekly carfilzomib has b een evaluated in A.R.R.O.W study (a randomized 
phase  3 study in 478 subjects with relapsed and refractory multiple myeloma receiving 
carfilzomib in combination with dexamethasone, comparing once -weekly versus 
twice -weekly carfilzomib dosing).  Incidence of  cardiac failure events reported in this 
study was as follows: all grades: Kd 20/70 mg/m2 once -weekly: 3.8%, Kd 20/27  mg/m2 
twice -weekly: 5.1%; serious adverse events: Kd 20/70 mg/m2 once -weekly: 3.4%, 
Kd 20/27  mg/m2 twice -weekly 3.4%; grade ≥ 3 adverse ev ents: Kd 20/70 mg/m2  
once -weekly: 2.9%, Kd  20/27  mg/m2 twice -weekly: 4.3%.  Adverse event outcomes were 
reported for serious adverse events only in A.R.R.O.W.  Almost all the cardiac failure 
serious adverse events were resolved (Kd 20/70  mg/m2 once -weekly: 2.9%, 
Kd 20/27  mg/m2 twice -weekly: 1.7%) or not resolved (Kd 20/70 mg/m2 once -weekly: 
0.4%, Kd 20/27  mg/m2 twice -weekly: 1.3%).  One fatal outcome was reported 
(Kd 20/70  mg/m2 once -weekly: 0%, Kd 20/27  mg/m2 twice -weekly: 0.4%).  Cardiac 
failure adverse events (all grades) leading to discontinuation of any investigational 
product were reported for 2.9% of subjects from the Kd 20/70 mg/m2 once -weekly group 
and 2.6% of subjects from the Kd 20/27  mg/m2 twice -weekly group.   
The risk of cardiac fa ilure is increased in elderly patients (≥ 75 years) and in Asian 
patients.  Subjects with New York Heart Association Class III and IV heart failure, recent 
myocardial infarction, and conduction abnormalities uncontrolled by medications were 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 36 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
not eligible fo r the clinical study and may be at greater risk for cardiac complications.  
While adequate hydration is required prior to dosing in cycle 1, all subjects should be 
monitored for evidence of volume overload, especially subjects at risk for cardiac failure.  
The total volume of fluids may be adjusted as clinically indicated in subjects with 
baseline cardiac failure or who are at risk for cardiac failure.   
3.3.3.1.2  Hypertension  
Hypertension has been reported as one of the common comorbidities in patients with 
multiple  myeloma.  Based on the MarketScan claims database, the prevalence of 
hypertension as a comorbidity among multiple myeloma patients is 46.9% 
(Song  et al, 2016 ) and there was a 30% increase in the risk of hypertension in multiple 
myeloma versus non -multiple  myeloma patients (Chari  et al, 2016).  The incidence of 
hypertension adverse events in ASPIRE was as follows: all grades: KRd: 17.1%, 
Rd: 8.7%, serious adverse events: KRd: 0%, Rd: 0.3%; grade ≥  3 adverse events: 
KRd:  6.4%, Rd: 2.3%.  The incidence of hyp ertension (all grades) was higher in subjects 
with a history of hypertension: with history of hypertension: KRd: 20.5%, Rd: 10.7%; 
without history of hypertension: KRd: 13.7%, Rd: 7.1%.  No fatal outcomes for 
hypertension adverse events (all grades) were r eported in ASPIRE.  Almost all the 
hypertension adverse events (all grades) were stabilized/not resolving (KRd: 8.7%; 
Rd: 4.4%) or resolved (KRd: 8.4%, Rd: 4.1%); resolved with sequelae was also reported 
(KRd: 0%, Rd: 0.3%).  Hypertension adverse events (a ll grades) led to discontinuation of 
any investigational product in 0.3% subjects from the KRd and Rd groups each.  
Hypertensive crisis occurred in ≤ 0.5% of subjects (KRd: 0.5%, Rd: 0.3%), all these 
adverse events were ≥  grade  3. 
The incidence of hyperten sion adverse events in A.R.R.O.W was as follows: all grades: 
Kd 20/70 mg/m2 once -weekly: 21.8%, Kd 20/27  mg/m2 twice -weekly: 21.3%, serious 
adverse events: Kd 20/70 mg/m2 once -weekly: 0%, Kd 20/27  mg/m2 twice -weekly: 0.4%; 
grade ≥  3 adverse events: Kd 20/7 0 mg/m2 once -weekly: 5.9%, Kd 20/27  mg/m2 
twice -weekly: 5.5%.  In A.R.R.O.W., the difference in incidence of hypertension (all 
grades) among subjects with or without a history of hypertension was similar between 
treatment groups (with history of hypertensi on: Kd 20/70  mg/m2 once -weekly: 22.2%, 
Kd 20/27  mg/m2 twice -weekly: 20.6%; subjects without history of hypertension: 
Kd 20/70  mg/m2 once -weekly: 21.6%, Kd 20/27  mg/m2 twice -weekly: 21.9%.  Adverse 
event outcomes were reported for serious adverse events onl y in A.R.R.O.W. The only 
hypertension serious adverse event was resolved (Kd 20/70  mg/m2 once -weekly: 0%, 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 37 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Kd 20/27 mg/m2 twice -weekly: 0.4%).  Hypertension adverse events (all grades) led to 
discontinuation of any  investigational product in 1.3% subjects f rom the Kd 20/70  mg/m2 
once -weekly and 0% from the Kd 20/27  mg/m2 twice -weekly group.  Hypertensive crisis 
occurred in ≤ 0.5% of subjects (Kd 20/70  mg/m2 once -weekly:  0%, Kd 20/27  mg/m2 
twice -weekly: 0.4%), all these adverse events were ≥  grade  3. 
Blood p ressure is monitored while on study and hypertension should be treated as 
needed.  If hypertension cannot be controlled, the carfilzomib dose should be held.  In 
case of hypertensive crisis, carfilzomib should be stopped until the hypertensive crisis 
resol ved.  The investigator may consider restarting carfilzomib based on an individual 
benefit -risk assessment.   
3.3.3.1.3  Acute Renal Failure  
Renal failure is a relatively common problem in patients with multiple myeloma 
(Dimopoulos et al,  2016; Blad é and Rosi ñol, 2005 ).  Acute renal failure occurs most 
often in patients with multiple myeloma who have high rates of production and excretion 
of immunoglobulin (Ig) -free light chains, which may be toxic to the basement membranes 
of the glomeruli and/or the renal tubules and  form obstructing tubular casts, particularly if 
the patient is dehydrated ( Dimopoulos et al, 2016; Sanders and Booker, 1992).  
Incidence of acute renal failure in ASPIRE was as follows: all grades: KRd: 9.2%, Rd: 
7.7%; serious adverse events: KRd: 2.6%, Rd : 1.8%; grade ≥ 3 adverse events: 
KRd:  3.8%, Rd: 3.3%.  Most of the acute renal failure adverse events (all grades) were 
resolved (KRd: 6.1%, Rd: 5.7%) or stabilized/not resolving (KRd: 2.8%, Rd: 1.8%) or 
resolved with sequelae (KRd: 0.3%, Rd: 0%).  No fat al outcomes were reported for the 
KRd group; in the Rd group, fatal outcomes were reported for 0.3% of the subjects.  
Acute renal failure adverse events (all grades) leading to discontinuation of any 
investigational product were reported for 0.5% subjects in the KRd group and 1.0% in 
the Rd group.      
The incidence of acute renal failure adverse events in A.R.R.O.W was as follows: all 
grades: Kd 20/70 mg/ m2 once -weekly: 7.1%, Kd 20/27  mg/m2 twice -weekly: 6.8%, 
serious adverse events: Kd 20/70 mg/m2 once -weekly: 4.6%, Kd 20/27  mg/m2 
twice -weekly:  5.1%; grade ≥  3 adverse events: Kd 20/70  mg/m2 once -weekly: 3.8%, 
Kd 20/27  mg/m2 twice -weekly: 5.5%. Adverse event outcomes were reported for serious 
adverse events only in A.R.R.O.W.  All of the acute rena l failure serious adverse events 
were resolved (Kd 20/70  mg/m2 once -weekly: 3.8%, Kd 20/27  mg/m2 twice -weekly:  
3.8%) or not resolved (Kd 20/70 mg/m2 once -weekly: 0.8%, Kd 20/27  mg/m2  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 38 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
twice -weekly: 1.3%).  None were reported as fatal or unknown in either treatment group.  
Acute renal failure adverse events (all grades) leading to discontinuation of any 
investigational product were reported for 2.1% subjects in the Kd 20/70  mg/m2 
once -weekly and Kd  20/27  mg/m2 twice -weekly groups, each.     
Acute renal fail ure was reported more frequently in patients with advanced RRMM who 
received carfilzomib monotherapy.  The incidence was increased in patients with a 
decrease in estimated creatinine clearance, calculated using Cockcroft and Gault 
equation, prior to receiv ing carfilzomib.  Renal function should be monitored with regular 
measurement of the serum creatinine and/or estimated creatinine clearance.  Reduce or 
stop dose as described in the dose modification Section  7.4.   
4. Objectives, Endpoints and Hypotheses  
4.1 Objectives and Endpoints  
 
Objectives  Endpoints  
Primary 
 compare efficacy of 
56 mg/m2 carfilzomib administered 
once -weekly in combination with 
lenalidomide and dexamethasone 
(KRd 56 mg/m2) to 
27 mg/m2 carfilzomib administered 
twice -weekly in combination with 
lenalidomide and dexamethasone 
(KRd 27 mg/m2) in subje cts with 
relapsed or refractory multiple 
myeloma (RRMM) with 1 to 3 prior 
lines of therapy   overall response, defined as the best 
overall response of stringent complete 
response [sCR], complete response 
[CR], very good partial response 
[VGPR], and partial r esponse [PR] per 
International Myeloma Working Group 
Uniform Response Criteria 
[IMWG -URC] over the duration of the 
study  
Key Secondary  
 compare progression -free survival 
(PFS) between treatment arms   PFS over the duration of the study  
 compare patient -reported 
convenience with carfilzomib -dosing 
schedule between treatment arms   convenience as measured by the 
Patient -reported Convenience With 
Carfilzomib -dosing Schedule Question 
after cycle 4 of treatment  
Secondary  
 describe safety and tolerability in 
treatment arms   incidence of treatment -emergent 
adverse events  
 compare additional efficacy 
parameters between treatment arms   time to response (TTR)  
 duration of response (DOR)  
 time to progression (TTP)  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 39 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Objectives  Endpoints  
 compare overall survival (OS) 
between treatment arms   OS over the duration of the study  
 compare rate of minimal residual 
disease negative (MRD[ -]) in bone 
marrow aspirates between treatment 
arms   MRD[ -]CR, defined as achievement of 
CR or better by Independent Revi ew 
Committee (IRC) per IMWG -URC and 
achievement of MRD negativity as 
assessed by next -generation 
sequencing method at a 10-5 
threshold over the duration of the 
study  
 MRD[ -] status at 12  months, defined 
as achievement of MRD negativity at 
12 months (±  4 weeks) from 
randomization, as assessed by 
next-generation sequencing method 
at a 10-5 threshold  
Secondary (continued)  
 compare patient -reported physical 
functioning and role functioning 
between treatment arms   physical functioning and role 
functioning over time as measured by 
the Physical Functioning and Role 
Functioning scales of the  European 
Organization for Research and 
Treatment of Cancer Quality -of-life 
Questionnaire Core 30 
(EORTC  QLQ -C30) over the duration 
of the study  
 compare patient -reported treatment 
satisfaction between treatment arms   treatment satisfaction as measured by 
the Satisfaction With Therapy (SWT) 
scale of the Cancer Therapy 
Satisfaction Questionnaire (CTSQ) 
after cycle  4 of treatment     
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 40 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Exploratory  
Objectives  Endpoints  

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 41 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Exploratory  
Objectives  Endpoints  
4.2 Hypotheses  
Once -weekly KRd 56  mg/m2 is non -inferior in terms of efficacy when compared with 
twice -weekly KRd 27  mg/m2.   
5. Study Design  
5.1 Overall Design  
This is a phase 3, multicenter, open -label, randomized study in subjects with RRMM  who 
have received 1 to 3 prior therapies.  T he study will consist of a screening period of up to 
28 days, a treatment duration of up to 12 cycles of 28  days, and a 30 -day safety 
follow -up period.    
Subjects will receive the study drug(s) determined by ra ndomization for a maximum of 
12 cycles.  No crossover between the treatment arms is allowed.  After discontinuation 
of study drug(s) subjects will have a safety follow -up visit 30 (+3) days after the last dose 
of all study drug(s).  After end of study, sub jects may continue treatment per local 
standard of care at the discretion of the investigator.   
All subjects will be assessed for multiple myeloma disease response according to the 
IMWG -URC (Section  12.11 ) every 28  ± 7 days from cycle 1 day 1 through the end of 
cycle 12 or disease progression  until death, loss to  follow -up, withdrawal of full , or until 
first subsequent antimyeloma treatment  consent (whichever occurs first), regardless of 
cycle duration, dose delays or treatment discontinuation.  
Subjects who end study drug(s) before completing 12  cycles without co nfirmed 
progressive disease (PD) are required to complete disease response assessments and 
report new antimyeloma treatment every 28 ± 7 days until 12 months after 
randomization,  first subsequent antimyeloma treatment, death, loss to follow -up, 
withdrawal of full consent, or confirmed PD, whichever comes first.  All subjects with 

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 42 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
confirmed disease progression within 12 months of randomization will be followed for 
survival every 28  7 days until 12  months after randomization, death, loss to follow -up, 
or wi thdrawal of full consent, whichever occurs first.  
The disease assessment schedule is independent of treatment schedules.   
Subjects will be randomized in a 1:1 ratio to 1 of 2 arms:  
 Arm 1:  KRd using once -weekly carfilzomib 56  mg/m2  
 Arm 2:  KRd using twic e-weekly carfilzomib 27  mg/m2  
Randomization will be performed using an interactive voice/web response system 
(IxRS) .  Subjects will be stratified based on the following criteria:  original (not revised) 
International Staging System (ISS) stage at the time of study entry (stage 1 or 2 vs stage 
3), prior lenalidomide treatment (yes vs no), prior PI treatment (yes vs no), prior 
anti-CD38 exposure (yes vs no).   
All subjects enrolled wi ll have pharmacokinetic samples assessed.  Approximately 
15 subjects in each arm will be invited to participate in the intensive pharmacokinetics 
(PK)/pharmacodynamics (PDn) substudy at selected sites.  Sparse PK samples will be 
collected from the rest of the subjects, eg, subjects who do not consent to participate in 
the intensive PK/PDn substudy.  See Sections 9.2.5  and 9.2.6  for more details.  
An independent data monitoring committee (DMC) will be convened for t his study and 
will act in an advisory capacity to the sponsor with respect to safeguarding the interests 
of study subjects, assessing interim data, monitoring the overall conduct of the study, 
and providing with recommendations relating to continuing, modi fying, or stopping the 
study based on these findings (International Council for Harmonisation Good Clinical 
Practice [ICH GCP 5.5.2]).  Details of the DMC will be described in the DMC Charter.  
The initial assessment from this committee will be planned aft er 30  subjects 
(approximately 15 for the experimental arm and 15 for the control arm) have been 
enrolled and have finished the first cycle of treatment to ensure safety of all arms.  
A provision will be made allowing an early follow -up DMC meeting to be de cided at the 
time of the initial assessment.  The DMC will meet approximately every 6 months to 
review safety data on a regular basis, and once to review the efficacy data for futility.  
The interim analysis for futility is planned to occur when the first  230 subjects have been 
randomized and had a best overall response (BOR) assessed by the date when 
treatment was completed, confirmed PD or death occurred, subject was lost to follow -up, 
withdrew full consent, or started new therapy, whichever occurred firs t.   
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 43 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
The individual subject disease response and disease progression for this study will be 
independently assessed by an Independent Review Committee (IRC) in accordance with 
the IMWG -URC (Section  12.11 ).  The membership criteria and operational details of the 
IRC will be described in the IRC Charter.  The IRC will centrally review the  
disease -related tests and assessments (Section  9.2.2 ) to evaluate disease progressions 
and responses without the knowledge of rand omization assignments or Investigator’s 
disease assessments.  The IRC assessment will be used for the primary analysis of 
efficacy endpoints except for MRD rate and COA endpoints.    
The overall study design is outlined in the study  schema in Section  2.1.  The endpoints 
are defined in Section  4.1. 
5.2 Number of Subjects  
Approximately 460 subjects will be enrolled in the study, with approximately 230 subjects 
per arm . 
Subjects in this clinical investigation shall be referred to as “subjects”.  For the sample 
size justification, see Section  10.1. 
5.2.1 Replacement of Subjects  
Subjects who are withdrawn or removed from treatment or the study will not be replaced . 
5.2.2 Number of Sites  
Approximately 100 investigative sites in North America, Europe, and Asia, including 
Japan  are planned for inclusion in the study.  Sites that do not enroll subjects within 
3 months  of site  initiation may be closed.  
5.3 End of Study  
5.3.1 End of Study Definition  
Primary Complet ion:  The primary completion date is defined as the date when the last 
subject across all sites is assessed or receives an intervention for the final collection of 
data for the primary endpoint(s), whether the study concluded as planned in the protocol 
or was terminated early.  
If the study concludes prior to the primary completion date originally planned in the 
protocol (ie, early termination of the study), then the primary completion will be the date 
when the last subject is assessed or receives an interve ntion for evaluation in the study 
(ie, last subject last visit).  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 44 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
End of Study:   The end of study date is defined as the date when the last subject 
across all sites is assessed or receives an intervention for evaluation in the study (ie, last 
subject last visit), following any additional parts in the study (eg, long -term follow -up), as 
applicable.     
5.3.2 Study Duration for Subjects  
The duration of screening is up to 28 days, and the duration of treatment for an 
individual subject is anticipated to be 12 cycles (or  approximately 12 months  from 
randomization),  followed by safety follow -up visit that occurs 30  (+3) days after the last 
dose of all study drug(s).  Following 12  cycles and the safety follow -up visit the study is 
completed for that subject.  
The total study duration for an individual subject is estimated to be approximately 
14 months.   If a subject experiences treatment delays requiring in excess of 14  months 
to complete all 12  cycles the investigator must contact the medical monitor to discuss in 
order to approve treatment continuation.  
5.4 Justification for Investigational Prod uct Dose  
The carfilzomib dose (56  mg/m2) in the once -weekly KRd arm is based on the objective 
to evaluate the benefit -risk profile of a weekly KRd dose regimen that will address the 
patient need for more convenient dosing schedule and to establish non -inferiority with 
the on -label twice -weekly KRd  27 mg/m2 dose regimen.  
Once -weekly carfilzomib has been evaluated in clinical studies at doses as high as 
88 mg/m2 and data have shown that weekly carfilzomib in combination with 
dexamethasone (Kd) can be used safely and effectively in patients with RRMM 
(Berenson et al, 2016).  
In the phase 1/2 CHAMPION1 study, the maximum tolerated dose of carfilzomib 
administered once -weekly with dexamethasone was 70  mg/m2 and an overall response 
rate of 77% was observed at t his dose (Berenson et al, 2016).  The randomized phase 3 
A.R.R.O.W. study demonstrated that treatment with carfilzomib (70  mg/m2) administered 
once -weekly with dexamethasone led to an improvement in PFS compared with 
carfilzomib (27  mg/m2) administered twice -weekly with dexamethasone (11.2 vs 
7.6 months; HR = 0.69; 95% CI, 0.54, 0.88) ( Mateos  et al, 2018 ).  
The safety experience from 56 subjects with RRMM with weekly KRd  56 mg/m2 (n = 10) 
or 70 mg/m2 (n= 46) in Study CFZ013 ([STUDY_ID_REMOVED]) has not identifi ed any safety 
concerns which would preclude the investigation of KRd 56 mg/m2 weekly in this study.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 45 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
The subject incidence of grade ≥  3 treatment -emergent adverse events was 70.0% in 
the KRd 56  mg/m2 group and 69.6% in the KRd 70  mg/m2 group.  Grade ≥  3 adverse 
events reported in more than 2 patients were thrombocytopenia (56  mg/m2, n = 2; 
70 mg/m2, n = 4), neutropenia (56  mg/m2, n = 1; 70  mg/m2, n = 4), anemia (56  mg/m2, 
n = 2; 70  mg/m2, n = 3), pneumonia (70  mg/m2, n = 4), decreased platelet count 
(56 mg/m2, n = 1; 70  mg/m2, n = 3), decreased neutrophil count (56  mg/m2, n = 2; 
70 mg/m2, n = 2), hypertension (56  mg/m2, n = 1; 70  mg/m2, n = 3), and 
hypophosphatemia (70 mg/m2, n = 4).  There were 3 deaths in the KRd 70  mg/m2 group 
(1 each due to cardiac arres t, cardiac disorder, and disease progression).  No deaths 
occurred in the KRd 56  mg/m2 group (Biran  et al, 2018).   The median weekly dose of 
carfilzomib was 53.2  mg/m2 for subjects administered 20/56 mg/m2 and 62.4  mg/m2 for 
subjects administered 20/70  mg/m2.  The median relative dose intensity of carfilzomib 
was 90.7 for subjects administered 20/56 mg/m2 and 88.2 for subjects administered 
20/70 mg/m2.  The median weekly dose and the relative dose intensity suggest that 
20/56 mg/m2 weekly dose was tolerable .     
Available efficacy results indicated similar efficacy (as determined by ORR) with either 
KRd 56  mg/m2 or KRd 70  mg/m2 (90.0% versus 89.1%, respectively) to the effect 
previously reported for twice -weekly KRd (27  mg/m2) in the randomized phase 3 
ASPIRE study (Biran et al, 2018).  In ASPIRE, KRd 27  mg/m2 was compared with Rd 
alone in a similar patient population proposed in this phase  3 study (Study  20180015).  
The carfilzomib arm proved superior at the first interim analysis for efficacy reducing the 
risk of progression or death by 31% (median PFS [KRd vs Rd]:  26.3  months vs 
17.6 months).  The ORR was 87.1% in the KRd versus 66.7% in the Rd arm.  The OS 
benefit seen at the final analysis was 8 months (median OS was 48.3 months for KRd 
arm vs 40.4 months for Rd arm; Siegel et al, 2018; Stewart  et al, 2015).  
Given these data, this phase 3 study will evaluate the 56  mg/m2 once -weekly dose 
schedule for carfilzomib in combination with lenalidomide and dexamethasone to 
establish non -inferiority to KRd 27  mg/m2 twice -weekly.   
5.5 Patient Input on Study Design  
No patient input was obtained for this study design .   
6. Study Population  
Investigators will be expected to maintain a screening log of all potential study 
candidates that includes limited information about the potential candidate (eg, date of 
screening).    
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 46 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Eligibility criteria will be evaluated during screening.  Eligibility labs are to be confirmed 
by central laboratory prior to enrollment.  
Before any study -specific activities/procedures, the appropriate written informed consent 
must be obtained (see Section  12.3). 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, will not be provided.  
6.1 Inclusion Criteria  
All screening laboratory assessments must done in accordance with Table 12 -1.  Local 
laboratory assessments may not be used in place of central labora tory assessments 
where required.  
Subjects are eligible to be included in the study only if all the following criteria apply:  
101 Subject has provided informed consent prior to initiation of any study -specific 
activities or procedures or subject’s legally accep table representative has 
provided informed consent prior to any study -specific activities/procedures being 
initiated when the subject has any kind of condition that, in the opinion of the 
Investigator, may compromise the ability of the subject to give writ ten informed 
consent.  
102 Males or females ≥ 18 years of age.  
103 Subject has multiple myeloma with documented relapse or progression after 
most recent myeloma treatment.  Subjects refractory to the most recent line of 
therapy are eligible, unless last treatment c ontained PI or lenalidomide and 
dexamethasone . 
 Refractory is defined as disease that is nonresponsive or progresses within 
60 days of last therapy  
104 Subjects must have at least PR to at least 1 line of prior therapy.  
105 Subjects must have received at least 1 but not more than 3 prior lines of therapy 
for multiple myeloma (induction therapy followed by stem cell transplant and 
consolidation maintenance therapy will be considered as 1 line of therapy).  See 
Section  12.8 for guidelines for documenting prior treatment.  
106 Prior therapy with a PI is allowed if the patient achieved at least a PR to most 
recent treatment with a PI, did not relapse within 60  days of discontinuation of th e 
PI and the PI was not removed due to toxicity.  A history of prior neuropathy is 
permitted if this was not grade 3, grade 4 or grade 2 with pain and if not resolved 
within the 14 days before enrollment, is less than o r equal to grade  2 without 
pain. 
107 Prior therapy with a lenalidomide and dexamethasone containing regimen is 
allowed if the patient achieved at least a PR to most recent treatment with 
lenalidomide and dexamethasone, did not progress within the first 3  months of 
initiating a lenalidomide and de xamethasone containing treatment or relapse 
within 60  days of discontinuation of lenalidomide and dexamethasone containing 
treatment and treatment was not discontinued due to toxicity.  A history of  prior 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 47 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
neuropathy is permitted if this was not grade 3, gr ade 4 or grade 2 with pain and 
if not resolved within the 14 days before enrollment, is less than or equal to 
grade  2 without pain.  Patients are permitted to have received single agent 
lenalidomide as maintenance therapy within 60  days of enrollment.  
108 Measurable disease with at least 1 of the following assessed within 2 8 days prior 
to randomization:  
 IgG multiple myeloma: serum monoclonal protein (M -protein) level ≥ 1.0 g/dL 
 IgA, IgD, IgE multiple myeloma: serum M -protein level ≥ 0.5 g/dL 
 urine M -protein  ≥ 200  mg per 24 hour s 
 in subjects without measurable serum or urine M -protein, serum -free light 
chain (SFLC) ≥ 100 mg/L (involved light chain) and an abnormal serum 
kappa lambda ratio  
109 Eastern Cooperative Oncology Group Performance Status (ECOG PS) of  2 
(see Section  12.9). 
6.2 Exclusion Criteria  
Subjects are excluded from the study if any of the following criteria apply:  
Disease -related 
201 Waldenström macroglobulinemia.  
202 Multiple myeloma of IgM subtype.  
203 POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal 
protein, and skin changes).  
204 Plasma cell leukemia (> 2.0 × 109/L circulating plasma cells by standard 
differential).   
205 Primary amyloidosis (patients with multiple myeloma with asymptomatic 
deposition of amyloid plaques found on biopsy would be eligible if all other 
criteria are met).  
206 Myelodysplastic syndrome.  
Other Medical Conditions  
207 History of other malignancy within the past 5 y ears, with the following exceptions:  
 Malignancy treated with curative intent and with no known active disease 
present for ≥  3 years before enrollment and felt to be at low risk for 
recurrence by the treating physician  
 Adequately treated non -melanoma skin cancer or lentigo maligna without 
evidence of disease  
 Adequately treated cervical carcinoma in situ without evidence of disease  
 Adequately treated breast ductal carcinoma in situ without evidence of 
disease  
 Prostatic intraepithelial neoplasia without evidence of prostate cancer  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 48 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 Adequately treated urot helial papillary noninvasive carcinoma or carcinoma in 
situ 
 Treated medullary or papillary thyroid cancer  
 Similar neoplastic conditions with an expectation of > 95% 5 -year 
disease -free survival  
208 Known HIV infection, hepatitis C infection (subjects with hepa titis C that achieve 
a sustained virologic response after antiviral therapy are allowed), or hepatitis B 
infection (subjects with hepatitis B surface antigen or core antibody that achieve 
sustained virologic response with antiviral therapy are permitted wi th a 
requirement for regular monitoring for reactivation for the duration of treatment on 
the study).    
209 Ongoing graft -vs-host disease.  
210 Acute active infection requiring systemic antibiotics, antifungal, antiviral (except 
antiviral therapy directed at hepati tis B) agents within 14 days prior to 
randomization.  
211 Known cirrhosis.  
212 Significant neuropathy (grades 3 to 4, or grade 2 with pain) within 14 days prior 
to randomization.  
213 Subjects with pleural effusions requiring thoracentesis or ascites requiring 
paracente sis within 14 days prior to randomization.  
Cardiopulmonary Conditions  
214 Uncontrolled hypertension, defined as a subject whose blood pressure is greater 
than or equal to  160 mmHg systolic or greater than or equal to  100 mmHg 
diastolic when taken in accordanc e with the European Society of 
Hypertension/European Society of Cardiology 2018 guidelines (Section 12.10 ; 
Williams et al, 2018).  
215 Active congestive heart failure (New York Heart Association Class III to IV), 
symptomatic ischemia, uncontrolled arrhythmias, screening ECG with corrected 
QT interval (QTc) of > 470 msec, pericardial disease, or myocardial infarction 
within 4 months prior to randomization.   
216 Intolerance to hydration due to pre -existing pulmonary or cardiac impairment.  
217 History of interstitial lung disease or ongoing interstitial lung dis ease.  
Prior/Concomitant Therapy  
218 Immunotherapy within 28 days prior to randomization.  
219 Monoclonal antibody therapy within 28 days prior to randomization.  
220 Chemotherapy with approved anticancer therapeutic within 28 days prior to 
randomization.  
221 Glucocorticoid therapy within 14 days prior to randomization that exceeds a 
cumulative dose of 160  mg of dexamethasone or equivalent dose of other 
corticosteroids.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 49 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
222 Focal radiation therapy within 7 days prior to randomization.  Radiation therapy to 
an extended field invol ving a significant volume of bone marrow within 2 8 days 
prior to randomization (ie, prior radiation must have been to < 30% of the bone 
marrow).  
223 Major surgery (except kyphoplasty) within 28 days prior to randomization.  
224 Autologous or allogeneic stem cell tr ansplant within 90 days prior to 
randomization.  
225 Contraindication or intolerance to lenalidomide, dexamethasone, or carfilzomib.  
226 Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize 
carfilzomib).  
227 Subject has known hypersensitiv ity to any of the products or components  to be 
administered during dosing, including hypersensitivity to antiviral drugs.  
Prior/Concurrent Clinical Study Experience  
228 Currently receiving treatment in another investigational device or drug study, or 
< 28 days  since ending treatment on another investigational device or drug 
study(ies).   
Organ Function Assessments  
229 Hepatic dysfunction within 2 8 days prior to randomization:  
 direct bilirubin  1.5x the upper limit of normal (ULN)  
 aspartate aminotransferas e (AST) or alanine aminotransferase (ALT) 
 2.5 x ULN  
230 Left ventricular ejection fraction < 40% assessed by transthoracic 
echocardiogram (ECHO).  
231 Absolute neutrophil count (ANC) < 1 x  109/L within 2 8 days prior to 
randomization.  Screening ANC should be independent of growth factor support 
for ≥ 1 week.  
232 Hemoglobin < 80  g/L within 2 8 days prior to randomization.  Use of erythropoietic 
stimulating factors and red blood cell (RBC) transfusions per instit utional 
guidelines is allowed; however, most recent RBC transfusion must not have been 
performed within 7 days prior to obtaining screening hemoglobin.  
233 Platelet count < 50 x 109/L (≤ 30 x 109/L if myeloma involvement in the bone 
marrow is >  50%) within 2 8 days prior to randomization.  Subjects should not 
have received platelet transfusions for at least 1 week prior to obtaining the 
screening platelet count.  
244 Calculated or measured creatinine clearance <  30 mL/min  (calculation must be 
based on the Cockcroft and Gault formula ) within 2 8 days prior to randomization.  
Other Exclusions  
235 Female subject is pregnant or breastfeeding or planning to become pregnant or 
breastfeed during treatment and for an additional 30 days after the last dose  of 
all study drug(s).  (F emales of childbearing potential should only be included in 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 50 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
the study after a confirmed menstrual period and a negative highly sensitive urine 
or serum pregnancy test).     
236 Female subjects of childbearing potential unwilling to use 2 methods of 
contracepti on (1 highly effective form of contraception and 1 additional effective 
contraceptive method) for at least 28 days before starting study drug(s), during 
treatment, during treatment interruptions, and for an additional 30 days after the 
last dose of all stu dy drug(s).  Refer to Section  12.5 for additional contraceptive 
information.  
237 Female subjects of childbearing potential with a positive pregnancy test 
assessed at screenin g (by a highly sensitive serum pregnancy test 10 to 14 days 
prior to first dose of study drugs).     
238 Male subjects with a female partner of childbearing potential who are unwilling to 
practice sexual abstinence (refrain from heterosexual intercourse) or use  a 
condom with spermicide during treatment and for an additional 90 days after the 
last dose of all  study drug(s), even if they have undergone a successful 
vasectomy.  Refer to Section  12.5 for additional contraceptive information.  
239 Male subjects with a pregnant partner who are unwilling to practice abstinence or 
use a condom with spermicide during treatment and for an additional 90 days 
after the last dose of all study drug(s).  
240 Male subjects unwilling to abstain from donating blood, semen, or sperm during 
treatment and for an additional 90 days after the last dose of all study drug(s).  
241 Females subjects unwilling to abstain from do nating blood during treatment and 
for an additional 90 days after the last dose of all study drug(s).  
242 Subject likely to not be available to complete all protocol -required study visits or 
procedures, and/or to comply with all required study assessments (inc luding 
COA) to the best of the subject and investigator’s knowledge.  
243 History or evidence of any other clinically significant disorder, condition or 
disease (with the exception of those outlined above) that, in the opinion of the 
investigator or Amgen physi cian, if consulted, would pose a risk to subject safety 
or interfere with the study evaluation, procedures or completion.   
6.3 Subject Enrollment  
Before subjects begin participation in any study -specific activities/procedures, Amgen 
requires a copy of the  site’s written institutional review board/independent ethics 
committee (IRB/IEC) approval of the protocol, informed consent form (ICF), and all other 
subject information and/or recruitment material, if applicable (see Section  12.3). 
The subject or the subject’s legally acceptable representative  must personally sign and 
date the IRB/IEC and Amgen approved informed consent before commencement of 
study -specific procedures.  
A subject is considered enrolled when the investigator decides that the subject has met 
all eligibility criteria.  The investigator is to document this decision and date in the 
subject’s medical record and in/on the enrollment electronic case report form (eC RF). 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 51 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Each subject who enters into the screening period for the study (defined as the point 
when the subject signs the informed consent) receives a unique subject identification 
number before any study -related activities/procedures are performed.  The subje ct 
identification number will be assigned via Interactive Voice/Web Response System 
(IxRS) .  This number will be used to identify the subject throughout the clinical study and 
must be used on all study documentation related to that subject.  
The subject ide ntification number must remain constant throughout the entire clinical 
study; it must not be changed after initial assignment, including if a subject is 
rescreened.  This number will not necessarily be the same as the randomization number 
assigned for the study.    
6.4 Screen Failures  
Screen failures are defined as subjects who consent to participate in the clinical study 
but are not subsequently enrolled in the study .  A minimal set of screen failure 
information will be collected that includes demographics,  screen failure details, eligibility 
criteria, and any serious adverse events.  If a serious adverse event is observed  from 
the time informed consent is signed up to the point of screen failure, then serious 
adverse events, medical history, and concomitant  medications will also be collected.   
Individuals who do not meet the criteria for participation in this study (screen failure) may 
be rescreened once.   Refer to  Section  9.1.1 .  
Subjects who experience a technical failure of central laboratory samples at screening 
(for example sample is lost or damaged in transit, or otherwise cannot be analyzed) will 
not be considered a screen failure. Central lab samples may be retested during 
screening in such cases, subject to the screening window not being exceeded.   
7. Treatments  
Study treatment is defined as any investigational product(s), non -investigational 
product(s), placebo, combination products, or medical device(s) intended to be 
administered to a study subject according to the study protocol.  
Note that in several countries, investigational product and non -investigational product 
are referred to as investigational medicinal product and non -investigational medicinal 
product, respectiv ely. 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 52 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
The Investigational Product Instruction Manual (IPIM), a document external to this 
protocol, contains detailed information regarding the storage, preparation, destruction, 
and administration of each treatment shown  below.  
7.1 Treatment Procedures  
7.1.1 Investigational Product: Carfilzomib  
7.1.1.1 Dosage Formulation  
Carfilzomib will be manufactured and packaged by Amgen and distributed using Amgen 
clinical study drug distribution procedures.  
Carfilzomib is supplied as a sterile, lyophilized, white to off -white powd er ready for 
reconstitution.  It is supplied for single use in 50  mL Type  1 glass vials containing 60  mg 
of carfilzomib drug product with an elastomeric stopper and flip -off lid.    
7.1.1.2 Dosage, Administration, and Schedule  
Hematology and chemistry samples will  be repeated within 3 days prior to cycle  1 day  1 
and reviewed by the investigator before first dose.  
Baseline laboratories for SPEP/UPEP/SIFE/UIFE/SFLC,  will also be collected and 
checked by the investigator or treating physician before treatment is administered on 
cycle 1 day 1 if the screening laboratory assessments were not performed within 14 
days of randomization.  
Both arms:  
Each subject’s first dose of carfilzomib will be calculated based upon baseline body 
surface area (BSA) using the Mosteller  formula.  In subjects with BSA > 2.2  m2, the dose 
should be capped based on a BSA of 2.2  m2.  The dose for each subject should not be 
revised unless the subject has a change in body weight of  > 20% (gain or loss)  in which 
case the BSA should be recalculat ed.  Carfilzomib dose is to be recalculated using the 
updated BSA and applied until such time that any future weight change requires further 
BSA recalculation.    The dose can also be modified in response to toxicity following the 
dose modification guidelin e tables using the most current BSA if this has been 
recalculated since the first cycle due to weight change .  
Carfilzomib will be administered as an IV infusion.  Mechanical infusion pumps are 
recommended, but gravity -dependent infusions are permitted if the infusion duration can 
be reliably maintained.   
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 53 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
The planned dose (mg/m2), quantity administered (mg), start date/time, stop date/time, 
reason for change in planned dose, reason for dose change/withheld, reason for dose 
delay, reason for dose interrupti on and package lot number of carfilzomib are to be 
recorded on each subject's eCRF.  
Arm 1 (once -weekly KRd 56  mg/m2): 
Carfilzomib will be administered once -weekly IV as a 30 ± 5 minute infusion using an 
infusion pump  on days 1, 8, and 15 of each 28 -day cyc le.  The dose will be 20  mg/m2 on 
day 1 of the first cycle and 56  mg/m2 beginning with day 8 of cycle 1 and thereafter.  All 
carfilzomib doses should be administered on the scheduled day  2 days, and the day 8 
and 15 doses should have at least a 5 -day tre atment -free interval.  Dose delays  > 2 
days are only permitted during the start of a new cycle.  
Arm 2 (twice -weekly KRd 27  mg/m2): 
Carfilzomib will be administered twice -weekly IV as a 10 minute ± 5 minute infusion 
using an infusion pump  on days  1, 2, 8, 9, 15, and 16 of each 28 -day cycle.  The dose 
will be 20  mg/m2 on days 1 and 2 of the first cycle and 27  mg/m2 beginning with day 8 of 
cycle 1 and thereafter.   
Every effort should be made to maintain the days 1, 2, 8, 9, 15, and 16  of 28-day 
schedule.  If this is not possible, then priority should be to maintain consecutive 
dosing  days.  For example, if  day 1 of a new cycle is started 2  days later than originally 
scheduled, the entire cycle should shift by 2  days, such that the new days 1, 2, 8, 9, 15, 
and 16 of the next cycle are maintained.  There must always be at least 5 days between 
the second dose of 1  week and the first dose of the following week (ie, between days 2 
and 8, and days 9 and 15).  Mid -cycle doses that are missed should not be made up 
unless these parameters are maintained.  
7.1.1.3 Intravenous Prehydration  
Subjects may receive IV prehydration (normal saline or other appropriate IV fluid) prior to 
each carfilzomib infusion during cycle 1.  Investigators must consider IV prehydrati on in 
subjects at high -risk for tumor lysis or renal toxicity.  All subjects must be monitored for 
fluid overload and hydration should be tailored to individual needs  
Thereafter, carfilzomib prehydration may only be administered if the subject’s condition  
and/or risk factors require it.  The total volume of prehydration and the indication will be 
recorded on the Concomitant Medications eCRF.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 54 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Carfilzomib infusion must occur at a facility capable of managing hypersensitivity 
reactions.   
7.1.1.4 Starting Dose in He patic Insufficiency  
For subjects with baseline chronic hepatic impairment (mild, moderate), reduce the 
starting and subsequent doses of carfilzomib by 25% (Brown et al, 2017):  
 for once -weekly arm: 15  mg/m2 day 1 of cycle 1 and 42  mg/m2 day 8 of cycle 1 and  
thereafter;  
 for twice -weekly arm: 15  mg/m2 day 1 and 2 of cycle 1 and 20  mg/m2 day 8 of cycle 1 
and thereafter.  
If hepatic function returns to normal, the dose may be re -escalated to 56  mg/m2 (for 
once -weekly arm) and 27  mg/m2 (for twice -weekly arm) afte r the first cycle.  For dose 
modification due to subsequent changes in hepatic function, refer to Section  7.4.1.1.2 . 
Mild and moderate hepatic dysfunction is defined as:  
 Mild:  1.0 x ULN < bilirubin ≤ 1.5 x ULN; or AST > ULN with bilirubin ≤  ULN 
 Moderate:  1.5 x ULN < bilirubin < 3 x ULN with any AST     
7.1.2 Non-investigational Products  
7.1.2.1 Dexamethasone:  Dosage, Administration, and Schedule  
Dexamethasone, a non -Amgen non -investigational product, will also be used in this 
study.  Dexamethasone should be taken weekly orally or by IV infusion at a dose of 
40 mg.  When d examethasone is administered on the same day as carfilzomib, it should 
be started and completed within  4 hours  of the start of carfilzomib infusion .  A 30  minute 
interval between the end of the dexamethasone infusion and the start of the carfilzomib 
infusion is recomme nded.   All doses should be administered on the scheduled days 
 2 days.  
The planned dose, quantity administered, start date/time, stop date/time, route, reason 
for dose change/withheld, reason for dose delay, reason for dose interruption are to be 
recorded  on each subject’s eCRF.   
7.1.2.2 Lenalidomide  
7.1.2.2.1  Prescribing Requirements  
Lenalidomide, a non -Amgen non -investigational product, will also be used in this study.   
Within the United States, lenalidomide should be administered in accordance with the 
REVLIMID REMS program of Celgene Corporation (http://www.revlimidrems.com/ .)  All 
physicians who prescribe lenalidomide for research subjects enrolled into this study, and 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 55 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
all research subjects enrolled on this study, must be registered in and comply with all 
requirements of the REVLIMID REMS program.   
Females of childbearing potential (FCBP) must agree to monitoring for pregnancy.  In 
addition, males and FCBP are subject to certain restrictions as detailed in Section  12.5 
while receiving lenalidomide.  
Outside the United States, all investigators and subjects must ad here to the 
requirements of the lenalidomide restricted distribution program in effect in their local 
country.   
7.1.2.2.2  Dosage, Administration, and Schedule  
In subjects with normal renal function, l enalidomide will be taken once -daily orally on 
days 1  to 21 of ea ch cycle at a dose of 25  mg.  In subjects with renal impairment (mild to 
moderate or severe), please refer to the regional product label.   Lenalidomide should be 
taken at home by the subject at about the same time each day.  Lenalidomide capsules 
should be  swallowed whole with water.  The capsules should not be opened, broken, or 
chewed.  If a planned dose is missed, it should be taken as soon as possible within the 
same calendar day and with a return to the regular schedule the following day.  If a 
planned  dose is missed for more than a calendar day, subjects should not make up 
doses, but should resume the dosing regimen as per schedule.  Dose modifications are 
permitted in response to toxicity following the dose modification guideline tables.  
The planned dose, quantity administered, start date, and reason for dose change are to 
be recorded on each subject’s eCRF.   
7.1.3 Medical Devices  
No investigational medical devices will be used.   
Other non -investigational medical devices may be used in t he conduct of this study as 
part of standard care.  
Non-investigational medical devices (eg, syringes, sterile needles), that are 
commercially available are not usually provided or reimbursed by Amgen (except, for 
example, if required by local regulation).  The investigator will be responsible for 
obtaining supplies of these devices.  
7.1.4 Other Protocol -required Therapies  
All other protocol -required therapies including , antiviral prophylaxis, thromboprophylaxis, 
tumor lysis prophylaxis, proton pump inhibitor, b isphosphonate therapy, and prophylaxis 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 56 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
for Pneumocystis jirovenci  pneumonia , that are commercially available are not provided 
or reimbursed by Amgen (except if required by local regulation).  The investigator will be 
responsible for obtaining supplies of t hese protocol -required therapies.  
7.1.4.1 Antiviral Prophylaxis  
An antiviral is a required concomitant medication for the duration of treatment with 
carfilzomib.  Acyclovir (eg,  400 mg orally 3  times a day, or 800  mg orally 2 times a day or 
per institutional stand ards), famcyclovir (eg, 125  mg orally given 3 days, twice a day or 
per institutional standards), or valacyclovir (eg, 500  mg orally, twice a day or per 
institutional standards), dose adjustments for renal function where appropriate, initiated 
within 1  week  of the first dose of carfilzomib and should continue for the duration of 
treatment with carfilzomib.  
7.1.4.2 Prophylaxis for Hepatitis B Reactivation  
Hepatitis B virus (HBV) reactivation prophylaxis should be considered for patients at risk 
(ie, patients tested positive on serology or had a prior history of HBV infection) as per 
institutional standards.  
7.1.4.3 Thromboprophylaxis  
It is strongly recommended that all subjects receive an anticoagulant (eg, low molecular 
weight heparin, direct oral anti -coagulant, warfarin, enteric -coated aspirin at standard 
prophylactic dose or other anticoagulant or antiplatelet medication).  Additional or 
secondary thromboprophyla xis medication is strongly recommended in subjects with 
elevated risk of thrombosis, based on an individual ben efit/risk assessment (Li et al, 
2017).  
7.1.4.4 Tumor Lysis Syndrome Prophylaxis  
An approved uric acid -lowering agent (eg, allopurinol) in subjects at high -risk for tumor 
lysis syndrome (TLS) due to high tumor burden may be prescribed at the investigator’s 
discreti on, according to the package insert.  
Subjects should be well hydrated to reduce the risk of TLS and decline in renal function; 
refer to the current Carfilzomib IB for safety guidance regarding TLS.  
7.1.4.5 Proton-pump Inhibitor  
Proton -pump inhibitor (omeprazole or  equivalent) is required while on dexamethasone.  
7.1.4.6 Bisphosphonate or Monoclonal Antibody Therapy  
Concomitant therapy should be administered to  all subjects with evidence of lytic 
destruction of bone or with osteopenia (Gralow et al; 2013; Terpos et al, 2013)  unless 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 57 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
contraindicated.   Commercially available therapies are preferred when available and 
should be used for subjects with osteolytic or osteopenic myelomatous bone disease 
according to the manufacturer’s recommendations, as described in the prescribing 
information.    
Subjects who are using bisphosphonate or monoclonal antibody therapy when they 
enter the study should continue the same treatment.  Subjects with evidence of lytic 
destruction of bone or with osteopenia who are not using a bisphosphonate or  
monoclonal antibody therapy at the time of randomization should start therapy as soon 
as possible during cycle 1 or 2 of treatment.  Investigators should not start 
bisphosphonate or monoclonal antibody therapy during the study, unless it has been 
agreed w ith the sponsor that there is no sign of disease progression.  
7.1.4.7 Prophylaxis for Pneumocystis Jirovenci   
Pneumocystis jirovenci  pneumonia prophylaxis should be considered, as per institutional 
guidelines while on dexamethasone.   
7.1.5 Other Treatment Procedures  
No other treatment procedures are required.     
7.1.6 Product Complaints  
A product complaint is any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of a drug , combination product, or device after it is released for distribution 
to market or clinic by either (1) Amgen or (2) distributors or partners for whom Amgen 
manufactures the material.  This includes all components distributed with the  drug, such 
as packaging drug containers, delivery systems, labeling, and inserts.  
This includes  any investigational products  provisioned and/or repackaged/modified by 
Amgen: carfilzomib .   
Any product complaint(s) associated with an investigational produc t(s) or  
non-investigational products(s)  supplied by Amgen are to be reported according to the 
instructions provided in the IPIM.  
7.1.7 Excluded Treatments, Medical Devices, and/or Procedures During 
Study Period  
7.1.7.1 Anticancer Therapeutic or Radiation  
Concurrent therapy with a marketed or investigational anticancer therapeutic or radiation 
to large marrow reserves for either a palliative or therapeutic intent is excluded.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 58 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
7.1.7.2 Corticosteroids  
Long -term corticosteroids for nonmalignant conditions (eg, asthma , inflammatory bowel 
disease) equivalent to a dexamethasone dose > 4.0  mg/day or prednisone >  20 mg/day 
are not permitted.  Corticosteroids given short -term (up to 2 weeks) for non -malignant 
conditions are permitted provided that the cumulative dose is les s than 40  mg per week 
dexamethasone equivalent.  Medical monitor should be contacted if short -term 
corticosteroid use is required > 2 weeks or at cumulative dose of more than 40  mg 
dexamethasone equivalent.  
7.1.7.3 Plasmapheresis  
Plasmapheresis is not permitted at  any time while the subject is receiving study 
treatment.  For subjects requiring plasmapheresis while on study treatment, every 
attempt should be made to document disease status by IMWG criteria first.  Study 
treatment must be discontinued.   
7.1.7.4 Myeloid Grow th Factors  
The prophylactic use of myeloid growth factors is prohibited, but they may be used for 
management of neutropenia in accordance with American Society of Clinical Oncology 
Guidelines (Smith  et al, 2015).  
7.2 Method of Treatment Assignment  
Subjects will be randomized in 1:1 allocation ratio to 1 of the 2 treatment arms in an 
open -label manner:  
 Arm 1:  KRd using once -weekly carfilzomib 56  mg/m2 (days 1, 8, 15; 30 minutes 
[ 5 minutes] IV) 
 Arm 2:  KRd using twice -weekly carfilzomib 27  mg/m2 (days 1, 2, 8, 9, 15, 16; 
10 minutes [ 5 minutes]  IV) 
The randomization will be performed  using an IxRS .  The randomization number will be 
provided  on the IxRS randomization confirmation document  and the randomization  date 
is to be documented in the subject ’s medical record and on the enrollment eCRF.  
The randomization will be stratified based on the following criteria:  
 original ISS stage at study entry  (stage 1 or 2 vs stage 3)  
 prior lenalidomide treatment (yes vs no)  
 prior PI treatment (yes vs no)  
 prior anti-CD38 exposure (yes vs no)   
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 59 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Subjects will receive the treatment determined by randomization for the duration of 
12 cycles or until treatment discontinuation for reasons outlined in Section  8.1.  No 
crossover between the treatment arms will be allowed.  
7.3 Blinding  
This is an open -label study; blinding procedures are not applicable .   
7.4 Dose Modification  
7.4.1 Dosage Adjustments, Delays, Rules for Withholding or Restarting, 
Permanent Discontinuation  
7.4.1.1 Amgen Investigational Product:  Carfilzomib  
Carfilzomib will be discontinued, temporarily delayed, or dosage  temporarily reduced, in 
the event of a treatment -related toxicity that, in the opinion of the investigator, warrants 
the discontinuation, temporary delay or dose reduction as indicated in Table 7 -2 and 
Table 7 -3. Dose reduction levels of carfilzomib for toxicity management of individual 
subjects are provided in  Table 7 -1.  Subjects that require a dose level reduction and 
tolerate the reduced dose for 1 full cycle may at the discretion of the treating physician 
increase the dose to a prior dose starting with  the next cycle except when the dose 
reduction is due to:  pulmonary hypertension, pulmonary toxicity, grade 3 or worse 
cardiac failure, and drug -induced hepatotoxicity.   
Table 7-1.  Dose Decrements for Carfilzomib  
Nominal Dose  
(mg/m2) Reduced Carfilzomib Doses (mg/m2) 
Dose -1 Dose -2 Dose -3 Dose -4 
20a, b 15 11 Discontinue  - 
27 20 15 11 Discontinue  
56  45  36  27 20 
 a If dose reduction of carfilzomib is required on cycle 1 day 1 or cycle 1 day 2, the investigator should 
contact the medical monitor to discuss the situation before any additional doses of carfilzomib are 
administered.  
b For subjects with baseline chronic hepatic impairment (mild, moderate), reduce the starting and 
subsequent doses of carfilzomib by 25% (ie, for once -weekly arm: 15  mg/m2 day 1 of cycle 1 and 
42 mg/m2 day 8 of cycle 1 and thereafter; for twice -weekly arm: 15  mg/m2 day 1 and 2 of cycle 1 and 
20 mg/m2 day 8 of cycle 1 and thereafter).  
The subject will be considered on protocol treatment while receiving carfilzomib or 
lenalidomide.  
If day 1 of a cycle is delayed, all subsequent doses within the cycle and also day 1 of 
subsequent cycles should b e adjusted accordingly to maintain the 28 -day cycle duration.  
However, if a within -cycle dose is delayed, then the dates of the subsequent within -cycle 
doses should not be adjusted.  For within -cycle doses, if administration does not 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 60 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
commence within the a llowable window of the scheduled administration date, then the 
dose will be considered a missed dose and this missed dose will not be made up .  
Administration may resume at the next planned dosing date.   
If a subject requires interruption of carfilzomib f or more than 6 consecutive weeks due to 
unresolved toxicities, the subject must be discontinued permanently from study 
treatment.  
If a subject requires interruption of carfilzomib for more than 6 weeks for reasons other 
than toxicity, medical monitor approval is required prior to resuming treatment.   The 
reason for dose change of carfilzomib  is to be recorded on each subject’s eCRF.  
7.4.1.1.1  Carfilzomib:  Guidelines for Hematologic Toxicity  
Guidelines for carfilzomib dose modification in the event of thrombocyt openia and 
neutropenia are summarized in Table 7 -2. 
Table 7-2.  Dose Modification Guidelines for Thrombocytopenia and Neutropenia  
Hematologic toxicity  Recommended Action  
Thrombocytopenia  
When platelets fall to 
< 30 x 109/L and for each 
subsequent drop to 
< 30 x 109/L If platelets 10 to 30 x 109/L 
without evidence of 
bleeding   hold  
 restart at previous dose 
when platelets >  30 x 109/L 
If evidence of bleeding or 
platelets < 10 x 109/L  hold  
 restart at 1  dose decrement 
when platelets >  30 x 109/L 
Neutropenia  
When ANC falls to 
< 0.75 x 109/L and for each 
subsequent drop to 
< 0.75 x 109/L  If ANC 0.5 to 0.75 x 109/L  continue at full dose  
If ANC < 0.5 x  109/L  hold dose  
 resume at 1 dose 
decrement when  
ANC ≥  0.5 x 109/L 
ANC = absolute neutrophil count.  
7.4.1.1.2  Carfilzomib:  Guidelines for Nonhematologic Toxicity  
Guidelines for dose modification in the event of nonhematologic toxicities are 
summarized in  Table 7 -3. 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 61 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Table 7-3.  Dose Modification Guidelines for Nonhematologic Toxicities  
Symptom/Sign/Investigation  Recommended Action  
Renal Dysfunctiona: 
CrCl ≥ 15 mL/min  Full dose  
CrCl < 15 mL/min (NCI -CTCAE 
grade  4) Hold dose and monitor renal function.  If attributable to 
carfilzomib, resume when renal function has recovered 
to within 25% of baseline; restart at  1 dose level 
reduction.  If not attributable to carfilzomib, dosing may 
be resumed at the discretion of the physician.  If dialysis 
required use the maximal dose of 20  mg/m2 and 
administer carfilzomib after dialysis.  
Chronic dialysis stable for 
≥ 30 days  Dose may be re -escalated up to full dose as clinically 
tolerated  
Hepatic Dysfunction and Related Investigations  
Mild to moderate liver dysfunction:  
defined as 2 consecutive values, 
at least 28  days apart, of:  
 (1) total bilirubin (> 33% direct) 
> 1x ULN  to < 3x ULN  
 OR 
 (2) an elevation of AST and/or 
ALT with normal bilirubin  25% dose reduction.  
Dose may be re -escalated if liver function tests return to 
normal and drug -induced hepatotoxicity is excluded.  
Grade 3 elevation in ALT and/or 
AST (> 5x ULN)  Hold carfilzomib until resolution to baseline.  
Monitor any abnormality weekly.  Resume carfilzomib 
with a 25% dose reduction if drug -induced hepatotoxicity 
is excluded.  
Grade 3 elevation in total bilirubin  Hold carfilzomib until resolution to baseline.  M onitor 
total bilirubin and direct bilirubin weekly.  
Upon resolution of total bilirubin to normal, resume 
carfilzomib dosing with a 25% dose reduction if 
drug-induced hepatotoxicity is excluded.  
Drug -induced hepatotoxicity 
(attributable to carfilzomib)  Discontinue carfilzomib  
Other Nonhematologic Toxicities  
Tumor lysis syndrome:  3 or more 
of the following:  
 increase in creatinine of ≥  50% 
 increase in uric acid, of ≥  50% 
 increase in phosphate of ≥  50% 
 increase in potassium of ≥  30% 
 decrease in calcium OR  
 increase in LDH of ≥  2-fold from 
baseline  Hold carfilzomib until all abnormalities in serum 
chemistries have resolved; resume at full dose.  
Page 1 of 3  
Footnotes defined on the last page of the table  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 62 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Table 7-3.  Dose Modification Guidelines for Nonhematologic Toxicities  
Symptom/Sign/Investigation  Recommended Action  
Congestive heart failure  Any subject with congestive heart failure, whether or 
not drug -related, must have the dose held until 
resolution or return to baseline.  Appropriate medical 
management should be initiated and continued as 
clinically indicated.  If no resolution after 4 weeks, 
carfilzomib w ill be permanently discontinued.  
< Grade 3  Once congestive heart failure resolves or returns to 
baseline, resume at full dose.  
 Grade 3  Once congestive heart failure resolves or returns to 
baseline, treatment may continue at 1 dose level 
reduction.   
Infection (grade 3 or 4)  Hold carfilzomib.  Once infection is controlled and 
the subject is without infection -related symptoms, 
and if ANC >  1.0 × 109/L, resume at full dose.   If 
ANC  < 1.0 × 109/L, follow hematologic toxicities 
dose reduction guidelines.   
Hepatitis B reactivation  Hold carfilzomib until infection is adequately 
controlled (see Section  9.2.3.4.3 ). 
Neuropathy (grade 2 with emergent 
pain, or grade 3)  Hold carfilzomib until resolved to ≤ grade 2 without 
pain; then resume at 1 dose decrement.  
Neuropathy (grade 4)  Permanently discontinue carfilzomib.  
Dyspnea (grade ≥ 2)  Hold carfilzomib until resolution to grade 1 or 
baseline, then resume at 1 dose decrement.  
Investigate cause and recor d findings.  If caused by 
another adverse event listed in this table, follow 
recommendations for that adverse event.  
Hypertension (SBP >  140 and/or DBP >  90, measured per Appendix 10  in Section 12.10 ) 
< grade 3  Continue at same dose and  initiate appropriate 
treatment to  control hypertension (see Section  12.10  
for guidance)  
Grade ≥  3 Hold carfilzomib until resolution to normal or 
baseline.  Initiate appropriate antihypertensive 
therapy prior to resuming carfilzomib at 1  dose 
decrement.  
Pulmonary toxicity:  
Non-infectious interstitial lung 
disease, acute respiratory failure, 
ARDS (≥  grade 3)  Hold carfilzomib until resolution to grade 1 or 
baseline and restart at 1  dose decrement.  
Pulmonary hypertension (grade ≥ 3)  Hold carfilzomib until resolution to grade 1 or 
baseline and restart at 1  dose decrement  
Posterior reversible encephalopathy 
syndrome:  
Headaches, altered mental status, 
seizures, visual loss, and hypertension  If PRES is suspected, hold carfilzomib.  Consider 
evaluation with neuroradiological imaging, 
specifically MRI, for onset of visual or neurological 
symptoms suggestive of PRES.  If PRES is 
confi rmed, permanently discontinue carfilzomib.  If 
the diagnosis of PRES is excluded, carfilzomib 
administration may resume at same dose, if clinically 
appropriate.   
Page  2 of 3  
Footnotes defined on the last page of the table  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 63 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Table 7-3.  Dose Modification Guidelines for Nonhematologic Toxicities  
Symptom/Sign/Investigation  Recommended Action  
Thrombotic microangiopathy:  
Fever, microangiopathic hemolytic 
anemia, renal failure, 
thrombocytopenia, neurological 
manifestations  If the diagnosis is suspected, hold carfilzomib and 
manage per standard of care including plasma 
exchange as clinically appropriate.  If  TMA is 
confirmed, permanently discontinue carfilzomib.  If 
the diagnosis is excluded, carfilzomib can be 
restarted  
Venous thrombosis (≥ grade 3)  Hold carfilzomib and adjust anticoagulation regimen; 
resume at full dose once anticoagulation has been 
optimized per treating investigator’s discretion.  
Any other drug -related nonhematologic 
toxicity ≥  grade  3b For carfilzomib attribution, hold dose.  Resume at 
1 dose decrement when toxicity has resolved to 
grade  1 or less or to baseline grade.   
Page 3 of  3 
ALT = alanine aminotransferase; ANC  = absolute neutrophil count; ARDS = acute respiratory distress 
syndrome ; AST =  aspartate aminotransferase; CrCl = creatinine clearance; DBP = diastolic blood 
pressure; LDH = lactate dehydrogenase; MRI  = magnetic reson ance imaging; NCI -CTCAE = National 
Cancer Institute -Common Terminology Criteria for Adverse Events; PRES  = Posterior Reversible 
Encephalopathy Syndrome; SBP = systolic blood pressure; TMA  = thrombotic microangiopathy; 
ULN = upper limit of normal.  
a For a r apid fall from baseline in CrCl or an absolute fall of ≥ 60 mL/min, contact the medical monitor.  
b In the event of a possible drug -related nonhematologic toxicity, the investigator should, to the best of 
his/her ability, assess its relationship to lenalido mide (R), carfilzomib (K), dexamethasone (d), or the 
combination of KRd to the extent possible.  If both carfilzomib and lenalidomide are considered likely to be 
involved, then recommended actions for both should be instituted.   
7.4.1.1.3  Conditions Not Requiring C arfilzomib Dose Reduction  
Carfilzomib do not need to be held in the following cases:  
 grade 3 nausea, vomiting, or diarrhea (that responds within 7 days to adequate 
treatment of antiemetics and/or antidiarrheal agents)  
 grade 3 dexamethasone -related hyperglycemia  
 isolated grade 3 -glutamyl transferase elevation  
 grade 3 fatigue (unless persisting for > 7 days)  
 alopecia  
7.4.1.2 Non-Amgen Non -Investigational Product:  Lenalidomide  
Lenalidomide may be discontinued, temporarily delayed, or dosage temporarily reduced, 
in the event of a treatment -related toxicity that, in the opinion of the investigator, 
warrants the discontinuation, temporary delay or dose reduction.   
Investigators ar e advised to consult the approved regional labeling for lenalidomide for 
additional details.   
The reason for dose change of lenalidomide  is to be recorded on each subject’s eCRF.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 64 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
7.4.1.3 Non-Amgen Non -Investigational Product:  Dexamethasone  
Dexamethasone may be d iscontinued, temporarily delayed, or dosage temporarily 
reduced, in the event of a treatment -related toxicity that, in the opinion of the 
investigator, warrants the discontinuation, temporary delay or dose reduction.   
Investigators are advised to consult the approved regional labeling for dexamethasone 
for additional details.   
The reason for dose change of dexamethasone  is to be recorded on each subject’s 
eCRF.   
7.5 Preparation/Handling/Storage/Accountability  
Guidance and information on preparation, handling, storage, accountability, destruction, 
or return of the investigational product and/or other protocol -required therapies  during 
the study are provided in the IPIM.  
7.6 Treatment Compliance  
Administration of  IV medicinal products will occur at the study center.  Oral medication 
may be dispensed for self -administration at home.  Subjects are to document all 
administered doses and missed doses in a medication diary for all study -required 
medication taken at hom e.   
7.7 Treatment of Overdose  
None of the investigational products in this study have specific antidotes.  Therapy for 
overdose involves monitoring and management of acute side effects until the subject is 
stable.  
7.8 Prior and Concomitant Treatment  
7.8.1 Prior Treatment  
Prior therapies for non -multiple myeloma conditions  that were being taken/used from 
30 days prior to signing of the informed consent form (ICF)  will be collected on the 
Concomitant Medications eCRF.   
Collect therapy name, indication, dose, unit , frequency, start date and stop date.  
Prior  therapies for multiple myeloma  must date back to the original diagnosis and will be 
collected on the Prior Multiple Myeloma Therapy eCRF.  For subjects who are being 
referred to the research site, critical refer ral information will constitute multiple myeloma 
information from source notes.  Prior lines of multiple myeloma treatment are defined as 
a planned course of therapy.  Therefore, during initial treatment, the induction ± 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 65 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
autologous stem cell transplant  ± consolidation and maintenance would be considered 
1 line of therapy (see Section  12.8 for additional guidance on lines of therapy).  
For prior antimyeloma therapies, collect transplant, best response, did subject 
relapse/progress on or after this regimen, date of relapse/progre ssion, drug name, 
reason for therapy, start date, stop date, reason medication was stopped.  
7.8.2 Concomitant Treatment  
Throughout the study, investigators may prescribe any concomitant medications or 
treatments deemed necessary to provide adequate supportive care except for those 
listed in Section  7.1.7 . 
Concomitant therapies are to be collected from informed consent  through the 30 days 
after the last dose of all study drug(s) . 
For all concomitant therapies, collect therapy name, indication, dose, unit, frequency, 
start date and stop date and record on Concomitant Medications eCRF.      
It is recommended to follow the Eighth Joint National Committee 2014 evidence -based 
guideline for the management of high blood pressure in adults (James et al, 
2014Section).  For elderly subjects, it is recommended to implement the 201 8 ESH and 
ESC guidelines  Section ( Williams et al, 2018 ).   
8. Discontinuation Criteria  
Subjects have the right to withdraw from investigational product and/or other 
protocol -required therapies, protocol procedures, or the study as a whole at any time 
and for any reason without prejudice to their future medical care by the physician or at 
the institution.  
The investiga tor and/or sponsor can decide to withdraw a subject(s) from investigational 
product, device, and/or other protocol -required therapies, protocol procedures, or the 
study as a whole at any time prior to study completion for the reasons listed in 
Sections  8.1, 8.2.1 , and 8.2.2 . 
8.1 Discontinuation of Study Treatment  
Subjects (or a legally acceptable representative) can decline to continue receiving 
investigational product and/or other protocol -required therapies or procedures at any 
time during the study but continue participation in the study.  If this occurs, the 
investigator is to discuss with the subject the appropriate processes for discontinuation 
from investigational product or other protocol -required therapies and must discuss with 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 66 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
the subject the possibilities for continuat ion of the Schedule of Activities (see Table 2 -1) 
including different options of follow -up (eg, in person, by phone/mail, through 
family /friends, in correspondence/communication with other treating physicians, from the 
review of medical records) and collection of data, including endpoints, adverse events, 
and must document this decision in the subject’s medical records.  Subjects who have 
discontinued investigational product and/or other protocol -required therapies or 
procedures should not be automatically removed from the study.  Whenever safe and 
feasible, it is imperative that subjects remain on study to ensure safety surveillance 
and/or  collection of outcome data.  
Subjects may be eligible for continued treatment with Amgen investigational product(s) 
and/or other protocol -required therapies by a separate protocol or as provided for by the 
local country’s regulatory mechanism, based on par ameters consistent with 
Section  12.3. 
Reasons for removal from protocol -required study drugs  or procedural assessments 
include any of the following:  
 Decision by Sponsor  
 Lost to follow -up 
 Death  
 Ineligibility determined  
 Protocol d eviation  
 Non-compliance  
 Adverse event  
 Subject request  
 Disease progression  
 Pregnancy  
8.2 Discontinuation From the Study  
Withdrawal of consent for a study means that the subject does not wish to receive 
further protocol -required therapies or procedures, and the subject does not wish to or is 
unable to continue further study participation.  Subject data up to withdrawal of consent 
will be included in the analysis of the study, and where permitted, publicly  available data 
can be included after withdrawal of consent.  The investigator is to discuss with the 
subject appropriate procedures for withdrawal from the study, and must document the 
subject’s decision to withdraw in the subject’s medical records.    
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 67 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
If a subject withdra ws from the study, he/she may request destruction of any samples 
taken and not tested, and the investigator must notify Amgen accordingly (see 
Section  12.6 for further details).  Refer to the Schedule of Activities ( Table 2 -1) for data 
to be collected at the time of study discontinuation and follow -up and for any further 
evaluations that need to be completed.  
8.2.1 Reasons for Removal From Washout, Run -in or Invasive Procedures  
Not applicable.   
8.2.2 Reasons for Removal From Study  
Reasons for removal of a subject from the study are:  
 Decision by sponsor  
 Withdrawal of consent from study  
 Death  
 Lost to follow -up  
8.3 Lost to Follow -up 
A subject will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled vi sits and is unable to be contacted by the study center.  
The following actions must be taken if a subject fails to return to the clinic for a required 
study visit:  
 The site must attempt to contact the subject and reschedule the missed visit as soon 
as poss ible and counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or is able to 
continue in the study.  
 In cases in which the subject is deemed lost to follow -up, the investigato r or 
designee must make every effort to regain contact with the subject (where possible, 
3 telephone calls and, if necessary, a certified letter to the subject’s last known 
mailing address or local equivalent methods).  These contact attempts are to be 
documented in the subject’s medical record.  
 If the subject continues to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up.  
 For subjects who are lost to follow -up, the investigator can search  publicly  available 
records (where permitted)  to ascertain survival status.  This ensures that the data 
set(s) produced as an outcome of the study is/are as comprehensive as possible.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 68 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9. Study Assessments and Procedures  
Study procedures and their time poi nts are summarized in the Schedule of Activities 
(see Table 2 -1).  
As protocol waivers or exemptions are not allowed if an enrolled subject is subsequently 
determined to be ineligible for the study, this must be discussed with the sponsor 
immediately upon  occurrence or awareness to determine if the subject is to continue or 
discontinue study treatment.  
Adherence to the study design requirements, including those specified in the Schedule 
of Activities, is essential and required for study conduct.  
9.1 General Study Periods  
9.1.1 Screening, Enrollment and/or Randomization  
Informed consent must be obtained before completing any screening procedure or 
discontinuation of standard therapy for any disallowed therapy.  After the subject has 
signed the ICF, the site will r egister the subject in the IxRS and screen the subject to 
assess eligibility for participation.  The screening window is up to 28 days from date of 
consent until randomization.  
All screening evaluations must be completed and reviewed to confirm that potent ial 
subjects meet all eligibility criteria.  The investigator will maintain a screening log to 
record details of all subjects screened and to confirm eligibility or record reasons for 
screening failure (see Section 6.4), as applicable.  
If a subject has not met all eligibility criteria at the end of the screening period, the 
subject will be registered as a screen fail.  Screen fail subjects may be eligible for 
rescreening 1  time.  
Rescreen subjects must first be registered as screen failures in IxRS and subsequently 
registered as rescreens.  Once the subject is reg istered as rescreened, a new 28-day 
screening window will begin.  Subjects will retain the same subject identification number 
assigned at the original screening.  If the rescreening period begins more than 28 days 
after the original signing of the ICF, all  screening procedures, including informed 
consent, must be repeated.  
9.1.2 Treatment Period  
Visits will occur per the Schedule of Activities ( Table 2 -1).  Subjects assessed as eligible 
for the study will be randomized to a treatment arm and must start study treatment within 
3 days of randomization.  The date of the first dose of protocol -required therapies  is 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 69 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
defined as day 1.  All subsequent doses and study visits will be scheduled based on the 
day 1 date (see Section  7.1.1.2  for additional details).  Protocol -required therapies  are to 
be administered last d uring each visit in which they are required, except for the ECGs 
required on cycle 1 day 8 and cycle 2 day 1 which should be  performed at the end of 
carfilzomib infusion.   
9.1.3 Safety Follow -up 
Upon permanent discontinuation from the study treatment for any reason (including 
subjects who complete 12 cycles of treatment), a safety follow -up visit will be performed 
approximately 30 (+3) days after  the last dose of all study drug(s) unless the subject is 
lost to follow -up, has withdrawn full consent, or has died .  Subjects who discontinue 
treatment due to confirmed PD are also to complete the safety follow -up visit.  
9.1.4 Long-term Follow -up 
After discontinuation from study treatment, subjects who do not have confirmed PD are 
required to continue follow -up every 28 ± 7 days for survival, disease response 
assessments and reporting of new antimyeloma treatment until 12  months after 
randomizati on, first subsequent antimyeloma treatment, death, loss to follow -up, 
withdrawal of full consent, or confirmed PD, whichever comes first.  For applicable study 
subjects, long -term follow -up will commence 28 days after the Safety Follow -up visit.  
All subjects with confirmed PD before 12  months from randomization will be followed for 
survival every 28  7 days until 12 months after randomization, death, loss to follow -up, 
or withdrawal of full consent, whichever comes first.  For applicable study su bjects, long 
term follow -up will commence 28 days after the Safety Follow -up visit. 
Disease response assessments and survival information will be collected as indicated in 
the Schedule of Activities ( Table 2-1). 
9.1.5 End of Study  
The end of study for each subject is the date they withdraw full consent from the study, 
completes the final safety follow -up visit (following 12 cycles of treatment)  or final 
long-term follow -up visit (whichever is later), or death.  This could be a safety follow -up 
visit 30 (+3) days after last dose of all study drug(s) or a final long -term follow -up 
response or survival assessment.   
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 70 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.2 Description of General Study A ssessments and Procedures  
The sections below provide a description of the individual study procedures for required 
time points.  
9.2.1 General Assessments   
9.2.1.1 Informed Consent  
All subjects or their legally authorized representative must sign and personally date the 
IRB/IEC approved ICF before any study -specific procedures are performed.  
9.2.1.2 Demographics  
Demographic data collection including sex, age, race, and ethnicity will be collected to 
study their possible association with subject safety and treatment e ffectiveness .  
Additionally, demographic data will be used to study the impact on biomarker variability 
and PK of the protocol -required therapies.  
9.2.1.3 Medical History  
The Investigator or designee will collect a complete medical and surgical history that 
started within 30 days prior to signing of the ICF.  In addition, medical history will include 
collecting information on the subject's significant medical conditions, prior surgeries, and 
neuropathy history, dating back to the original diagnosis.  Record al l findings on the 
medical history eCRF.  The current toxicity grade will be collected for each condition that 
has not resolved.   Cardiovascular risk factors, which include family history of 
cardiovascular disease and smoking history, will also be collecte d.   
In addition  to the medical history above, multiple myeloma history must date back to the 
original diagnosis.  For subjects who are being referred to the research site, critical 
referral information will constitute multiple myeloma information from sou rce notes.  Prior 
lines of multiple myeloma treatment are defined as a planned course of therapy.  
Therefore, during initial treatment, the induction ± autologous stem cell 
transplant  ± consolidation and maintenance would be considered 1  line of therapy (s ee 
Section  12.8 for additional guidance on lines of therapy).   
9.2.1.4 Physical Examination   
Physical examination will be performed as per standard of care.  Physical examination 
findings should be recorded on the appropriate eCRF (eg, medical history, event).  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 71 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.2.1.5 Physical Mea surements  
Height (in centimeters) should be measured without shoes.  Weight (in kilograms) should 
be measured without shoes.  
Body Surface Area should be calculated using the Mosteller Formula (Mosteller, 1987):   
BSA (m²) = ([Height(cm) × Weight(kg)]/36 00) ½ .  
9.2.1.6 Substance Abuse History  
Obtain a detailed history of prior and/or concurrent use of tobacco.  
9.2.1.7 Performance Status  
The subject’s performance status will be assessed using the ECOG PS (Section  12.9).   
9.2.2 Efficacy Assessments  
Disease assessments will be based on central laboratory data and local imaging 
obtained every 28  ± 7 days until confirmed PD (Section  9.2.2.5 ) irrespective of cycle 
duration including dose delays and treatment discontinuation.   
Disease response and progression assessments include: serum protein electrophoresis 
(SPEP), urine protein electrophoresis (UPEP), serum -free light chain (SF LC), serum and 
urine immunofixation (SIFE, UIFE, respectively) (Section  9.2.2.1 ), bone marrow sample 
evaluation (Section  9.2.2.2 ), serum calcium, bone lesion evaluation (Section  9.2.2.3 ) and 
plasmacytoma evaluation (Section  9.2.2.4 ). 
9.2.2.1 SPEP, UPEP, SFLC, SIFE, and UIFE  
Serum protein electrophoresis, UPEP, SIFE, UIFE, and SFLC will all be conducted at 
the central laboratory.  Samples will be collected every 28 ± 7 days (sta rting from cycle 1 
day 1) irrespective of cycle duration including dose delays and treatment discontinuation.  
Blood will be obtained for SFLC, SPEP, and SIFE.  Twenty -four-hour urine samples will 
be obtained for UPEP and UIFE.  A 24-hour urine sample obta ined as standard of care 
may be used as the screening assessment, if obtained within 24 -hours prior to signing 
consent and sent to central lab for analysis.   Results for SPEP, UPEP, or SFLC must be 
available at screening and before randomization.  Serum pr otein electrophoresis, UPEP, 
and SFLC will be repeated on cycle 1 day 1 (unless screening values are within 14  days 
of cycle 1 day 1).   
Post cycle 1 day 1, UPEP and UIFE will be collected every 28 days as part of every 
myeloma disease assessment , along wi th SPEP , SIFE , and SFLC, and submitted to the 
central laboratory for processing.     
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 72 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Subjects will be evaluated for disease response and progression according to the IMWG 
response criteria in  Section  12.11 .  Disease status categories include sCR, CR, VGPR, 
PR, SD, and PD.  Investigator evaluation of disease respon se is to be based solely on 
the central laboratory results, not on local laboratory results for laboratory -based 
parameters.  
The following confirmation assessments are required for all response categories (sCR, 
CR, VGPR, and PR; refer to definitions in Sec tion 12.11 ): 
 all response categories require 2 consecutive  assessments before initiation of any 
new therapy  
 all categories also require no known evidence of progression including new bone 
lesions if radiographic studies were performed   
 confirmation of CR or better requires bone marrow assessment (aspirate or biopsy 
per IMWG -URC guidelines ; sCR determination in this study requires a bone marrow 
biopsy or aspirate clot for immunohistochemistry)  
 extramedullary plasmacytoma evaluation (if present at screening)  
9.2.2.2 Bone Marrow Sample Evaluation Including FISH and MRD[ -]CR 
Assessment  
A baseline bone marrow aspirate sample will be collected during the 28 -day screening  
period , or prior to dosing at cycle 1 day 1 and used to confirm the diagnosis and quantify 
the percent (%) of myeloma cell involvement.  Where the screening  platelet count is 
< 50 x 109/L, the  site must allow sufficient time for the bone marrow sample to be 
processed and the percent (%) myeloma cell involvement reported before  
randomization.   
The priority order of testing of the baseline bone marrow aspirate  sample by the central 
laboratory, based on the volume and quality of sample obtained, will be  
 for tumor specific sequence identification for MRD measurement by next -generation 
sequencing (NGS)  
 cytomorphology analysis to confirm multiple myeloma diagnosis  and to quantify the 
percent of myeloma cells in bone marrow  
 fluorescent in situ hybridization (FISH).  
Sites should also follow this guidance when collecting sample from the subject:  i f the 
bone marrow aspirate sample taken at baseline and received  by the  central lab are 
found  to be of insufficient quantity or quality for testing at least 1 measure above, the site 
may be contacted to request provision of a suitable archival bone marrow aspirate or 
core sample to send to the central laboratory for analysis . 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 73 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
After screening, bone marrow samples are required at 2 subsequent time points : 
 to confirm a response of CR or better , bone marrow samples should be collected 
within 35  days of the second consecutive laboratory disease assessment which 
shows CR .  Samples t o be collected at CR confirmation are: 
 Cytomorphology to assess percent (%) plasma cells:  from a  bone marrow 
aspirate  
 MRD:  from a bone marrow aspirate, which should be frozen  
 Immunochemistry to confirm sCR:  a bone marrow biopsy (trephine)  or an 
aspirate clot  
 At 12 months (± 4 weeks) from randomization (fixed landmark analysis), a sample is 
required for MRD assessment unless MRD analysis was done within the past 
4 months, or if the subject has started new anti -myeloma therapy prior to 12 -month 
landmark, or disease progression is  recorded.   
9.2.2.3 Bone Lesion Assessment (Skeletal Survey, CT, or PET/CT)  
Skeletal survey will include lateral radiograph of the skull, anteroposterior and lateral 
views of the spine, and anteroposterior views of the pelvis, ribs, femora, and humeri.  
Low-dose whole body computed tomography or fluorodeoxyglucose -positron emission 
tomography/computed tomography (FDG -PET/CT) may be used in place of skeletal 
survey.  A standard of care bone lesion radiographic assessment performe d within 
45 days of Cycle 1 Day 1 may be used as the Screening assessment, and does not 
need to be repeated, unless standard of care method of assessment is different from as 
specified above, ie, MRI bone lesion assessment would not be allowed to substitut e for 
the Screening bone lesion assessment.  
It should be repeated if worsening clinical symptoms suggest PD or as clinically 
indicated.  The same method of assessment used at baseline will be used throughout 
the study.  These imaging studies will be read l ocally.   
9.2.2.4 Extramedullary Plasmacytoma  
Extramedullary plasmacytoma evaluation will be conducted at screening only if a lesion 
is suspected clinically.  The evaluation may be done within 28 day screening window , if 
performed as a part of standard of care.  I f a measurable extramedullary plasmacytoma 
is detected during screening, evaluation will be repeated during treatment to confirm a 
response of PR or better, or to confirm PD or as clinically indicated.  Clinical assessment 
of measurable sites of extramedul lary disease will be performed and evaluated locally 
every 28 (  7) days for subjects with a history of plasmacytoma or as clinically indicated 
during treatment for other subjects.  If assessment can only be performed radiologically, 
then evaluation of ext ramedullary plasmacytomas may be done every 12 weeks.  The 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 74 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
same technique, which may include clinical evaluation by palpation, ultrasound, CT 
scan, magnetic resonance imaging (MRI), or PET/CT should be employed for each 
measurement of plasmacytoma dimensio ns as clinically appropriate (refer to Section  
12.11 ).  Bidimensional lesion measurements must be performed and recorded in the 
designated eCRF.   
9.2.2.5 Progressive Disease Assessment  
Confirmation of PD requires 2 consecutive assessments made before the institution of 
any new therapy, as well as no known evidence of pr ogressive or new bone lesions if 
radiographic studies were performed.  Radiographic studies are not required to satisfy 
these response requirements.  Bone marrow, plasmacytoma, and skeletal survey 
assessments are not required to be confirmed by repeat test ing. 
Local laboratory evaluation will not be accepted.  The assessments outlined in 
Section  12.11  are required for PD.  Subjects will be considered to have PD if they meet 
the criteria for progression by a variable that was not considered measurable at 
baseline; however, for subjects who had a measurable serum or urine M -spike at 
baseline, progression cannot be defined by increases in SFLC alone  
(Kumar  et al, 2016 ). 
9.2.3 Safety Assessments  
Planned time points for all safety assessments are listed in the Schedule of Activities 
see (Table 2 -1). 
9.2.3.1 Adverse Events  
9.2.3.1.1  Time Period and Frequency for Collecting and Reporting Safety 
Event Information  
9.2.3.1.1.1  Adverse Events  
The adverse event grading scale to be used for this study will be the Common 
Terminology Criteria for Adverse Events (CTCAE)  and is described in Section  12.4. 
The investigator is responsible for ensuring that all adverse events observed by the 
investigator or reported by the subject that occur after signing of the ICF  through the 
30 (+3) days afte r the last dose of all study drug(s)  are reported using the Event eCRF.  
9.2.3.1.1.2  Serious Adverse Events  
The investigator is responsible for ensuring that all serious adverse events observed by 
the investigator or reported by the subject that occur after signing of the ICF  through 
30 (+3) days after the last dose of all study drug(s)  are reported using the Event eCRF.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 75 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
All serious adverse events will be collected, recorded and reported to the sponsor or 
designee within 24  hours, as indicated in Section  12.4.  The investigator will submit any 
updated serious adverse event data to the sponsor within 24  hours of it being available.  
The criteria for grade 4 in the CTCAE grading scale differs from the regulatory criteria for 
serious adverse events.  It is left to the investigator’s judgment to report these grade 4 
abnormalities as serious adverse events.  
9.2.3.1.1.3  Serious Adverse Events After the Pr otocol-required Reporting 
Period 
If the investigator becomes aware of serious adverse events suspected to be related to 
IP or fatal serious adverse events (regardless of causality) after completion of the 
protocol -required reporting period (as defined in S ection  9.2.3.1.1.2 ), then these serious 
adverse events will be reporte d to Amgen within 24 hours following the investigator’s 
awareness of the event on the Events CRF.    
After End of Study, there is no requirement to actively monitor study subjects after  the 
study has ended with regards to study subjects treated by the investigator.  However, if 
the investigator becomes aware of serious adverse events suspected to be related to 
investigational product , then these serious adverse events will be reported to  Amgen 
within 24 hours following the investigator’s awareness of the event.  
Serious adverse events reported outside of the protocol -required reporting period will be 
captured within the safety database as clinical trial cases and handled accordingly based 
on relations hip to investigational product.  
If further safety related data i s needed to fulfill any regulatory reporting requirements for 
a reportable event, then additional information may need to be collected from the 
subject’s records after the subject ends the study.  
The method of recording, evaluating, and assessing causality  of adverse events, and 
serious adverse events and the procedures for completing and transmitting serious 
adverse event reports are provided in Section 12.4. 
9.2.3.1.2  Method of Detecting Adverse Events and Serious Adverse Events  
Care will be taken not to introduce bias when detecting adverse events and/or serious 
adverse events.  Open -ended and non -leading verbal questioning of the subject is the 
preferred m ethod to inquire about adverse event  occurrence.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 76 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.2.3.1.3  Follow-up of Adverse Events and Serious Adverse Events  
After the initial adverse event/serious adverse event report, the investigator is required to 
proactively follow each subject at subsequent visits/contacts.  All adverse events and 
serious adverse events will be followed until resolution, stabilization, un til the event is 
otherwise explained, or the subject is lost to follow -up (as defined in Section  8.3).  
Further information on follow -up procedures is given in Section  12.4. 
All new information for previously reported serious adverse events must be sent to 
Amgen within 24 hours following knowledge of the new information.  If specifically 
requested, the investigator may need to provide additional follow -up information, such as 
discharge summaries, medical records, or extracts from the medical records.  
Information provided a bout the serious adverse event must be consistent with that 
recorded on the Event eCRF.  
9.2.3.1.4  Regulatory Reporting Requirements for Serious Adverse Events  
If subject is permanently withdrawn from protocol -required therapies because of a 
serious adverse event, th is information must be submitted to Amgen.  
Prompt notification by the investigator to the sponsor of serious adverse events is 
essential so that legal obligations and ethical responsibilities towards the safety of 
subjects and the safety of a study treatme nt under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study treatment under clinical 
investigation.  The sponsor will comply with c ountry -specific regulatory requirements 
relating to safety reporting to the regulatory authority, IRBs/IECs, and investigators.  
Individual safety reports must be prepared for suspected unexpected serious adverse 
reactions according to local regulatory requ irements and sponsor policy and forwarded 
to investigators as necessary.  
An investigator who receives an individual safety report describing a serious adverse 
event or other specific safety information (eg, summary or listing of serious adverse 
events) fro m the sponsor will file it along with the IB and will notify the IRB/IEC, if 
appropriate according to local requirements.  
9.2.3.1.5  Safety Monitoring Plan  
Subject safety will be routinely monitored as defined in Amgen’s safety surveillance and 
signal management proc ess.   
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 77 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.2.3.1.6  Pregnancy and Lactation  
Details of all pregnancies and/or lactation in female subjects and female partners of 
male subjects  will be collected after the start of study treatment and until 30 days (for 
female subjects) and 90  days (for female partners  of male subjects) after the last dose of 
all study drug(s) .   
If a pregnancy is reported, the investigator is to inform Amgen within 24 hours of learning 
of the pregnancy and/or lactation and is to follow the procedures outlined in 
Section  12.5.  Amgen Global Patient Safety will follow -up with the investigator regarding 
additional information that may be requested.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered serious adverse events.  
Further details regarding pregnancy and lactation are provided in Section  12.5. 
9.2.3.2 Vital Signs  
The following measurements must be performed: systolic/diastolic blood pressure, heart 
rate, respiratory rate, and t emperature.   
Subject must be in a supine position in a rested and calm state for at least 5 minutes 
before blood pressure assessments are conducted.  If the subject is unable to be in the 
supine position, the subject should be in most recumbent position a s possible.  The 
position selected for a subject should be the same that is used throughout the study and 
documented on the vital signs eCRF.  Take 3 blood pressure measurements spaced 1 to 
2 minutes apart and additional measurements if the first 2 are more than 10  mmHg apart 
for either systolic or diastolic blood pressure (see Section  12.10 ).   
The temperature location selected for a subject should be the same that is used 
throughout the study and documented on the vital signs eCRF.   
Additional Vital Sign Measurements  
In cycles 1 and 6, an add itional blood pressure measurement post -carfilzomib infusion 
will be collected (within 30 minutes of the end of infusion).  
Record all measurements on the vital signs eCRF.  For blood pressure, record the 
average blood pressure.   
9.2.3.3 Electrocardiograms (ECGs ) 
Subject must be in supine position in a rested and calm state for at least 5 minutes 
before ECG assessment is conducted.  If the subject is unable to be in the supine 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 78 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
position, the subject should be in most recumbent position as possible.  The ECG must  
include the following measurements: heart rate, QRS, QT, QTc, and PR intervals.  The 
principal investigator or (eg, designated site physician, central reader) will review all 
ECGs.  Once signed, the original ECG tracing will be retained with the subject's  source 
documents.  At the request of the sponsor, a copy of the original ECG will be made 
available to Amgen.   
Electrocardiograms will be required in all subjects at screening.  Electrocardiogram 
monitoring is required on cycle 1 day 8 and cycle 2 day 1 at the end of the carfilzomib 
infusion, and as clinically indicated.  
9.2.3.4 Other Safety  
9.2.3.4.1  Echocardiogram  
All subjects will have a baseline ECHO, including assessments of systolic and diastolic 
left ventricular function and right ventricular function.  Screening ECHO may be done 
within 30 days prior to randomization, if performed as a part of standard of care.   
Echocardiogram is to be repeated approximately every 6  months (±  2 weeks) from cycle 
1 day 1 until safety follow -up visit, and additionally, if clinically indicated.  An ECHO must 
be performed within 72 hours of the onset of a cardiac failure event.  
9.2.3.4.2  Pulmonary Function Tests (PFTs)  
Baseline and surveillance pulmonary function tests are may be performed if clinically 
indicated at the discretion of the investigator.  
9.2.3.4.3  Hepatitis B  
All hepatitis testing will be performed locally.  All subjects will be tested  at screening for 
hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti -HBs), and 
hepatitis B core antibody (anti -HBc), unless performed within 6  months of screening and 
there was no change in the subject’s risk factors within these 6  months. 
Subjects with no history of HBV infection that are negative for hepatitis serologies at 
screening should be followed as clinically indicated.  
Subjects with positive testing or who have a prior history of HBV infection should have 
consultation with a s pecialist in HBV and have HBV DNA testing and monitoring of HBV 
DNA every 12  weeks ( 2 weeks) or more frequently, if clinically indicated, through 
safety follow -up.  Subjects that have received hepatitis B vaccination with only anti -HBs 
positivity and no clinical signs of hepatitis do not require HBV DNA monitoring.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 79 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Any subject who becomes HBV DNA positive or develops reactivation of HBV will have 
study treatment interrupted and receive appropriate antiviral treatment as per a specialist 
in hepatitis B.  R esumption of clinical study therapy may be considered in subjects 
whose HBV reactivation is controlled and where the benefits of clinical study therapy 
outweigh the risks.  After cessation of study therapy for any reason, any ongoing 
monitoring and antivir al treatment should be under the guidance of a specialist in HBV.  
9.2.4 Clinical Laboratory Assessments  
Refer to Section  12.2 for the list of clinical laboratory tests to be performed and to the 
Schedule of Activities ( Table 2 -1) for the timing and frequency.  
The investigator is responsible for reviewing laboratory test results and recording any 
clinically relevant changes occurring during the study in the Event eCRF.  The 
investigator must determine whether an abnormal value in an individual study subject 
represents a clinically significant change from the subject’s baseline values.  In general, 
abnormal laboratory findings without clinical significance (based on the investigator's 
judgment) are not to be recorded as adverse events.  However, laboratory value 
changes that require treatment or adjustment in current therapy are considered adverse 
event s.  Where applicable, clinical sequelae (not the laboratory abnormality) are to be 
recorded as the adverse event.  
All protocol -required laboratory assessments, as defined in Section  12.2, must be 
conducted in accordance with the laboratory manual and the Schedule of Activities 
(Table 2 -1).   
9.2.4.1 Pregnancy Testing  
A serum pregnancy test must be completed at screening (10 to 14 days prior to cycle 1 
day 1).   A serum or urine pregnancy test must be completed within 24 hours of initiation 
of lenalidomide for FCBP.  Additional pregnancy testing must also be performed du ring 
treatment, as per Schedule of Activities ( Table 2 -1) and at the safety follow -up visit.   
Note:  Females who have undergone a bilateral tubal ligation/occlusion do not require 
pregnancy testing per protocol requirements.  (If a female subject, or the partner of a 
male subject, becomes pregnant it must be reported on the Pregnancy Notification 
Form , see Figure 12 -2).  Refer to Section  12.5 for contraceptive requirements.   
Additional on -treatment pregnancy testing may be performed at the investigator’s 
discretion or as required per local laws and regulations.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 80 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.2.4.2 Prespecified Biomarker Assessments  
Minimal residual disease in bone marrow is a mandatory measurement in this study.  
Minimal residual disease will be measured by a NGS -based assay.  Bone marrow 
aspirate sample will be collected as per Schedule of Activi ties ( Table 2 -1).  The bone 
marrow aspirate sample  will be processed and stored according to a protocol that is 
provided by the central lab.  The samples will be analyzed centrally by the NGS -based 
MRD assay.  See Section  9.2.2.2  for details on priority of samples for bone marrow 
aspirate testing.    
9.2.5 Pharmacokinetic Assessments  
All subjects enrolled will have pharmacokinetic (PK) samples assessed.  Approximately 
15 subjects in each ar m will be invited to participate in the intensive PK/PDn substudy at 
select sites (see Section  9.2.9 ).  Sparse PK samples will be collected from the rest of the 
subjects,  eg, subjects who do not consent to participate in the optional intensive PK/PDn 
substudy.   
Venous samples of approximately 2.5  mL will be collected for measurement of plasma 
concentrations of carfilzomib as specified in the Schedule of Activities ( Table 2 -1).  
Instructions for the collection and handling of biological samples will be provided by the 
sponsor.  The actual date and time (24 -hour clock time) of each sample will be recorded.   
Samples will b e collected within ±  5-minute time windows around the nominal time points 
(except for the time point immediately prior to the end of infusion, for which the PK 
collection needs to occur prior to the end of infusion).   
9.2.6 Pharmacodynamic Assessments (Only f or Subjects Participating in 
the Optional Intensive PK/PDn Substudy)  
Venous blood samples of approximately 2 mL will be collected for measurement of 
carfilzomib PDn as per Schedule of Activities ( Table 2 -1).  Blood samples will onl y be 
collected from approximately 15 subjects in each arm who consent to participate in 
optional intensive PK/PDn substudy (see Section  9.2.9 ).   
9.2.7 Clinical Outcome Assess ments  
All COAs will be completed via electronic tablet at the site prior to any other 
assessments or procedures.  
9.2.7.1 EORTC QLQ -C30  
The EORTC QLQ -C30 is a self -reported 30 -item generic instrument for use in cancer 
subjects across tumor types.  It assesses 15 domains consisting of 5 functional domains 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 81 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
(physical, role, emotional, cognitive, social), 9 symptom domains (fatigue, nausea and  
vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, financial 
difficulties), and a GHS or QOL scale (Aaronson et al, 1993).   
9.2.7.3 Patient-reported Convenience With Carfilzomib -dosing Schedule 
Question  
This is a car filzomib -specific convenience single -item/question.  This item was modified 
from a question used in the A.R.R.O.W. study (“neutral” option was removed).  This item 
is not psychometrically validated (see Section  12.12  for more details).   
9.2.7.5 Cancer Therapy Satisfaction Questionnaire (CTSQ)  
The CTSQ measures treatment satisfaction in individuals with cancer (Trask et al, 2008). 
The CTSQ contains 3 domains covering 16 items (Cheung et al, 2016):  
 Expectations of Therapy  
 Feelings about side effects  
 Satisfaction with therapy   

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 82 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 83 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
9.2.9 Optional Substudies  
9.2.9.1 Intensive Pharmacokinetic/Pharmacodynamic Substudy  
Approximately 15 subjects in each arm will be invited to participate in the intensive 
PK/PDn substudy at select sites.  See Sections  9.2.5  and 9.2.6  for more details on the 
assessments.   
Documentation of informed consent for the optional intensive P K/PDn substudy must be 
confirmed prior to performing intensive PK/PDn procedures.  
9.2.10 Other Assessments   
Not applicable.   
10. Statistical Considerations  
10.1 Sample Size Determination  
The sample size was determined so that the primary objective could be test ed via 
synthesis method at 1 -sided 2.5% significance level with 80% power, including an 
interim analysis for futility when the first 230 subjects have been randomized and had 
the best overall response assessed by the date when treatment was completed, dise ase 
progression/death occurred, patient dropped out or started new therapy, whichever 
occurred first.  
A sample size of 460 subjects is needed to achieve 80% power for demonstrating that 
once -weekly KRd 56  mg/m2 preserves at least 60% of twice -weekly KRd 27  mg/m2 
effect in terms of ORR at a 1 -sided 2.5% significance level by the synthesis method.  
The stratified relative risk (RR) of ORR during the first 12 cycles of treatment in ASPIRE 
study (twice -weekly Rd vs KRd 27  mg/m2 RR and 95% CI: 0.755 [0.696, 0.81 8]) will be 
used as the historical reference for the test of non -inferiority.  This calculation assumes a 
true RR of 1 with ORR = 86.6% for both arms (once -weekly KRd 56  mg/m2 vs 
twice -weekly KRd 27  mg/m2), and an interim analysis for futility at 50% infor mation 
fraction using O’Brien -Fleming beta-spending function.  The reference ORR = 86.6% 
was determined based on the BOR observed by the end of 12  cycles of treatment in 
ASPIRE study (Amgen data on file).  

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 84 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
10.2 Analysis Sets, Subgroups, and Covariates  
10.2.1 Analysis Sets  
The analysis and reporting of the data from this study will be performed using the 
following analysis populations:  
10.2.1.1 Intent-to-Treat Population  
The Intent -to-Treat (ITT) population constitutes all randomized subjects and will be the 
basis for  the analyses of efficacy in this study.  Subjects in the analyses based on the 
ITT population will be analyzed according to the treatment group to which they were 
randomized.  
10.2.1.2 Safety Population  
The safety population includes all randomized subjects who rec eive at least 1 dose of 
any study treatment (carfilzomib, lenalidomide, or dexamethasone), and will be the basis 
for the analyses of safety.  Subjects in the analyses based on the safety population will 
be analyzed according to the treatment group correspo nding to the actual treatment 
received.  Any subject who received at least 1 weekly dose of carfilzomib 56  mg/m2 will 
be included in arm 1 (once -weekly KRd 56  mg/m2).  Otherwise, subjects will be included 
in arm 2 (twice -weekly KRd 27  mg/m2).  
10.2.1.3 Per-Protocol  Population  
The per -protocol population will include all randomized subjects who do not have any 
major protocol deviations that might affect the interpretation of the analyses of the 
efficacy endpoints.  The major protocol deviations include:  
 Major inclusi on criteria not met  
 Major exclusion criteria not met  
 Major treatment non -compliance  
 Treatment received different from treatment randomized  
 Concomitant use of protocol prohibited medications.  
10.2.2 Covariates  
In addition to the stratification factors for ra ndomization (original ISS stage at study 
entry , prior lenalidomide treatment, prior PI treatment, prior anti -CD38 exposure), other 
baseline covariates may be considered to examine primary and selected secondary 
endpoints in subgroups or in sensitivity anal yses, as appropriate. More details will be 
described in the statistical analysis plan (SAP).   
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 85 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
10.2.3 Subgroups  
The ORR will be estimated for selected subgroups if appropriate:  
 original ISS stage at baseline  (stage 1 or 2 vs stage 3)  
 prior lenalidomide treatment (yes vs no)  
 prior PI treatment (yes vs no)  
 prior anti -CD38 exposure (yes vs no)  
 prior bortezomib treatment (yes, no)  
 age (< 65,  65; 18 to  65, 65 to  75,  75) 
 number of prior therapies (1 vs > 1; 1 vs 2 vs > 2)  
 cytogenetic risk measured by FISH (high -risk vs standard risk)  
 bortezomib refractory status (yes vs no)  
 lenalidomide refractory status (yes vs no)  
 prior transplant (yes vs no)  
10.2.4 Handling of Missing and Incomplete Data  
Subjects may have missing data points for various reasons and the  impact on the 
analysis might differ from 1 endpoint to another.  The general rules for accommodating 
the missing or incomplete data may be refined during the blind review of the data, and 
they will be described in detail in SAP.  Sensitivity analyses migh t be needed to evaluate 
the robustness of the primary analysis and/ or key secondary analyses results in case of 
significant missing data.  
Incomplete dates for the start of adverse event, concomitant medications, and death will 
be imputed and the detailed rules will be specified in SAP.   
The calculation of scores and methods to deal with missing data will be handled 
according to the EORTC QLQ -C30 questionnaire's standard scoring guidelines.  
No imputation will be done for the analysis of the primary and key  secondary endpoints.  
The frequency of missing disease assessments and deviation of the actual disease 
assessment times from the scheduled assessment times will be summarized by 
treatment arms.  Sensitivity analyses will be performed to assess the impact of missing 
any disease or response assessment on the analysis of ORR and PFS.  Similar analysis 
will be performed for QOL endpoints.   
Details of missing data analysis and imputation rules will be described in SAP.   
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 86 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
10.3 Statistical Analyses  
The SAP will b e developed and finalized before database lock.  Below is a summary of 
the timing and methods for the planned statistical analyses.  To preserve study integrity, 
the final analysis will be conducted and reported following the end of study, as defined in 
Section  5.3.1 . 
10.3.1 Planned Analyses  
10.3.1.1 Interim Analysis and Early Stopping Guidelines  
An interim futility analysis will be performed to limit the number of patients exposed to 
treatment in case of low activity.   
The primary purpose of this interim analysis is to assess the likelihood that the treatment 
effect of the once -weekly KRd 56  mg/m2 will preserve at least 60% of twice -weekly 
KRd 27 mg/m2 effect in terms of ORR.  The date of the analysis will be set up by Amgen 
based on the date when the first 230 subjects have been randomized and had a BOR 
assessed by the date when treatment was com pleted, confirmed PD or death occurred, 
subject was lost to follow -up, withdrew consent, or started new therapy, whichever 
occurred first.  
This interim data analysis will address the primary and key secondary study objectives 
for the selected subjects.  Th is analysis will be performed by an independent contract 
research organization, and the sponsor will be blinded to the results.  An independent 
DMC will review the unblinded results and may suggest early termination of the trial.  
Using an O’Brien -Fleming beta-spending function, the stopping boundary for futility in  
p-value scale is 0.28 9.  This stopping boundary corresponds to an approximate RR of 
0.930, meaning that the study is futile if the observed ORR in the once -weekly KRd 
56 mg/m2 arm is < 80.8%, w hen the observed ORR in the twice -weekly KRd  27 mg/m2 
arm is 86.6%.  With such a stopping boundary, the trial has over 70% probability to stop 
for futility when the null hypothesis of inferiority is true.   
Based on this stopping criteria and clinical eval uation of the benefit/risk ratio, the DMC 
may recommend the continuation of study for the final analysis including all subjects 
enrolled in the study.  
Data will be subject to ongoing checks for integrity, completeness, and accuracy in 
accordance with the D ata Management Plan with the expectation that all outstanding 
data issues are resolved ahead of the snapshot.  The data will be locked to prevent 
further changes, and a snapshot of the locked database will be used in the analysis.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 87 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
10.3.1.2 Primary Analysis  
The primary analysis corresponds to the final analysis.  
10.3.1.3 Final Analysis  
Amgen will set a final analysis data cut -off date for efficacy and safety analysis in 
anticipation of the date when all subjects have completed the study.  Final analysis will 
address all t he study objectives.  Data will be subject to ongoing checks for integrity, 
completeness, and accuracy in accordance with the Data Management Plan with the 
expectation that all outstanding data issues are resolved ahead of the snapshot.  The 
data will be l ocked to prevent further changes, and a snapshot of the locked database 
will be used in the analysis.  
The hypotheses for the primary and key secondary objectives (ORR, PFS, and 
convenience after cycle 4 of treatment) will be tested using a fixed sequence h ierarchical 
testing procedure to control the family -wise type I error rate at 1 -sided 0.025 level.  The 
testing is ordered as follows: non -inferiority of ORR, non -inferiority of PFS, and 
superiority of patient -reported convenience after cycle 4 of treatmen t.  
Starting with the hypothesis of ORR, if any hypothesis in the sequence is rejected at a 
1-sided significance level of 0.025, then the subsequent hypothesis will be tested.  
Otherwise, if any hypothesis failed to be rejected, then the subsequent hypothe ses will 
not be tested.   
For the primary endpoint, the stopping boundary (0.02 5 in p-value scale) corresponds to 
an approximate RR = 0.975, meaning that the study meets the primary objective if the 
observed ORR for the once -weekly KRd 56  mg/m2 arm is at l east 84.3%, when the 
observed ORR in the twice -weekly KRd  27 mg/m2 arm is 86.6%.   
The final analysis of efficacy endpoints will be based on the ITT population, while the 
final analysis of safety endpoints will be based on the safety population.   
10.3.2 Methods of Analyses  
10.3.2.1 General Considerations  
The analyses of efficacy and safety endpoints will be based on the analysis sets defined 
in Section  10.2.1 .  The primary and final analyses of the efficacy endpoints will use the 
ITT population, while the per -protocol population will be used for sensitivity analyses, if 
applicable.  The final analysis of the safety endpoint will use the safety population.   
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 88 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
10.3.2.2 Efficacy Analyses  
 
Endpoint  Statistical Analysis Methods  
Primary Overall response over the duration of the study:  Clopper -Pearson 
method for by treatment overall response rate  (ORR) estimate and CI.  
Mantel -Haenszel  stratified RR for the inference of treatment effect.  
The synthesis approach will be used to show that once -weekly 
KRd 56 mg/m2 preserves at least 60% of twice -weekly KRd 27  mg/m2 
effect vs Rd.  
Secondary  PFS over the duration of the study : Kaplan -Meier (KM) estimates for 
PFS distribution by treatment and PFS rates and CI at 6 and 12 
months, stratified Cox proportional hazards (PH) model for HR and CI 
estimate, and the synthesis approach will be used to show that once -
weekly KRd  56 mg/m2 preserves at least 50% of twice -weekly KRd 
27 mg/m2 effect vs Rd.  
The stratified HR of PFS observed during the first 12  months of 
treatment in ASPIRE study (twice -weekly Rd vs KRd 27  mg/m2 
RR 1.81; 95% CI: 1.39, 2.38) will be used as the historical reference 
for the test of non -inferiority.  
Patient -reported convenience after cycle 4 of treatment:  
Cochran -Mantel -Haenszel method will be used to evaluate the 
treatment effect (OR) for whether carfilzomib dosing is rep orted as 
convenient or inconvenient; a logistic regression model including the 
randomization stratification factors and treatment group will be 
considered for sensitivity analysis.   
TTR: mean, SD, median, minimum and maximum among responders.  
DOR: KM met hod among responders.  
TTP: KM method and stratified Cox PH model  
OS over the duration of the study : KM estimates for OS distribution by 
treatment and OS rates and CI at 6 and 12 months, stratified Cox PH 
model for HR and CI estimate.  
MRD[ -]CR: proportion of MRD[ -]CR will be reported with CI calculated 
using Clopper -Pearson method.  
MRD[ -] status at 12 months from randomization: proportion of MRD[ -] 
will be reported with CI calculated using Clopper -Pearson method.  
Physical functioning and role functioning (EORTC  QLQ -C30)  over 
time: a repeated measures analysis of covariance adjusting for the 
baseline covariates.  A restricted maximum likelihood -based mixed 
model for repeated measures (MMRM) will be considered as 
sensitivity analysis.  
Patient -reported treatm ent satisfaction (CTSQ) after cycle  4 of 
treatment: analysis of covariance at the corresponding fixed time point.  
Exploratory  Will be described in the statistical analysis plan finalized before 
database lock  
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 89 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
10.3.2.3 Safety Analyses  
10.3.2.3.1  Adverse Events  
Incidence of all treatment -emergent adverse events will be tabulated by system organ 
class and preferred term.  Tables of fatal adverse events, serious adverse events, 
adverse events leading to withdrawal from investigational product or other 
protocol -requi red therapies, and adverse events of interest  will also be provided.   More 
details will be included in the SAP.   
10.3.2.3.2  Laboratory Test Results  
The laboratory test results and their change from baseline will be summarized by cycle.   
10.3.2.3.3  Vital Signs  
The vita l signs and their change from baseline will be summarized by cycle.  
10.3.2.3.4  Physical Measurements  
The physical measurements and their change from baseline will be summarized by 
cycle.   
10.3.2.3.5  Electrocardiogram  
The ECG measurements from this clinical study were performed as per standard of care 
for routine safety monitoring, rather than for purposes of assessment of potential QTc 
effect.  Since these evaluations may not necessarily be performed under the rigorous 
conditions expected to lead to meaningful evaluati on of QTc data; summaries and 
statistical analyses of ECG measurements are not planned, and these data would not be 
expected to be useful for meta -analysis with data from other studies.   
10.3.2.3.6  Exposure to Investigational Product  
The extent of exposure to all study treatments (carfilzomib, lenalidomide, and 
dexamethasone) will be evaluated for each arm with respect to treatment duration 
number of cycles started, total dose received, number of doses administered, dose 
intensity.  Th e reasons for dose modifications, or discontinuation from any study 
treatment will be summarized separately.  More details will be included in the SAP.   
10.3.2.3.7  Exposure to Concomitant Medication  
Number and proportion of subjects receiving therapies of intere st will be summarized by 
preferred term for each treatment group as coded by the World Health Organization 
Drug dictionary.   
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 90 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 91 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
11. References  
Aaronson NK, Ahmedzai S, Bergman B, et al.  The European Organization for Research 
and Treatment of Cancer QLQ -C30: a quality -of-life instrument for use in international 
clinical trials in oncology.  J Natl Cancer Inst .  1993;85(5):365 -376. 
American Medical Association.  The one graphic you need for  accurate blood pressure 
reading.  https://www.ama -assn.org/delivering -care/hyperten sion/one -graphic -you-need -
accurate -blood -pressure-reading .  2019.  Accessed 13 March 2020.  
Amgen Inc.  A Randomized, Open -label, Phase 3 Study in Subjects with Relapsed and 
Refractory Multiple Myeloma Receiving Carfilzomib in Combination with 
Dexamethasone, Comparing Once -weekly versus Twice -weekly Carfi lzomib Dosing.  
Clinical Study Report 20140355.  27 March 2018.   
Barrett -Lee P, Bloomfield D, Dougherty L, et al.  An audit to determine the time taken to 
administer intravenous bisphosphonate infusions in patients diagnosed with metastatic 
breast cancer to bone in a hospital setting.  Curr Med Res Opin .  2007;23:1575 -1582.  
Berenson JR, Cartmell A, Bessudo A, et al.  CHAMPION -1: a phase 1/2 study of 
once -weekly carfilzomib and dexamethasone for relapsed or refractory multiple 
myeloma.  Blood.   2016;127:33 60-3368.   
Biran N, Siegel DSD, Berdeja JG, et al.  Weekly carfilzomib, lenalidomide, and 
dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b 
study [abstract].  J Clin Oncol.   2018;36.  Abstract 8022.  
Bladé J, Rosiñol L.  Ren al, hematologic and infectious complications in multiple 
myeloma.  Best Pract Res Clin Haematol.   2005;18:635 -652.   
Bringhen S, Larocca A, Rossi D, et al.  Efficacy and safety of once -weekly bortezomib in 
multiple myeloma patients.  Blood.   2010;116:4745 -4753.   
Brown J, Plummer R, Bauer TM, et al.  Pharmacokinetics of carfilzomib in patients with 
advanced malignancies and varying degrees of hepatic impairment: an open -label, 
single -arm, phase 1 study.  Exp Hematol Oncol .  2017;6:27.   
Carfilzomib Investig ator’s Brochure.  Thousand Oaks, CA.  Amgen Inc.  
Cella, D.  Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) 
measurement system.  Version 4.1.  Evanston, IL: Center on Outcomes, Research and 
Education (CORE) Evanston Northwestern Hea lthcare and Northwestern University; 
2004.  
Cella DF, Tulsky DS, Gray G, et al.  The Functional Assessment of Cancer Therapy 
scale: development and validation of the general measure.  J Clin Onco l.  
1993;11:570 -579.  
Chanan -Khan AA, Giralt S.  Importance of  achieving a complete response in multiple 
myeloma, and the impact of novel agents.  J Clin Oncol .  2010;28:2612 -2624.   
Chari A, Mezzi K, Zhu S, Werther W, Felici D, Lyon AR.  Incidence and risk of 
hypertension in patients newly treated for multiple myelo ma: a retrospective cohort 
study.  BMC Cancer.   2016;16:912.  
Cheung K, de Mol M, Visser S, Den Oudsten BL, Stricker BH, Aerts JG.  Reliability and 
validity of the Cancer Therapy Satisfaction Questionnaire in lung cancer.  Qual Life Res .  
2016;25:71 -80. 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 92 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Christiansen CF, Johansen MB, Langeberg WJ, Fryzek JP, Sorensen HT.  Incidence of 
acute kidney injury in cancer patients: A Danish population -based cohort study.  Eur J 
Intern Med.   2011;22:399 -406. 
Cocks K, Cohen D, Wisloff F, et al.  An international fie ld study of the reliability and 
validity of a disease -specific questionnaire module (the QLQ -MY20) in assessing the 
quality of life of patients with multiple myeloma.  Eur J of Cancer .  2007;43:1670 -1678.  
Cook G, Zweegman S, Mateos MV, Suzan F, Moreau P.  A question of class: Treatment 
options for patients with relapsed and/or refractory multiple myeloma.  Crit Rev Oncol  
Hematol .  2018;121:74 -89.  
Dexamethasone United States Prescribing Information.  Whitehouse Station NJ: Merck; 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/11664slr062_decadron_lbl.
pdf.  Accessed 12 June 2018.  
Dexamethasone Summary of Product Characteristics.  Dublin, Ireland: Aspen; 
23 January 2018.  https://www.medicines.org.uk/emc/product/5411/smpc .  Accessed 
12 June 2018.  
Dimopoulos M, Wang M , Maisnar V, et al.  Response and progression -free survival 
according to planned treatment duration in patients with relapsed multiple myeloma 
treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide 
and dexamethasone (Rd) in the  phase III ASPIRE study.  J Hematol Oncol.   2018;11:49.  
Dimopoulos MA, Sonneveld P, Leung N, et al.  International Working Group 
recommendations for the diagnosis and management of myeloma -related renal 
impairment.  J Clin Oncol.   2016;34:1544 -1557.  
Durie BG, Harousseau JL, Miguel JS, et al.  International uniform response criteria for 
multiple myeloma.  Leukemia .  2006;20:1467 -1473.   
Ferlay J, Soerjomataram I, Dikshit R, et al.  Cancer incidence and mortality worldwide: 
sources, methods and major patter ns in GLOBOCAN 2012.  Int J Cancer .  
2015;136:E359 -E386.  
Gralow JR, Biermann JS, Farooki A, et al.  NCCN Task Force Report: Bone Health In 
Cancer Care.  J Natl Compr Canc Netw .  2013;11(Suppl  3):S1 -S50. 
He W, Goodkind D, Kowal P.  US Census Bureau, International Population Reports, 
P95/16 -1.  An Aging World: 2015.  Washington, DC: U.S. Government Publishing Office; 
2016.  
Hoy SM.  Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple 
Myeloma.  Target Oncol.  2016;11:2552 -2562.  
James P A, Oparil S, Carter BL, et al.  2014 Evidence -Based Guideline for the 
Management of High Blood Pressure in Adults.  Report from the panel members 
appointed to the eighth Joint National Committee (JNC 8).  JAMA .  2014;311:507 -520. 
Kistler K, Murphy B, Kalma n J, et al.  A comparison of cardiac event rates in patients 
with or without multiple myeloma in the US. ASCO Annual Meeting Abstract.  2014.  
Knauf WU, Otremba B, Overkamp F, Kornacker M.  Bortezomib in Relapsed Multiple 
Myeloma – Results of a Non -Interven tional Study by Office -Based Haematologists.  
Onkologie .  2009;32:175 -180. 
Kortuem KM, Stewart AK.  Carfilzomib.  Blood.   2013;121:893 –897. 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 93 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Kumar SK, Lee JH, Lahuerta JJ, et al.  Risk of progression and survival in multiple 
myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international 
myeloma working group study.  Leukemia.   2012;26:149 -157.   
Kumar S, Paiva B, Anderson KC, et al.  International Myeloma Working Group 
consensus criteria for response and minimal residual disease asses sment in multiple 
myeloma.  Lancet Oncol.   2016;17:328 -346.  
Laubach J, Garderet L, Mahindra A, et al.  Management of relapsed multiple myeloma: 
recommendations of the International Myeloma Working Group.  Leukemia.   
2016;30:1005 -1017.  
Li W, Garcia D, Cor nell RF, et al.  Cardiovascular and Thrombotic Complications of 
Novel Multiple Myeloma Therapies: A Review.  JAMA Oncol .  2017;3(7):980 -988.  
 Mateos MV, Moreau P, Berenson JR.  Once -weekly vs twice -weekly carfilzomib (K) 
dosing plus dexamethasone (d) in p atients with relapsed and refractory multiple 
myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.  J Clin Oncol.   
2018;36.  Abstract 8000.   
Moreau P, Pylypenko H, Grosicki S, et al.  Subcutaneous versus intravenous 
administration of bortezo mib in patients with relapsed multiple myeloma: a randomised, 
phase 3, non -inferiority study .  Lancet Oncol .  2011;12:431 -440. 
Mosteller RD.  Simplified calculation of body -surface area.  N Engl J Med .  
1987;317(17):1098.  
Noone AM, Howlader N, Krapcho M, e t al.  SEER Cancer Statistics Review, 1975 -2015, 
National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/ , based 
on November 2017 SEER data submission, posted to the SEER web site, April 2018.  
Accessed 04 October 2018.   
Oken MM, Creech RH, Tormey DC, et al.  Toxicity and response criteria of the Eastern 
Cooperative Oncology Group.  Am J Clin Oncol .  1982;5( 6):649 –655. 
Papadas A, Asimakopoulos F.  Mechanisms of Resistance in Multiple Myeloma.  Handb 
Exp Pharmacol.  2017.  
Pearman TP, Beaumont JL, Mroczek D, O’connor M, Cella D.  Validity and usefulness of 
a single‐item measure of patient ‐reported bother from s ide effects of cancer therapy. 
Cancer.  2018;124:991 -997. 
Rajkumar SV, Harousseau JL, Durie B, et al.  Consensus recommendations for the 
uniform reporting of clinical trials: report of the International Myeloma Workshop 
Consensus Panel 1.  Blood .  2011;117( 18):4691 -4695.  
Reeder CB, Reece DE, Kukreti V, et al.  Once - versus twice -weekly bortezomib 
induction therapy with CyBorD in newly diagnosed multiple myeloma.  Blood .  
2010;115(16):3416 -3417.  
REVLIMID® (lenalidomide) United States Prescribing Information.  Summit NJ: Celgene 
Corporation; December 2017.  http://www.revlimid.com/wp -content/uploads/full -
prescribing -information.pdf .  Accessed 5 June 2018.  
REVLIMID® (lenalidomide) Summary of Product Characteristics.  Uxbridge, UK: Celgene 
Ltd; 18  September 2017.   http://www.revlimid.com/wp -content/uploads/full -prescribing -
information.pdf Accessed 5 June 2018  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 94 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Richardson P, Mitsiades C, Schlossman R, et al.  The treatment of relapsed and 
refractory multiple myeloma.  Hematology Am Soc Hematol Educ Program .  
2007:31 7-223. 
Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones 
proteins.  J Clin Invest .  1992;89:630.  
Siegel DS, Dimopoulos MA, Ludwig H , et al.  Improvement in Overall Survival With 
Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory 
Multiple Myeloma.  J Clin Oncol .  2018;36:728 -734.  
Simon R, Makuch RW.  A non -parametric graphical representation of the re lationship 
between survival and the occurrence of an event: application to responder versus 
non-responder bias.  Stat Med.   1984;3:35 -44. 
Song X, Cong Z, Wilson K.  Real -world treatment patterns, comorbidities, and 
disease -related complications in patients  with multiple myeloma in the United States.  
Curr Med Res Opin.   2016;32:95 -103. 
Smith TJ, Bohlke K, Lyman GH, et al.  Recommendations for the Use of WBC Growth 
Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.  J 
Clin Oncol .  2015;33:3199 -3212.  
Stewart AK, Dimopoulos MA, Masszi T, et al.  Health -Related Quality -of-Life Results 
From the Open -Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, 
Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexameth asone in 
Patients With Relapsed Multiple Myeloma.  J Clin Oncol .  2016; 34:3921 -3930.  
Stewart AK, Rajkumar SV, Dimopoulos MA, et al.  Carfilzomib, lenalidomide, and 
dexamethasone for relapsed multiple myeloma.  N Engl J Med.  2015;372:142 -152.  
Teng Z, Gup ta N, Hua Z, et al.  Model‐Based Meta ‐Analysis for Multiple Myeloma: A 
Quantitative Drug ‐Independent Framework for Efficient Decisions in Oncology Drug 
Development.  Clin Transl Sci.   2018;11:218 –225. 
Terpos E, Morgan G, Dimopoulos MA, et al.  Internationa l Myeloma Working Group 
recommendations for the treatment of multiple myeloma -related bone disease.  J Clin 
Oncol.   2013;31:2347 -2357.  
Trask PC, Tellefsen C, Espindle D, Getter C, Hsu MA.  Psychometric validation of the 
cancer therapy satisfaction question naire.  Value Health.   2008;11:669 -679. 
Williams B, Mancia G, Spiering W, et al.  2018 Practice Guidelines for the management 
of arterial hypertension of the European Society of Cardiology and the European Society 
of Hypertension:  ESC/ESH Task Force for t he Management of Aterial Hypertension.  J 
Hypertens .  2018;36(12):2284 -2309.  
 
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 95 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12. Appendices  
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 96 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.1 Appendix 1.  List of Abbreviations and Definitions of Terms  
 
Abbreviation or Term  Definition/Explanation  
ALT alanine aminotransferase  
ANC  absolute neutrophil  count  
anti-HBc hepatitis B core antibody  
anti-HBs hepatitis B surface antibody  
AST aspartate aminotransferase  
BOR  best overall response  
BSA body surface area  
CFR US Code of Federal Regulations  
COA  Clinical Outcome Assessment  
CR complete response  
CRF case report form  
CTCAE  Common Terminology Criteria for Adverse Events  
CT computed tomography  
CTSQ  Cancer Therapy Satisfaction Questionnaire  
DMC  data monitoring committee  
DOR  duration of response  
ECG  electrocardiogram  
ECHO  echocardiogram  
ECOG PS  Eastern Cooperative Oncology Group Performance Status  
eCRF  electronic case report form  
EDC  electronic data capture  
EORTC  European Organization for Research and Treatment of Cancer  
EORTC QLQ -C30 European Organization for Research and Treatment of Cance r 
Quality -of-life Questionnaire Core 30  
FACIT  Functional Assessment of Chronic Illness Therapy  
FCBP  females of childbearing potential  
FDA Food and Drug Administration  
FISH  fluorescence in situ hybridization  
GCP  Good Clinical Practice  
GHS  global health status  
HBsAg  hepatitis B surface antigen  

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 97 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Abbreviation or Term  Definition/Explanation  
HBV hepatitis B virus  
HR hazard ratio  
HRQOL  health -related quality -of-life 
HRT hormone -replacement therapy  
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
Ig immunoglobulin  
IMiD immunomodulatory drug  
IMWG -URC  International Myeloma Working Group  Uniform Response 
Criteria  
Interactive Voice/Web 
Response System (IxRS)  telecommunication/web -based technology that is linked to a 
central computer in real time as an interface to collect and 
process information   
IPIM Investigational Product Instruction Manual  
IRB Institutional Review Boards  
IRC  Independent Review Committee  
ISS International Staging System  
IV intravenous  
KM Kaplan -Meier  
KRd carfilzomib in combination with lenalidomide and 
dexamethasone  
MM multiple myeloma  
MMRM  mixed model for repeated measures  
MRD  minimal residual disease  
MRD[ -] minimal residual disease negative  
MRI magnetic resonance imaging  
NCI National Cancer Institute  
NDMM  newly diagnosed multiple myeloma  
NGS  next-generation sequencing  
OR odds ratio  
ORR  overall response rate  
OS overall survival  
PD progressive disease  
PDn pharmacodynamics  
PET/CT  positron emission tomography/computed tomography  
PFS progression -free survival  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 98 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Abbreviation or Term  Definition/Explanation  
PH proportional hazard  
PI proteasome inhibitor  
PK pharmacokinetics  
PR partial response  
RBC  red blood cell  
Rd lenalidomide with dexamethasone  
REMS  Risk Evaluation and Mitigation Strategy  
RR relative risk  
RRMM  relapsed or refractory multiple myeloma  
SAP Statistical Analysis Plan  
sCR stringent complete response  
SFLC  serum -free light chain  
SIFE  serum immunofixation  
SmPC  Summary of Product Characteristics  
Source Data  Information from an original record or certified copy of the 
original record containing patient information for use in clinical 
research.   The information may include, but is not limited to, 
clinical findings, observations, or other activities in a clinical 
study necessary for the reconstruction and evaluation of the trial.  
Source data are contained in source documents (original records 
or certified copies).  (ICH Guideline [E6]).  Exampl es of source 
data include Subject identification, Randomization identification, 
and Stratification Value.  
SPD maximal perpendicular diameter  
SPEP  serum protein electrophoresis  
SWT  Satisfaction With Therapy  
TLS tumor lysis syndrome  
TTP time to progression  
TTR time to response  
UIFE  urine immunofixation  
UPEP  urine protein electrophoresis  
ULN upper limit of normal  
US United States  
USPI  United States Prescribing Information  
VGPR  very good partial response  
 

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 99 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.2 Appendix 2.  Clinical Laboratory Tests 
The tests detailed in Table 12 -1 will be performed by the central laboratory and by the 
local laboratory .  
Local laboratory results may be  used in the event that the central laboratory results are 
not available for the purpose of a time sensitive  study treatment decision, including 
laboratories for efficacy assessment.  A  sample for central analysis is to be obt ained at 
the same time  for each laboratory assessment in  Table 12 -1.  Any local laboratory result 
used to make a study treatment decisi on must be entered into the electronic case report 
form (eCRF) with the exception of the myeloma response assessment where only the 
central laboratory results are to be entered . 
Protocol -specific requirements for inclusion or exclusion of subjects are deta iled in 
Sections  6.1 to 6.2 of the protocol.  
Subjects must fast for at least 9 hours before screening hematology and serum 
chemistries.  If central lab oratory  results for lactate dehydrogenase, b ilirubin, aspartate 
aminotransferase , and potassium are not reported/available at screening, local 
laboratory  results may be utilized if completed within the screening window and must be 
reported on the eCRF .  Screening coagulation , pregnancy, and hepatiti s B serology  tests 
will be done at local laboratories.  Post -enrollment, l aboratory  samples may be collected 
and analyzed by local laboratories if immediate results are necessary for management of 
treatment -emergent adverse events or dosing determination .  Evaluation of lab results 
for dose determination as required per Schedule of Assessments must be documented 
prior to dosing in each cycle.  Any local lab values that lead to dose modification 
decisions must be recorded in the eCRF.  Any local lab results that fulfill ≥ grade 3 
values per Common Terminology Criteria for Adverse Events (CTCAE) must be 
recorded in the eCRF.  
For cycle 1 day 1, hematology and serum chemistry panel from screening may be used 
if within 3  days of day 1  and within 48  hours of D1 of  a cycle from C2 onwards.      
Additional tests may be performed at any time during the study as determined necessary 
by the investigator or required by local regulations.  
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 100 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Table 12-1.  Analyt e Listing  
Central Laboratory  
Chemistry  Hematology  Disease Assessments  Other Labs  
Sodium  
Potassium  
Chloride  
Bicarbonate  
Albumin  
Calcium  
Corrected calcium  
Glucose  
BUN or Urea  
Creatinine  
Total bilirubin  
Direct bilirubin  
Alk phosphatase  
AST (SGOT)  
ALT (SGPT)  
Phosphate  
Magnesium  RBC  
Hemoglobin  
Hematocrit  
Platelets  
WBC  
Differential  
Neutrophils  
Bands/stabs  
Segs  
Eosinophils  
Basophils  
Lymphocytes  
Monocytes  
Plasma cell count : 
 plasma cell percent  MRD assessment by 
NGS (bone marrow 
aspirate)  
FISH (bone marrow 
aspirate)  
SPEP  
Serum Immunofixation  
UPEP  
Urine immunofixation  
SFLC  Pharmacokinetics  
Pharmacodynamics  
Central Laboratory Screening Only  
Screening only:  
LDH 
Uric acid  
Amylase  
Lipase  
Fasting lipid panel:  
 Total cholesterol  
 HDL 
 LDL 
 Triglycerides  Screening only:  
HbA1c   Screening only:  
NT-proBNP  
Screening only unless 
clinically indicated : 
Quantitative 
immunoglobulins 
(serum): IgA, IgD, IgE, 
IgG, IgM  
beta2 -microglobulin 
(serum)  
Local Laboratory  
 Screening only - 
Coagulation:  
PT/INR  
PTT  Screening and as 
required by protocol : 
Other:  
Serum pregnancy  
Urine pregnancy  
HBV serologies  
 Hepatitis B surface 
antigen (HBsAg)  
 Hepatitis B surface 
antibody (anti -HBs)  
 Hepatitis B core 
antibody (anti -HBc)  
HBV DNA testing  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 101 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
ALT = alanine aminotransferase; anti-HBc = hepatitis B core antibody; anti -HBs = hepatitis B surface 
antibody; AST = aspartate aminotransferase; BUN = blood urea nitrogen; FISH  = fluorescent in situ 
hybridization; HbA1c  = hemoglobin A1c; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus;  
HDL = high density lipoprotein; Ig  = immunoglobulin; INR  = international normalized ratio; LDH = lactate 
dehydrogenase; LDL  = low density lipoprotein; MRD = minimal residual disease; NGS  = next-generation 
sequencing; NT -proBNP  = N termin al of the prohormone brain natriuretic peptide; PT = prothrombin time; 
PTT = partial thromboplastin time;  RBC = red blood cell count; SFLC = serum -free light chain; 
SGOT  = serum glutamic -oxaloacetic transaminase; SGPT - serum glutamic -pyruvic transaminase ; 
SPEP  = serum protein electrophoresis; UPEP  = urine protein electrophoresis; WBC = white blood cell count.  
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 102 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.3 Appendix 3.  Study Governance Considerations  
Data Monitoring Committees and Independent Review Committee  
Data Monitoring Committee  
An indepen dent data monitoring committee (DMC) will be convened for this study and 
will act in an advisory capacity to the sponsor with respect to safeguarding the interests 
of study subjects, assessing interim data, monitoring the overall conduct of the study, 
and providing with recommendations relating to continuing, modifying, or stopping the 
study based on these findings (International Council for Harmonisation Good Clinical 
Practice [ICH GCP 5.5.2]).  Details of the DMC will be described in the DMC Charter.  
The initial assessment from this committee will be planned after 30 subjects 
(approximately 15 for the experimental arm and 15 for the control arm) have been 
enrolled and have finished the first cycle of treatment to ensure safety of all arms.  A 
provision wi ll be made allowing an early follow -up DMC meeting to be decided at the 
time of the initial assessment.  The DMC will meet approximately every 6 months to 
review safety data on a regular basis, and once to review the efficacy data for futility.  
The interi m analysis for futility is planned to occur when the first  230 subjects have been 
randomized and had a best overall response (BOR) assessed by the date when 
treatment was completed, confirmed progressive disease or death occurred, subject was 
lost to follo w-up, withdrew full consent, or started new therapy, whichever occurred first.  
Records of all meetings will be maintained by the DMC for the duration of the study.  
Records of all meetings will be transferred and stored in the trial master folder at the 
conclusion of the study.  Further details are provided in the DMC charter.  
Independent Review Committee  
The individual subject disease response and disease progression for this study will be 
independently assessed by an Independent Review Committee (IRC) in  accordance with 
the International Myeloma Working Group Uniform Response Criteria (IMWG -URC) 
(Section  12.11 ).  The membership criteria and operational details of the IRC will be 
described in the IRC Charter.  The IRC will centrally review the disease -related tests and 
assessments (Section  9.2.2 ) to evaluate disease progressions and responses without 
the knowledge of randomization assignments or Investigator’s disease assessments.  
The IRC assessment will be used for the primary analysis of efficacy endpoints except 
for minimal residual disease ( MRD) rate and clinical outcome assessments (COA) 
endpoints.   
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 103 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with:  
 Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences International Ethical Guidelines  
 Applicable ICH GCP Guidelines  
 Applicable ICH laws and regulations  
The protocol, protocol amendments, informed consent form (ICF), Investi gator’s 
Brochure, and other relevant documents (eg, subject recruitment advertisements) must 
be submitted to an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)  
by the investigator and review ed and approved by the IRB/IEC .  A copy of the  written 
approval of the protocol and informed consent form must be received by Amgen before 
recruitment of subjects into the study and shipment of Amgen investigational product.  
Amgen may amend the protocol at any time.  The investigator must submit and, where 
necessary, obtain approval from the IRB/IEC  for all subsequent protocol amendments 
and changes to the informed consent document.  The investigator must send a copy of 
the approval letter from the IRB/IEC  and amended protocol Investigator’s Signature 
page to Amgen prior to implementation of the protocol amendment at their site.  
 The investigator will be responsible for the following:  
 Providing written summaries of the status of the study to the IRB/IEC  annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC  
 Obtaining annual IRB/IEC  approval/renewal throughout the duration of the study.  
Copies of the investigator’s reports and the IRB/IEC  continuance of approval must be 
sent to Amgen  
 Notifying the IRB/IEC  of serious adverse events occurring at the site, deviations from 
the protocol or other adverse event reports received from Amgen, in accordance with 
local procedures  
 Overall conduct of the study at the site and adherence to requirements of Titl e 21 of 
the US Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC , and all 
other applicable local regulations  
Recruitment Procedures  
Site staff will identify potential subjects from their existing patient population or may seek 
referral patient s through existing professional networks or other community sources such 
as patient advocacy groups.  All patient -facing materials must be reviewed/approved by 
the sponsor and the local IRB/IEC.   
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 104 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Informed Consent Process  
An initial sample informed consent form is provided for the investigator to prepare the 
informed consent document to be used at his or her site.  Updates to the sample 
informed consent form are to be communicated formally in writing from the Amgen  Trial 
Manager to the investigator.  The written informed consent form is to be prepared in the 
language(s) of the potential patient population.  
The investigator or his/her delegated representative will explain to the subject, or his/her 
legally authorized represen tative, the aims, methods, anticipated benefits, and potential 
hazards of the study before any protocol -specific screening procedures or any 
investigational product(s) is/are administered, and answer all questions regarding the 
study.   
Subjects must be in formed that their participation is voluntary.  Subjects or their legally 
authorized representative defined as an individual or other body authorized under 
applicable law to consent, on behalf of a prospective subject, to the subject’s 
participation in the clinical study  will then be required to sign a statement of informed 
consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, 
Health Insurance Portability and Accountability Act requirements, where applicable, and 
the IRB/IEC  or study center.  
The medical record must include a statement that written informed consent was obtained 
before the subject was enrolled in the study and the date the written consent was 
obtained.  The authorized person obtaining the informed consent must al so sign the 
informed consent form.  
The investigator is also responsible for asking the subject if the subject has a primary 
care physician and if the subject agrees to have his/her primary care physician informed 
of the subject’s participation in the clini cal study unless it is a local requirement.  The 
investigator shall then inform the primary care physician.  If the subject agrees to such 
notification, the investigator is to inform the subject’s primary care physician of the 
subject’s participation in th e clinical study.  If the  subject does not have a primary care 
physician and the investigator will be acting in that capacity, the investigator is to 
document such in the subject’s medical record.  
The acquisition of informed consent and the subject’s agreement or refusal of his/her 
notification of the primary care physician  is to be documented in the subject’s medical 
records, and the informed consent form is to be signed and personally dated by the 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 105 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
subject or a legally acceptable representative and by  the person who conducted the 
informed consent discussion.  Subject withdrawal of consent or discontinuation from 
study treatment and/or procedures  must also be documented in the subject’s medical 
records; refer to Section  8. 
Subjects must be re -consented to the most current version of the informed consent 
form(s) during their participation in the study.  
The original signed informed consent  form is to be retained in accordance with 
institutional policy, and a copy of the informed consent form(s) must be provided to the 
subject or the subject’s legally authorized representative.  
If a potential subject is illiterate or visually impaired and d oes not have a legally 
acceptable representative, the investigator must provide an impartial witness to read the 
informed consent form to the subject and must allow for questions.  Thereafter, both the 
subject and the witness must sign the informed consent  form to attest that informed 
consent was freely given and understood.  (Refer to ICH GCP guideline, Section  4.8.9.)  
A subject who is rescreened is not required to sign another informed consent form if the 
rescreening occurs within 28 days from the previous informed consent form signature 
date. 
The informed consent form (ICF) will contain a separate section that addresses the use 
of remaining mandatory samples for optional future research.  The investigator or 
authorized designee will explain to each  subject the objectives of the future research.  
Subjects will be told that they are free to refuse to participate and may withdraw their 
specimens at any time and for any reason during the storage period.  A separate 
signature will be required to document  a subject’s agreement to allow any remaining 
specimens to be used for future research.  Subjects who decline to participate will not 
provide this separate signature.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 106 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Data Protection/Subject Confidentiality  
The investigator must ensure that the subject’s c onfidentiality is maintained for 
documents submitted to Amgen.  
Subject will be assigned a unique identifier by the sponsor.  Any subject records or 
datasets that are transferred to the sponsor will contain the identifier only; subject names 
or any informat ion which would make the subject identifiable will not be transferred.  
On the Case Report Form (CRF) demographics page, in addition to the unique subject 
identification number, include the age at time of enrollment.  
For serious adverse events reported to Amgen, subjects are to be identified by their 
unique subject identification number, initials (for faxed reports, in accordance with local 
laws and regulations), and age (in accordance with local laws and regulations).  
Documents that are not submitted to Am gen (eg, signed informed consent forms) are to 
be kept in confidence by the investigator, except as described below.  
In compliance with governmental regulations/ICH GCP Guidelines , it is required that the 
investigator and institution permit authorized repr esentatives of the company, of the 
regulatory agency(s), and the IRB/IEC  direct access to review the subject’s original 
medical records for verification of study -related procedures and data.  Direct access 
includes examining, analyzing, verifying, and repr oducing any records and reports that 
are important to the evaluation of the study.   
The investigator is obligated to inform and obtain the consent of the subject to permit 
such individuals to have access to his/her study -related records, including persona l 
information.  
Publication Policy  
To coordinate dissemination of data from this study, Amgen may facilitate the formation 
of a publication committee consisting of several investigators and appropriate Amgen 
staff, the governance and responsibilities of whi ch are set forth in a Publication Charter.  
The committee is expected to solicit input and assistance from other investigators and to 
collaborate with authors and Amgen staff, as appropriate, as defined in the Publication 
Charter.  Membership on the commit tee (both for investigators and Amgen staff) does 
not guarantee authorship.  The criteria described below are to be met for every 
publication.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 107 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Authorship of any publications resulting from this study will be determined on the basis 
of the Uniform Requireme nt for Manuscripts Submitted to Biomedical Journals 
International Committee of Medical Journal Editors Recommendations for the Conduct of 
Reporting, Editing, and Publications of Scholarly Work in Medical Journals, which states:  
Authorship credit is to be based on:  (1) substantial contributions to conception and 
design, acquisition of data, or analysis and interpretation of data; (2) drafting the article 
or revising it critically for important intellectual content; (3) final approval of the version to 
be published; and (4) agreement to be accountable for all aspects of the work in 
ensuring that questions related to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved.  Authors need to meet conditions 1, 2, 3, and 4.  
When a large, multicenter group has conducted the work, the group is to identify the 
individuals who accept direct responsibility for the manuscript.  These individuals must 
fully meet the criteria for authorship defined above.  Acquisition of funding, col lection of 
data, or general supervision of the research group, alone, does not justify authorship.  All 
persons designated as authors must qualify for authorship, and all those who qualify are 
to be listed.  Each author must have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content.  All publications (eg, manuscripts, 
abstracts, oral/slide presentations, book chapters) based on this study must be 
submitted to Amgen for review.  The Clinical Trial Agreem ent among the institution, 
investigator, and Amgen will detail the procedures for, and timing of, Amgen’s review of 
publications.  
Investigator Signatory Obligations  
Each clinical study report is to be signed by the investigator or, in the case of multicent er 
studies, the coordinating investigator.  
The coordinating investigator, identified by Amgen, will be any or all of the following:  
 A recognized expert in the therapeutic area  
 An Investigator who provided significant contributions to either the design or 
interpretation of the study  
 An Investigator contributing a high number of eligible subjects  
Data Quality Assurance  
All subject data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronic ally (eg, laboratory data, centrally or 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 108 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
adjudicated data).  The investigator is responsible for verifying that data entries are 
accurate and correct by physically or electronically signing the CRF.  
The investigator must maintain accurate documentation (so urce data) that supports the 
information entered in the CRF.  
The investigator must permit study -related monitoring, audits, IRB/IEC  review, and 
regulatory agency inspections and provide direct access to source data documents.   
The sponsor or designee is responsible for the data management of this study including 
quality checking of the data.  
Clinical monitors will perform ongoing source data verification to confirm that data 
entered into the CRF by authorized site personnel are  accurate, complete, and verifiable 
from source documents; that the safety and rights of subjects are being protected; and 
that the study is being conducted in accordance with the currently approved protocol and 
any other study agreements, ICH GCP, and all  applicable regulatory requirements per 
the sponsor’s monitoring plan.  
The investigator agrees to cooperate with the clinical monitor to ensure that any 
problems detected in the course of these monitoring visits, including delays in 
completing CRFs, are r esolved.  
The Amgen representative(s) and regulatory authority inspectors are responsible for 
contacting and visiting the investigator for the purpose of inspecting the facilities and, 
upon request, inspecting the various records of the clinical study (eg, CRFs and other 
pertinent data) provided that subject confidentiality is respected.  
In accordance with ICH GCP and the sponsor’s audit plans, this study may be selected 
for audit by representatives from Amgen’s Global Research and Development 
Compliance and  Audit function (or designees).  Inspection of site facilities (eg, 
pharmacy, protocol -required therapy storage areas, laboratories) and review of 
study -related records will occur to evaluate the study conduct and compliance with the 
protocol, ICH GCP, and  applicable regulatory requirements.  
Retention of study documents will be governed by the Clinical Trial Agreement.  
Case report forms must be completed in English.  TRADENAMES® (if used) for 
concomitant medications may be entered in the local language.  Co nsult the 
country -specific language requirements.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 109 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
All written information and other material to be used by subjects and investigative staff 
must use vocabulary and language that are clearly understood.  
Source Documents  
The investigator is to maintain a lis t of appropriately qualified persons to whom he/she 
has delegated study duties.  All persons authorized to make entries and/or corrections 
on CRFs will be included on the Amgen Delegation of Authority Form.  
Source documents provide evidence for the existen ce of the subject and substantiate 
the integrity of the data collected.  Source documents are filed at the investigator’s site.  
Source documents are original documents, data, and records from which the subject’s 
CRF data are obtained.  These include but ar e not limited to hospital records, clinical 
and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, 
and correspondence.  Source documents may also include data captured in the 
Interactive Voice Response System/Interactive Web  Response System (IxRS)  system (if 
used , such as subject ID and randomization number) and CRF entries if the CRF is the 
site of the original recording (ie, there is no other written or electronic record of data, 
such as paper questionnaires for a COA).  
Data reported on the CRF or entered in the electronic CRF that are transcribed from 
source documents must be consistent with the source documents or the discrepancies 
must be explained.  The investigator may need to request previous medical records or 
transfe r records, depending on the study.  Also, current medical records must be 
available.  
The Investigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation, suitable for  
inspection at any time by representatives from Amgen and/or applicable regulatory 
authorities.  
 Subject files containing completed CRFs, informed consent forms, and subject 
identification list  
 Study files containing the protocol with all amendments, Invest igator’s Brochure, 
copies of prestudy documentation, and all correspondence to and from the IRB/IEC 
and Amgen  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 110 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 Investigational product -related correspondence including (Proof of Receipts, 
Investigational Product Accountability Record[s], Return of Investiga tional Product for 
Destruction Form[s], Final Investigational Product Reconciliation Statement, as 
applicable)  
 Non-investigational product(s), and/or medical device(s) or combination product(s) 
documentation, as applicable  
Retention of study documents will  be governed by the Clinical Trial Agreement.  
Study and Site Closure  
Amgen or its designee may stop the study or study center participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable 
laws, regulations, and GCP.  
Both Amgen and the Investigator reserve the right to terminate the Investigator’s 
participation in the study according to the Clinical Trial Agreement.  The investigator is to  
notify the IRB/IEC  in writing of the study’s completion or early termination and send a 
copy of the notification to Amgen.  
Subject s may be eligible for continued treatment with Amgen investigational product(s) 
by an extension protocol or as provided for by the local country’s regulatory mechanism.  
However, Amgen reserves the unilateral right, at its sole discretion, to determine 
whether to supply Amgen investigational product(s) and by what mechanism, after 
termination of the study and before the product(s) is/are available commercially.  
Compensation  
Any arrangements for compensation to subjects for injury or illness that arises in t he 
study are described in the Compensation for Injury section of the Informed Consent that 
is available as a separate document.  
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 111 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.4 Appendix 4.  Safety Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up and Reporting  
Definition of Adverse Event  
Adverse Event Definition  
 An adverse event is any untoward medical occurrence in a clinical study subject 
irrespective of a causal relationship with the study treatment.   
 Note: An adverse event can therefore be any unfavorable and unintended  sign 
(including an abnormal laboratory finding), symptom, or disease (new or 
exacerbated) temporally associated with the use of a treatment, combination 
product, medical device or procedure.  
 Note:  Treatment -emergent adverse events will be defined in the statistical analysis 
plan (SAP)  
 
Events Meeting the Adverse Event Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (eg, electrocardiogram [ECG], radiological scans, vital 
signs measurements), including those that worsen from baseline, that are 
considered clinically significant in the medical and scientific judgment of the 
investigator (ie, not related to progression of underlying disease).  
 Exacerbation of a chronic or intermitten t pre-existing condition including either an 
increase in frequency and/or intensity of the condition.  
 New conditions detected or diagnosed after study treatment administration even 
though it may have been present before the start of the study.  
 Signs, sympt oms, or the clinical sequelae of a suspected drug -drug interaction.  
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
treatment or a concomitant medication.  Overdose per se will not be reported as an 
adverse event/serious a dverse event unless it is an intentional overdose taken with 
possible suicidal/self -harming intent.  Such overdoses are to be reported 
regardless of sequelae.  
 For situations when an adverse event or serious adverse event is due to multiple 
myeloma  report a ll known signs a nd symptoms.  Death due to disease progression 
in the absence of signs and symptoms should be reported as the primary tumor 
type (eg, multiple myeloma).  Note: The term “disease progression” should not be 
used to describe the disease -relate d event or adverse event.  
 “Lack of efficacy” or “failure of expected pharmacological action” per se will not be 
reported as an adverse event or serious adverse event.  Such instances will be 
captured in the efficacy assessments.  However, the signs, sympto ms, and/or 
clinical sequelae resulting from lack of efficacy will be reported as adverse event or 
serious adverse event if they fulfill the definition of an adverse event or serious 
adverse event.  
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 112 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Events NOT Meeting the Adverse Event Definition  
 Medical  or surgical procedure (eg, endoscopy, appendectomy):  the condition that 
leads to the procedure is the adverse event.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
 Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
Definition of Serious Adverse Event  
A Serious Adverse Event is defined as any untoward medical occurrence 
that, meets at least 1 of the following serious criteria:  
Results in death (fatal)  
Immediately life -threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which 
the subject was at risk of death at the time of the event.  It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.  
Requires inpatient hospitalization or prolongation of existing hospitalization  
In general, hospitalization signifies that the subject has been detained (usually 
involving a t least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting.  Complications that occur during 
hospitalization are an adverse event.  If a  complication prolongs hospitalization or 
fulfills any other serious criteria, the event is serious.  When in doubt as to whether 
“hospitalization” occurred or was necessary, the adverse event is to be considered 
serious.  Hospitalization for elective trea tment of a pre -existing condition that did 
not worsen from baseline is not considered an adverse event.  
Results in persistent or significant disability/incapacity  
The term disability means a substantial disruption of a person’s ability to conduct 
normal l ife functions.  This definition is not intended to include experiences of 
relatively minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which 
may interfere with or pr event everyday life functions but do not constitute a 
substantial disruption.  
Is a congenital anomaly/birth defect  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 113 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
A Serious Adverse Event is defined as any untoward medical occurrence 
that, meets at least 1 of the following serious criteria:  
Other medically important serious event  
Medical or scientific judgment is to be exercised in deciding whether serious 
adverse event reporti ng is appropriate in other situations such as important 
medical events that may not be immediately life -threatening or result in death or 
hospitalization but may jeopardize the subject or may require medical or surgical 
intervention to prevent 1 of the oth er outcomes listed in the above definition.  
These events are typically to be considered serious.  
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias  or convulsions that do not result in hospitalization, or development of 
drug dependency or drug abuse.  
Recording Adverse Events and Serious Adverse Events  
Adverse Event and Serious Adverse Event Recording  
 When an adverse event or serious adverse event occurs, it is the responsibility of 
the investigator to review all documentation (eg, hospital progress notes, 
laboratory, and diagnostics reports) related to the event.  
 The investigator will then record all relevant adverse event/serious adverse event 
information in the Event case report form (CRF).  
o Additionally, the investigator is required to report a fatal disease -related event 
on the Event CRF.  
 The investigator must assign the following adverse event attributes:  
o Adverse event diagnosis or syndrome(s ), if known (if not known, signs or 
symptoms);  
o Dates of onset and resolution (if resolved);  
o Severity (or toxicity defined below);  
o Assessment of relatedness to investigational product, other protocol -required 
therapies, and/or study -mandated activity and/or  procedures  
o Action taken and 
o Outcome of event  
 If the severity of an adverse event changes from the date of onset to the date of 
resolution, record as a single event with the worst severity on the Event CRF.  
 It is not acceptable for the investigator to send  photocopies of the subject’s medical 
records  to Amgen  in lieu of completion of the Event CRF page.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 114 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Adverse Event and Serious Adverse Event Recording  
 If specifically requested, the investigator may need to provide additional follow -up 
information, such as discharge summaries, medical records, or extracts from the 
medical records.  In this case, all subject identifiers, with the exception of the 
subject number, will be blinded on the copies of the medical records before 
submission to Amgen . 
 The investigator will record the adverse event by the diagnostic term for that 
adverse event (not the individual signs/symptoms).  Only in the event that no  
diagnosis  can be made should the  individual signs/symptoms be documented as 
an adverse event /serious adverse event.  
Evaluating Adverse Events and Serious Adverse Events  
Assessment of Severity  
The investigator will make an assessment of severity for each adverse event and 
serious adverse event reported during the study.  The assessment of severity will be 
based on:   
The Common Terminology Criteria for Adverse Events , version 5.0 which is available 
at the following location:  
http://ctep.cancer.gov/pro tocolDevelopment/electronic_applications/ctc.htm . 
 
Assessment of Causality  
 The investigator is obligated to assess the relationship between investigational 
product , protocol -required therapies, and/or study -mandated activity and/or 
procedure (s) and each occurrence of each adverse event/serious adverse event.  
 Relatedness means that there are facts or reasons to support a relationship 
between investigational product and the event.  
 The investigator will use clinical judgment to determine the relati onship.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study treatment 
administration will be considered and investigated.  
 The investigator will also cons ult the Investigator’s Brochure and/or Product 
Information, for marketed products, in his/her assessment.  
 For each adverse event/serious adverse event, the investigator must document in 
the medical notes that he/she has reviewed the adverse event/serious a dverse 
event and has provided an assessment of causality.  
 There may be situations in which a serious adverse event has occurred and the 
investigator has minimal information to include in the initial report.  However, it is 
very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the serious adverse event data.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 115 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Assessment of Causality  
 The investigator may change his/her opinion of causality in light of follow -up 
information and send a serious adverse eve nt follow -up report with the updated 
causality assessment.  
 The causality assessment is 1 of the criteria used when determining regulatory 
reporting requirements.  
 
Follow-up of Adverse Event and Serious Adverse Event  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by 
Amgen  to elucidate the nature and/or causality of the adverse event or serious 
adverse event as fu lly as possible.  This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health 
care professionals.  
 If a subject is permanently withdrawn from protocol -required therapies because of 
a serious adverse event, this information must be submitted to Amgen.  
 If a subject dies during participation in the study or during a recognized follow -up 
period, the investigator will provide Amgen with a copy of any post -mortem findings 
including histopath ology.   
 New or updated information will be recorded in the originally completed Event 
CRF.  
 The investigator will submit any updated serious adverse event data to Amgen  
within 24 hours of receipt of the information.  
Reporting of Serious Adverse Event  
Serious Adverse Event Reporting via Electronic Data Collection Tool  
 The primary mechanism for reporting serious adverse event will be the electronic 
data capture (EDC) system via the Events form .  
 If the EDC system is unavailable for more than 24 hours, then the site will report 
the information to Amgen using a paper -based  Serious Adverse Event 
Contingency Report Form (also referred to as the electronic Serious Adverse 
Event [eSAE] Contingency Repor t Form)  (see Figure 12 -1) within 24  hours of the 
investigator’s knowledge of the event.  
 The site will enter the serious adverse event data into the electronic system as 
soon as it becomes available.  
 After the study i s completed at a given site, the EDC system will be taken off -line to 
prevent the entry of new data or changes to existing data.  
 If a site receives a report of a new serious adverse event from a study subject or 
receives updated data on a previously report ed serious adverse event after the 
EDC has been taken off -line, then the site can report this information on the 
paper -based Serious Adverse Event Contingency Report Form  (see Figure 12 -1). 
 Once the study has ended, serious adverse event(s) suspected to be related to 
investigational product  will be reported to Am gen if the investigator becomes aware 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 116 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
of a serious adverse event.  The investigator should use the paper -based Serious 
Adverse Event Contingency Report Form to report the event.  
 
Figure 12-1.  Sample Electronic Serious Adverse Event Contingency Report Form  
 

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 117 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
  

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 118 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 119 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 120 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 
 

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 121 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.5 Appendix 5.  Contraceptive Guidance and Collection of Pregnancy 
and Lactation Information  
For the region -specific guidance regarding the use o f lenalidomide, please refer to the 
regional label.  
Study -specific contraception requirements for males and females of childbearing 
potential  are outlined in Section  6.2. 
12.5.1 Risks Associated With Pregnancy  
Male and female subjects of childbearing potential must receive pregnancy prevention 
counseling and be advised of the risk to the fetus if they become pregnan t or father a 
child during treatment and for 30 days (for female subjects) and 90 days (for male 
subjects) after the last dose of protocol -required therapies.  
12.5.2 Counseling  
12.5.2.1 Female Subjects of Childbearing Potential  
For a female of childbearing potential, len alidomide is contraindicated unless all of the 
following are met (ie, all females of childbearing potential [FCBP] must be counseled 
concerning the following risks and requirements prior to the start of lenalidomide study 
therapy):  
 She understands the pote ntial teratogenic risk to the unborn child.  
 She understands the need for effective contraception, without interruption, 28 days 
before starting study treatment, throughout the entire duration of study treatment,  
during treatment interruptions, and for an  additional 30 days after the last dose of all 
study drug(s)  
 She should be capable of complying with effective contraceptive measures.  
 She is informed and understands the potential consequences of pregnancy and the 
need to notify her study doctor immediately if there is a risk of pregnancy.  
 She understands the need to commence the study treatment as soon as study drug 
is dispensed after a negative pregnancy test.  
 She understands the need and accepts to undergo pregnancy testing based on the 
frequency outlined in this protocol.  
 She acknowledges that she understands the hazards and necessary precautions 
associated with the use of lenalidom ide. 
The investigator must ensure that for FCBP:   
 Complies with the conditions for pregnancy risk minimization, including confirmation 
that she has an adequate level of understanding.  
 Acknowledge the aforementioned requirements.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 122 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.5.2.2 Female Subjects Not of C hildbearing Potential  
For a female NOT of childbearing potential, lenalidomide is contraindicated unless all of 
the following are met (ie, all females NOT of childbearing potential must be counseled 
concerning the following risks and requirements prior to the start of lenalidom ide study 
therapy):  
 She acknowledges that she understands the hazards and necessary precautions 
associated with the use of lenalidomide  
12.5.2.3 Male Subjects:  
 Traces of lenalidomide have been found in blood, sperm, and semen.  Male subjects 
taking lenalidomide m ust meet the following conditions (ie, all males must be 
counseled concerning the following risks and requirements prior to the start of 
lenalidomide study therapy):  
 Understand the potential teratogenic risk if engaged in sexual activity with a 
pregnant f emale or a female of childbearing potential  
 Understand the need for the use of a condom with spermicide even if he has had 
a vasectomy, if engaged in sexual activity with a pregnant female or a female of 
childbearing potential.  
 Counseling about the requir ement for latex condom with spermicide use during 
sexual contact with FCBP and the potential risks of fetal exposure must be 
conducted at a minimum of every 28 days and at the time that lenalidomide 
treatment is discontinued.  During counseling, subjects m ust be reminded to not 
share study drug and to not donate blood, sperm, or semen.  
12.5.3 Definition of Females of Childbearing Potential  
A female is considered fertile after menarche and until becoming postmenopausal 
unless permanently sterile.  Permanent sterili zation methods include hysterectomy, 
bilateral salpingectomy, and bilateral oophorectomy.  
Females in the following categories are not considered female of childbearing potential : 
 Premenopausal female with 1 of the following:  
 Documented hysterectomy;  
 Docume nted bilateral salpingectomy; or  
 Documented bilateral oophorectomy.  
Note:  Site personnel documentation from the following sources is acceptable: 
1) review of subject’s medical records; 2) subject’s medical examination; or 
3) subject’s medical history inte rview.  
 Premenarchal female  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 123 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 Postmenopausal female  
 A postmenopausal state is defined as no menses for 12 consecutive  months 
without an alternative medical cause.  A high follicle stimulating hormone (FSH) 
level in the postmenopausal range may be used to conf irm a postmenopausal 
state in women not using hormonal contraception or hormonal replacement 
therapy (HRT).  However, in the absence of 12  months of amenorrhea, a single 
FSH measurement is insufficient.  
 Females on HRT and whose menopausal status is in doubt will be required to 
use 1 of the non -hormonal highly effective contraception methods if they wish to 
continue their HRT during the study.  Otherwise, they must discontinue HRT to 
allow confirmation of postmenopausal status before study enrollment  
12.5.4 Contraception Methods  
12.5.4.1 Contraception Methods for Female Subjects  
Females of childbearing potential should be advised to avoid becoming pregnant while 
being treated with carfilzomib or lenalidomide.  Lenalidomide is structurally related to 
thalidomide.  Thalid omide is a known human teratogenic active substance that causes 
severe life -threatening birth defects. An embryo -fetal development study in animals 
indicates that lenalidomide produced malformations in the offspring of female monkeys 
who received the drug during pregnancy.  The teratogenic effect of lenalidomide in 
humans cannot be ruled out.  Therefore, a risk minimization plan to prevent pregnancy 
must be observed.  
Carfilzomib was clastogenic in the in vitro chromosomal aberration test in peripheral 
blood lymphocytes.   
Therefore, as a precaution, FCBP and/or their male partners must agree to use 
2 methods of contraception as described below or abstain from sexual activity 28 days 
before treatment, during treatment, during treatment interruptions, and for  an additional 
30 days after the last dose of all study drug(s).  
Female subjects of childbearing potential must agree to use 2 methods of contraception 
simultaneously (1 highly effective form of contraception as described below, and 
1 additional effective contraceptive method [male latex or synthetic condom with 
spermicide for male partners of FCBP, or a diaphragm or cervical cap]).  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 124 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Highly Effective Contraceptive Methods  
Note: Failure rate of <  1% per year when used consistently and correctly.  
 combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation (oral, intravaginal, or transdermal)  
 progestogen -only hormonal contraception associated with inhibition of ovulation 
(oral, injectable, implantable)  
 intrau terine device  
 intrauterine hormonal -releasing system  
 bilateral tubal ligation/occlusion  
 vasectomized partner (provided that partner is the sole sexual partner of the female 
subject of childbearing potential and that the vasectomized partner has received 
medical assessment of the surgical success)  
 sexual abstinence (defined as refraining from heterosexual intercourse during the 
entire period of risk associated with the study treatments; the reliability of sexual 
abstinence must be evaluated in relation to the duration of the study and the 
preferred and usual lifestyle of the subject)  
12.5.4.2 Contraception Methods for Male Subjects  
 Sexual abstinence (defined as refraining from heterosexual intercourse during the 
entire period of risk associated with protocol -requir ed therapies; the reliability of 
sexual abstinence must be evaluated in relation to the duration of the study and the 
preferred and usual lifestyle of the subject).  
 Use a condom with spermicide during treatment and for an additional 90 days  after 
the last  dose of protocol -required therapies even if he has undergone a successful 
vasectomy.  
The female partner should consider using an acceptable method of effective 
contraception such as: hormonal, intrauterine device, intrauterine hormonal -releasing 
system, f emale barrier method (diaphragm, cap, sponge [a female condom is not an 
option because there is a risk of tearing when both partners use a condom]).  
Male subjects with a pregnant partner must practice sexual abstinence or wear a 
condom with spermicide to p revent exposure of the unborn child to carfilzomib or 
lenalidomide through semen.  
Male subjects will be warned that sharing study drug is prohibited and will be counseled 
about pregnancy precautions and potential risks of fetal exposure.  
Note: If the male’ s sole female partner is of non -childbearing potential or has had a 
bilateral tubal ligation/occlusion, he is not required to use additional forms of 
contraception during the study.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 125 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.5.4.3 Unacceptable Methods of Birth Control for  Male and Female 
Subjects  
Birth c ontrol methods that are considered unacceptable in clinical studies include:  
 Periodic abstinence (calendar, symptothermal, post -ovulation methods)  
 Withdrawal (coitus interruptus)  
 Spermicides only  
 Lactational amenorrhea method  
12.5.5 Pregnancy Testing  
12.5.5.1 Female Subj ects 
Medically supervised pregnancy tests with a minimum sensitivity of 50  mIU/mL must be 
performed for FCBP, including FCBP who commit to complete abstinence, as outlined 
below.  
Before starting lenalidomide:  
Female Subjects : 
 FCBP must have 2 negative pregnancy tests (sensitivity of at least 50  mIU/mL) prior 
to starting lenalidomide.  The first pregnancy test must be performed within 10 to 
14 days prior to the first dose of study drugs and the second pregnancy test must be 
performed within 24 hours prio r to the start of lenalidomide.  The subject may not 
receive lenalidomide until the Investigator has verified that the results of these 
pregnancy tests are negative.  
 Will be warned that sharing study drug is prohibited and will be counseled about 
pregnancy  precautions and potential risks of fetal exposure.  
 Must agree to abstain from donating blood during study participation and for at least 
90 days after the last dose of all study drug(s).  
During study participation and for 30  days after discontinuation fro m the study:  
Female Subjects:  
 FCBP with regular menstrual cycles must agree to have pregnancy tests weekly for 
the first 28 days of study participation and then every 28 days while on study, and 
30 [+3] days after the last dose of all study drug(s).  If me nstrual cycles are irregular, 
the pregnancy testing must occur weekly for the first 28 days and then every 14 days 
while on study, 30 [+3]  days after the last dose of all  study drug(s).  
 In addition to the required pregnancy testing, the Investigator must c onfirm with 
FCBP that she is continuing to use 2 reliable methods of birth control at each visit.  
 Counseling about pregnancy precautions and the potential risks of fetal exposure 
must be conducted at a minimum of every 28 days and at the time that lenalido mide 
treatment is discontinued.  During counseling, subjects must be reminded to not 
share study drug and to not donate blood.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 126 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 Pregnancy testing and counseling must be performed if a subject misses her period 
or if her pregnancy test or her menstrual bleed ing is abnormal.  Lenalidomide 
treatment must be discontinued during this evaluation.  
 Females must agree to abstain from breastfeeding during study participation and for 
at least 30 days after the last dose of all study drug(s).  
 If pregnancy or a positive pregnancy test does occur in a study patient, study drug 
must be immediately discontinued.  
12.5.5.2 Male Subjects:  
If pregnancy or a positive pregnancy test does occur in the partner of a male study 
patient during study participation, the investigator must be noti fied immediately.  
12.5.6 Additional Precautions  
 Subjects should be instructed never to give lenalidomide to another person and to 
return any unused lenalidomide to the study doctor at the end of treatment.  
 Only enough lenalidomide for 1 cycle of therapy may be  dispensed with each cycle 
of therapy.  
 Implants and levonorgestrel -releasing intrauterine systems are associated with an 
increased risk of infection at the time of insertion and irregular vaginal bleeding.  
Prophylactic antibiotics should be considered par ticularly in subjects with 
neutropenia.  
 Carfilzomib could decrease the effectiveness of oral contraceptives.  The investigator 
should notify subjects of this risk when choosing the methods of birth control. 
Additional medications given during the study ma y alter the contraceptive .  The 
investigator must discuss these contraceptive changes with the subject.  
 Female subjects should not donate blood during therapy and for at least 90 days 
after the last dose of all study drug(s).  
 Male subjects should not dona te blood, semen, or sperm during therapy and for at 
least 90 days after the last dose of all  study drug(s).  
 Additional medications given during the study may alter the contraceptive 
requirements.  These additional medications may require female subjects t o use 
different method of highly effective methods of contraception and/or for an increased 
length of time.  The investigator must discuss these contraceptive changes with the 
subject.   
12.5.7 Collection of Pregnancy Information  
Female Subjects Who Become Pregna nt 
 Investigator will collect pregnancy information on any female subject who becomes 
pregnant while taking protocol -required therapies through 30-days after the last 
dose of protocol -required therapies.  
 Information will be recorded on the Pregnancy Notification Form (see 
Figure 12 -2).  The form must be submitted to Amgen Global Patient Safety within 
24 hours of learning of a subject’s pregnancy.  (Note: Sites are not required to 
provide any information on the Pregnancy Notification Form that violates the 
country or regions local privacy laws).  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 127 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 After obtaining the female subject’s signed authorization for release of pregnancy 
and infant health information, the investigator will collect  pregnancy and infant 
health information and complete the pregnancy questionnaire for any female subject 
who becomes pregnant while taking protocol -required therapies through 30 days 
after the last dose  of all study drugs.  This information will be forwarded to Amgen 
Global Patient Safety.  Generally, infant follow -up will be conducted up to 12  months 
after the birth of the child (if applicable).  
 Any termination of pregnancy will be reported to Amgen Global Patient Safety, 
regardless of fetal status (presence or absence of anomalies) or indication for 
procedure.  
 While  pregnancy itself is not considered to be an adverse event or serious adverse 
event, any pregnancy complication or elective termination of a pregnancy for 
medical reasons will be reporte d as an adverse event or serious adverse event.  
Abnormal pregnancy outcomes (eg, spontaneous abortions, stillbirth, fetal death, 
congenital anomalies) will be reported as an adverse event or serious adverse 
event.   Note that an elective termination with no information on a fetal congenital 
malformation or maternal complication is generally not considered an adverse 
event, but still must be reported to Amgen as a pregnancy exposure case.  
 If the outcome of the pregnancy meets a criterion for immediate class ification as a 
serious adverse event (eg, female subject has a spontaneous abortion, stillbirth, or 
neonatal death or there is a fetal or neonatal congenital anomaly) the investigator 
will report the event as a serious adverse event.  
 Any serious adverse ev ent occurring as a result of a poststudy pregnancy which is 
considered reasonably related to the study treatment by the investigator, will be 
reported to Amgen Global Patient Safety as described in Section  12.4.  While the 
investigator is not obligated to actively seek this information in former study 
subjects, he or she may learn of a serious adverse event through spontaneous 
reporting.  
 Any female  subject who becomes pregnant while participating will discontinue study 
treatment  (see Section  8.1 for details).  
Male Subjects With Partners Who Become Pregnant   
 In the event a male subject fathers a child during treatment, and for an additional 
90 days after discontinuing protocol -required therapies, the information will be 
recorded on the Pregnancy Notification Form.  The form ( see  
Figure 12 -2) must be submitted to Amgen Global Patient Safety within 24 hours of 
the site’s awareness of the pregnancy.  (Note: Sites are not required to provide any 
information on the Pregnancy Notification Form that violates the country or regions 
local privacy law s).   
 The investigator will attempt to obtain a signed authorization for release of 
pregnancy and infant health information directly from the pregnant female partner to 
obtain additional pregnancy information.   
 After obtaining the female partner’s signed authorization for release of pregnancy 
and infant health information, the investigator will collect pregnancy outcome and 
infant health information on the pregnant partner and her baby and complete the 
pregnancy questionnaires.  This information will be fo rwarded to Amgen Global 
Patient Safety.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 128 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 Generally, infant follow -up will be conducted up to 12 months after the birth of the 
child (if applicable).  
 Any termination of the pregnancy will be reported to Amgen Global Patient Safety 
regardless of fetal status  (presence or absence of anomalies) or indication for 
procedure.  
12.5.8 Collection of Lactation Information  
 Investigator will collect lactation information on any female subject who breastfeeds 
while taking protocol -required therapies through  30 days after the la st dose of  
protocol -required therapies . 
 Information will be recorded on the Lactation Notification Form (see below) and 
submitted to Amgen Global Patient Safety within 24 hours of the investigator’s 
knowledge of event.  
 Study treatment will be discontinued if female subject breastfeeds during the study 
as described in exclu sion criterion 235.   
 With the female subjects signed authorization for release of mother and infant health 
information, the investigator will collect mother and infant health information and 
complete the lactation questionnaire on any female subject who breastfeeds while 
taking protocol -required therapies through 30 days after discontinuing protocol -
required therapies.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 129 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
Figure 12-2.  Pregnancy and Lactation Notification Forms  
 
 
Amgen Proprietary - Confidential  
Pregnancy Notification Form 
 
Report to Amgen at: USTO fax: +1-888-814-8653, Non -US fax : +44 (0)207 -136-1046 or email  (worldwide) : svc-ags-in-us@amgen.com  
 
1. Case Administrative Information 
Protocol/Study Number:  20180015   
 
Study Design:  X Interventional Observational (If Observational: Prospective Retrospective) 
 
2. Contact Information 
Investigator Name   _ Site #    
 
Phone (  )  _ Fax (_     _)    
Email    
Institution    
Address     
 
3.  Subject Information 
Subject ID #   _ Subject Gender: Female Male Subject age (at onset):        (in years)  
 
4.  Amgen Product Exposure  
 
 
Amgen Product Dose at time of 
conception  
Frequency  
Route   
Start Date 
     
mm  /dd  /yyyy   
 
Was the Amgen product (or study drug) discontinued? Yes No 
If yes, provide product (or study drug) stop date: mm    /dd   /yyyy   
Did the subject withdraw from the study? Yes No 
 
 
5.  Pregnancy  Information 
Pregna nt female’s last menstrual period (LMP)  mm   / dd_____ _/ yyyy    Unknown  N/A 
 Estimated date of delivery   mm  / dd  _/ yyyy   
If N/A, date of termination (actual or planned) mm    / dd   _/ yyyy    
Has the pregnant female already delivered? Yes No  Unkno wn N/A 
If yes, provide date of delivery:  mm     / dd    / yyyy   
Was the infant healthy? Yes No Unknown N/A 
If any Adverse Event was experienced by the infant, provide brief details:   
 
 
 
 
 
Form Completed by: 
 
Print Name:      
 
 
 
Title:     
 
Signature:      
Date:     
 
 
 
FORM -115199                                                                                        Version 1.0                                                                          Effective Date: 24 -Sept -2018  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 130 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
 
Amgen Proprietary - Confidential  
 
Lactation Notification Form  
 
 
Report to Amgen at: USTO fax : +1-888-814-8653, Non -US fax : +44 (0)207 -136-1046 or email  (worldwide) : svc-ags-in-us@amgen.com  
1. Case Administrative Information 
Protocol/Study Number:  20180015   
 
Study Design:  X Interventional Observational (If Observational: Prospective Retrospective) 
 
2.  Contact Information 
Investigator Name     
 
Site #    
 
Phone (  )    
Fax (  )    
Email    
Institution    
Address     
 
 3.  Subject Information 
Subject ID #     
 
 
 
Subject age (at onset):        (in years)
 
4.  Amgen Product Exposure 
 
 
Amgen Product Dose at time of 
breast feeding   
Frequency  
Route   
Start Date 
     
mm  /dd  /yyyy   
 
Was the Amgen product (or study drug) discontinued? Yes No 
If yes, provide product (or study drug) stop date: mm    /dd   /yyyy   
Did the subject withdraw from the study? Yes No 
 
5.  Breast Feeding Information 
 
Did the mother breastfeed or provide the infant with pumped breast milk while actively taking an Amgen product? Yes No 
 
If No, provide stop date:  mm    /dd   /yyyy   
Infant date of birth: mm  /dd  /yyyy    
Infant gender: Female Male 
 
Is the infant healthy? Yes No Unknown N/A 
 
 
If any Adverse Event was experienced by the mother or the infant, provide brief details:   
 
 
 
 
 
 
  Form Completed by: 
 
Print Name:      
 
Title:     
 
Signature:      
Date:     
 
FORM -115201                                                                                      Version 1.0                                                                            Effective Date: 24 -Sept-2018  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 131 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.6 Appendix 6.  Sample Storage and Destruction  
Any blood or bone marrow  sample  collected according to the Schedule of Activities 
(Table 2 -1) can be analyzed for any of the tests outlined in the protocol and for any tests 
necessary to minimize risks to study subjects.  This includes testing to ensure analytical 
methods produce reliable and valid data throughout the course of the study.  This can 
also include, but is no t limited to, investigation of unexpected results, incurred sample 
reanalysis, and analyses for method transfer and comparability.  
All samples and associated results will be coded prior to being shipped from the site for 
analysis or storage.  Samples will be tracked using a unique identifier that is assigned to 
the samples for the study.  Results are stored in a secure database to ens ure 
confidentiality.  
If informed consent is provided by the subject, Amgen can do additional testing on 
remaining samples (ie, residual and back -up) to investigate and better understand 
multiple myeloma , the dose response and/or prediction of response to  carfilzomib , and 
characterize aspects of the molecule (eg, mechanism of action/target, metabolites).  
Results from this analysis are to be documented and maintained but are not necessarily 
reported as part of this study.  Samples can be retained for up to 20 years.   
Since the evaluations are not expected to benefit the subject directly or to alter the 
treatment course, the results of pharmacogenetic, biomarker development,  or other 
exploratory studies are not placed in the subject’s medical record and are not to be 
made available to the subject, members of the family, the personal physician, or other 
third parties, except as specified in the informed consent.  
The subject re tains the right to request that the sample material be destroyed by 
contacting the investigator.  After the request from the subject, the investigator is to 
provide the sponsor with the required study and subject number so that any remaining 
blood or bone marrow  samples and any other components from the cells can be located 
and destroyed.  Samples will be destroyed once all protocol -defined procedures are 
completed.  However, information collected from samples prior to the request for 
destruction, will be r etained by Amgen.  
The sponsor is the exclusive owner of any data, discoveries, or derivative materials from 
the sample materials and is responsible for the destruction of the sample(s) at the 
request of the subject through the investigator, at the end of t he storage period, or as 
appropriate (eg, the scientific rationale for experimentation with a certain sample type no 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 132 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
longer justifies keeping the sample).  If a commercial product is developed from this 
research project, the sponsor owns the commercial pro duct.  The subject has no 
commercial rights to such product and has no commercial rights to the data, information, 
discoveries, or derivative materials gained or produced from the sample.  See 
Section  12.3 for subject confidentiality.   
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 133 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.7 Appendix 7.  Hepatotoxicity Stopping Rules: Suggested Actions and 
Follow-up Assessments and Study Treatment Rechallenge 
Guidelines  
Hepatotoxicity stopping rules are described in Section  7.4.1.1.2 . 
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 134 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.8 Appendix 8.  Guidelines for Documenting Prior Treatment  
Subjects  must have documented relapse after  at least 1, but no more than 3 prior 
treatment regimens or lines of therapy for multiple myeloma including relapse after the 
last line of therapy prior to enrollment .  When documenting prior treatments for multiple 
myeloma, the following guidelines should  be used:  
 A new line of therapy is considered to start when a planned course of therapy is 
modified to include other treatment agents (alone or in combination) as a result of 
lack of adequate response, progressive disease (PD) (even if the level of 
progres sion has not yet met International Myeloma Working Group -Uniform 
Response Criteria [IMWG -URC] for PD), relapse, or toxicity.  
 An increase in dose of therapy, with the intention of recapturing response in a 
subject who has evidence of progression on that the rapy, is considered a new 
therapy.  
 A new line of therapy is also considered to start when a planned period of 
observation of therapy is interrupted by a need for additional treatment for the 
disease.  
 Examples of 1 line of therapy include:  
 Induction therapy  and stem cell transplant followed by planned maintenance 
therapy (provided there is no intervening PD)  
 Induction therapy followed by maintenance therapy (provided there is no 
intervening  PD) 
 Documentation of at least partial response (PR) to at least 1 pr ior therapy  
 For patients with prior carfilzomib therapy, documentation of response (≥  PR) must 
be available for the most recent previous carfilzomib therapy as well as stop date.  
Documentation that the subject was not removed from carfilzomib therapy due to 
toxicity must also be available.  For patients with prior therapy with either carfilzomib, 
the start of the 6 -month treatment -free interval is when either carfilzomib is 
discontinued even if other portions of the regimen are continued.  
 
 
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 135 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.9 Appendix 9.  E COG Performance Status  
Grade  Description  
0 Normal activity, fully active, able to carry on all predisease performance 
without restriction.  
1 Symptoms, but fully ambulatory, restricted in physically strenuous but 
ambulatory and able to carry out work of a  light or sedentary nature 
(eg, light housework, office work).  
2 Ambulatory and capable of all self -care but unable to carry out any work 
activities.  Up and about more than 50% of waking hours.  
3 Capable of only limited self -care, confined to bed or chair more than 
50% of waking hours.  
4 Completely disabled.  Cannot carry on any self -care.  Totally confined to 
bed or chair.  
5 Dead  
ECOG = Eastern Cooperative Oncology Group.  
Source:  Oken et al, 1982.  
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 136 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.10 Appendix  10.  2018 ESH/ESC Office Blood Pressure Measurement  
  
For more information, please see American Medical Association, 2019 (https://www.ama -
assn.org/delivering -care/hypertension/one -graphic -you-need -accurate -blood -pressure -reading).  
 
 
  
 
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 137 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.11 Appendix 11.  Sum mary of International Myeloma Working Group - 
Uniform Response Criteria  
Response 
Subcategory  Multiple Myeloma Response Criteria  
sCR  Negative immunofixation on the serum and urine and  
 Disappearance of any soft tissue plasmacytomas and 
 < 5% plasma cells in bone marrow aspirate and  
 Normal SFLC ratio and  
 Absence of clonal cells in bone marrow biopsy by immunohistochemistry  or 
2- to 4-color flow cytometrya  
CR  Negative immunofixation on the serum and urine and  
 Disappearance of any soft tissue plasmacytomas and 
 < 5% plasma cells in bone marrow  
 In subjects with baseline measurable disease only by SFLC, normal SFLC 
ratio 
VGPR   Serum and urine M -protein detectable by immunofixation but not on 
electrophoresis or  
  90% reduction in serum M -protein with urine M -protein <  100 mg per 
24 hours  
 In subjects with baseline measurable disease only by SFLC, a decrease 
 90% in the difference between involved and uninvolved FLC levels  
 In subjects  achieving a VGPR by other crit eria, a soft tissue plasmacytoma 
must decrease by more than 90% in the SPD compared with baseline  
PR   50% reduction of serum M -protein and reduction in 24 -hour urinary 
M-protein by  90% or to < 200  mg per 24 hours   
 In subjects with measurable disease only by SFLC, a decrease  50% in 
the difference between involved and uninvolved FLC levels is required in 
place of the M -protein criteria.  
 In addition to these criteria, if present at baseline, a  50% reduction in the 
size (SPD) of soft tissue plasmacytomas is also required  
SD  Not meeting criteria for CR, VGPR, PR, or PD  
PD  Increase of 25% from lowest confirmed  response value in 1 or more of the 
following:  
 Serum M -component (absolute increase must be  0.5 g/dL if the 
lowest M -component was < 5 g/dL  
 Urine M -component (absolute increase must be  200 mg per 24  hours)  
 Only in subjects  without measurable serum and urine M  protein levels:  
the difference between involved and uninvolved FLC levels (absolut e 
increase must be >  10 mg/dL)  
 Increase of serum M -component of ≥ 1 g/dL if the lowest M -component was 
≥ 5 g/dL)  
 Appearance of new lesion(s),  50% increase from nadir in SPD of > 
1 lesion, or  50% increase in longest diameter of a previous lesion > 1  cm 
in short axis  
  50% increase in circulating plasma cells (minimum of 200 cells per μL) if 
this is the only measure of disease  
CR = complete response; FC = flow cytometry; FLC = free light chain; PD  = progressive disease; 
PR = partial response; sCR = stringent complete response; SFLC = serum -free light chain; SPD  = maximal 
perpendicular diameter; VGPR = very good partial response  
a In this study, only immunohistochemistry is used for respons e assessment.  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 138 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
All response categories (complete response [CR], stringent complete response [sCR], 
very good partial response [VGPR], partial response [PR]) require 2  consecutive 
assessments before the initiation of any new therapy, as well as no known evid ence of 
progressive or new bone lesions if radiographic studies were performed.   Radiographic 
studies are not required to satisfy these response requirements.   Bone marrow, 
plasmacytoma, and skeletal survey assessments are not required to be confirmed by 
repeat testing.    
Subjects will continue in the last confirmed response category until there is confirmation 
of progression or improvement to a higher response status; subjects cannot move to a 
lower response category.  
For sCR:   presence/absence of clonal c ells is based upon the kappa/lambda (κ/λ) ratio. 
An abnormal kappa lambda ratio by immunohistochemistry and/or immunofluorescence 
requires a minimum of 100 plasma cells for analysis.  
Response criteria for all categories and subcategories of response, excep t CR, sCR,  
and PD are applicable only to patients that have measurable disease, defined by at least 
1 of:   
 Immunoglobulin (Ig) G multiple myeloma:  serum monoclonal paraprotein (M -protein) 
level ≥ 1.0 g/dL,  
 IgA, IgD, IgE multiple myeloma:  serum M -protein  level ≥ 0.5 g/dL,  
 urine M -protein ≥ 200 mg/24 hours,  
 in subjects without measurable serum or urine M -protein, serum -free light chain 
(SFLC) ≥  100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio  
Determination of PD while on study requ ires 2 consecutive assessments (to confirm 
response or PD, 2  discrete samples are required; samples may be drawn on the same 
day) before classification of PD and/or the institution of new therapy.  Confirmative 
samples for PD after new therapy can be used.   Serum M -component increases of 
≥ 1 g/dL from nadir are sufficient to define progression if nadir M -component is ≥ 5 g/dL.  
Plasmacytomas:   A plasmacytoma is considered measurable if the longest diameter is at 
least 1  cm and the product of the cross diamet ers is at least 1  cm2.  Progression is 
defined as appearance of a new lesion(s), ≥ 50% increase from nadir of the sum of the 
products of the maximal perpendicular diameter (SPD) of the measurable lesion as 
measured serially, or a ≥  50% increase in the long est diameter of a previous lesion 
> 1 cm short axis; ≥ 50% increase in plasma cells if this is the only measure of disease.     
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 139 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
For defining nadir, in the case where a value is felt to be a spurious result per 
physician/Independent Review Committee (IRC) di scretion (eg, a possible laboratory 
error), that value will not be considered when determining the lowest value.  
Sources:   Kumar et al, 2016; Rajkumar et al, 2011; Durie et al, 2006.  
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 140 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   
12.12 Appendix 12.  Patient-reported Convenience With 
Carfilzomib -dosing Sche dule Question  
Instructions: We want to ask you a question about the convenience of the 
carfilzomib -dosing schedule you are receiving in this clinical study.  Please provide 
1 response.  
I find the carfilzomib -dosing schedule   
1 Very Inconvenient 2 Inconvenient  3 Convenient 4 Very Convenient  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 141 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 142 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 143 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 144 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   

Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  02 September 2021  Page 145 of 145 
CONFIDENTIAL  FORM -001520, v.22, 05 February 2018   

Product:  Carfilzomib  
Protocol  Number:  20180015  
Date:  02 September 2021 Page 1 of 2 
Amgen Proprietary - Confidential  
FORM-492529,   Effective Date: 02 Mar 2020 ,  Version: 6.0   Superseding Amendment 3 
Protocol Title:  A Randomized, Open -label, Phase 3 Study Comparing Once -
weekly vs Twice -weekly Carfilzomib in Combination With Lenalidomide and 
Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma 
(A.R.R.O.W.2)  
 
Amgen Protocol Number Carfilzomib 20180015  
EudraCT Number:  2018 ‐000665‐36 
NCT Number:  03859427  
 
Amendment Date:  02 September  2021  
 
Rationale:    
The protocol amendment dated 02 September  2021  is being amended to:   
 revise exclusion criterion 214 from ‘exceeds’ to ‘greater than or equal to’ in order to 
retain consistency with Protocol Amendment 2 on the exact cutoff blood pressure for 
exclusion.    
 correct an error in Section 9.2.2 .2 to clarify that the percent myeloma cell 
involvement must be reported before randomization for subjects with a screening 
platelet count  50 x 109/L.   
 update the protocol on typographical, fo rmatting, and editorial changes.   
 
 
 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  12  August 2021 Page 1 of 27 
Amgen Proprietary - Confidential  
FORM-492529, Effective Date: 02 Mar 2020 , Version:  6.0 Amendment 3  
Protocol Title:  A Randomized, Open -label, Phase 3 Study Comparing Once -
weekly vs Twice -weekly Carfilzomib in Combination With Lenalidomide and 
Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma 
(A.R.R.O.W.2)  
 
Amgen Protocol Number Carfilzomib 20180015  
EudraCT Number:  2018 ‐000665‐36 
NCT Number:  03859427  
 
Amendment Date:  12 August  2021  
Rationale:  
The protocol amendment dated 12 August  2021 is being amended to:  
 to remove the word “rate” from overall response rate of the primary endpoint  
 update the Schedule of Activities to align with language updates  
 clarify study duration for subjects (Section 5.3.2)  
 clarify inclusion criterion 103  
 replace inclusion criteria 106 and 107  with 110 and 111, respectively  
 clarify exclusion criterion 214 and replace exclusion criterion 234 with 244  
 clarify administration of Dexamethasone (Section 7.1.2.1)  
 update the section 7.1.2.2.2. Dosage, Administration, and S chedule to clarify the 
dosage of Lenalidomide that investigator should refer to the regional product label for 
dose adjustments in patients with renal impairment  
 update other protocol -required therapies include thromboprophylaxis 
(Section  7.1.4.3) and bisphosphona te or monoclonal antibody therapy 
(Section  7.1.4.6)  
 clarify that the study treatment with lenalidomide and dexamethasone will be 
discontinued upon confirmation of disease progression (Section 7.4.1.2 and 7.4.1.3)  
 update Section 9.1.4 to clarify long -term f ollow -up will commence 28 -days after the 
safety follow -up visit  
 update SPEP, UPEP, SFLC, SIF E, and UIFE (Section 9.2.2.1)  
 update bone marrow sample assessment at baseline (remove permission to use 
archival material) (Section 9.2.2.2)  
 update Bone Lesion Ass essment (Section 9.2.2.3)  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  12  August 2021 Page 2 of 27 
Amgen Proprietary - Confidential  
FORM-492529, Effective Date: 02 Mar 2020 , Version:  6.0  update language in the SAE safety reporting sections to align with the alternative 
protocol language provided in the Memorandum sent out on 16Jul2021  
 update  Pulmonary Function Tests  (Section 9.2.3.4.2) to clarify that the Baseline  and 
surveillance pulmonary function tests are optional; may be performed if clinically 
indicated at the discretion of the investigator.   
 update Planned Analysis  (Section 10.3.1 ) and Methods of Analysis (Section 10.3.2)  
 update Appendix 4 to align to eSAE Timed Transmission process  
 update Appendix 11 to align with IMWG guidance  
 aligned the protocol with current Amgen protocol template and safety reporting 
language  
 typographical, formatting, and editorial changes were done throughout the protocol  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  24 August 2020  Page 1 of 57 
Confidential   
Amendment 2 
Protocol Title:  A Randomized, Open -label, Phase 3 Study Comparing 
Once-weekly vs Twice -weekly Carfilzomib in Combination With 
Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory 
Multiple Myeloma (A.R.R.O.W.2)  
 
Amgen Protocol Number (Carfi lzomib)  20180015  
EudraCT number 2018‐000665‐36 
Amendment Date:  24 August  2020  
 
Rationale:  
 To amend the secondary objective to collect progression free survival and overall 
survival over the duration of the study  
 Overall study design language amended to assess subjects with multiple 
myeloma disease response until first subsequent antimyeloma treatment  
 Updated language for randomization with regard to the staging syst em to be 
used  
 Updated language for data monitoring committee to meet approximately every 
6 months to review safety and efficacy data for futility planned to occur when the 
first 230 subjects are randomized  
 Added information of dose infusion using an infusi on pumps  
 Study procedures section amended to remove conduct of interviews with 
subjects to validate questionnaires for multiple myeloma module  
 Deleted early success for efficacy from interim analysis  
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  10 October 2019  Page 1 of 45 
CONFIDENTIAL   
  Amendment 1 
Protocol Title:  A Randomized, Open -label, Phase 3 Study Comparing 
Once-weekly vs Twice -weekly Carfilzomib in Combination with Lenalidomide and 
Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma 
(A.R.R.O.W.2)  
 
Amgen Protocol  Number (carfilzomib) 20180015  
 
 
Amendment Date:  10 October 2019  
 
Rationale:  
This protocol is amended to:  
 Hepatitis B testing (hepatitis B surface antigen, hepatitis B surface antibody, and 
hepatitis B core antibody) has been added at screening  for all su bjects who have not 
had testing within 6 months of screening .  In addition, guidance has been provided 
regarding hepatitis B virus ( HBV) DNA testing and monitoring for subjects with 
positive hepatitis B serology or a prior history of HBV.  
 Overall survival at 1 year has been added as a secondary endpoint  to satisfy 
requests to collect information on overall survival .   
 A long -term follow -up (LTFU)  period with a duration of 12  months after randomization 
was added to separate this period from the safety follow -up period after cessation of 
treatment .  The LTFU period outlines the collection of overall survival data for all 
subjects up to 12  months from randomization.  In addition, clarifications were made 
regarding the collection of disease response assessments and subsequent 
antimyeloma therapy every 28   7 days until end of study for subjects who 
discontinued study treatment and do not have confirmed progressive disease.   End 
of study for each subject was clarified to account for the long -term follow -up period.  
 Dexamethasone is to be administered 40 mg weekly.  Clarifications were made to 
the treatment descriptions and the study schema to specify  the weekly  dose regimen 
for dexamethasone.  
 For disease response assessments, a bone marrow sample is to be collected and for 
confirmation of stringent complete response ( sCR) a bone biopsy or aspirate clot is 
required for immunohistochemistry.  Clarifications were made to the notes of the 
Schedule of A ctivities  to specify the type of bone marrow sample required for speci fic 
assessments.  Additionally, clarifications on sample requirements, timing of 
assessments, and response categories/subcategories were made  to descriptions of 
the efficacy assessments and the IMWG summary in the protocol appendix.  
 Dose modification guide lines for non -hematological toxicities were revised for renal 
dysfunction  to align with the product labeling.  The guidelines for congestive heart 
failure  were clarified for events < grade 3 and  grade 3.   Guidelines were added for 
hepatitis B reactivatio n. 
Product:  Carfilzomib  
Protocol Number:  20180015  
Date:  10 October 2019  Page 2 of 45 
CONFIDENTIAL   
   The planned interim analysis will be for futility and early success for efficacy.   
Additionally, c larifications were made on the disposition of  the database  for the 
respective planned analyses.  
 
 The analyte listing was formatted to better clarify which assessments should be 
performed by central laboratory and those which could be handled by a local 
laboratory.  New analytes were listed and clarifications were made to which an alytes 
were required at screening only.  
 Recording the severity of an adverse event was clarified for when the severity 
changes from the date of onset to the date of resolution.  
 Inclusion criteria for prior therapy was clarified with the addition of bullets .  No 
changes were made to the requirements.  
 Administration, typographical and formatting changes were made throughout the 
protocol.  Updates have been implemented to align with the current template.  
